QResear.ch

#20564727 at 2024-03-14 03:57:05 (UTC+1)
Q Research General #25222: Night Shift, Now With More Images Edition

Texans Seek Justice Against Dr. Fauci, Medical Establishment

By CDM Staff
March 13, 2024

The Vires Law Group together with the Chris Byrd Law firm, and with the support of the Former Feds
Group Freedom Foundation, announce the submission of requests to the District Attorneys of twenty-two Texas counties to initiate criminal investigations of Dr. Anthony Fauci and other officials for alleged
crimes committed against citizens of Texas prior to and during the COVID-19 pandemic.

This effort to investigate Dr. Fauci
and other accused persons is supported by donations from individuals and organizations such as the Fight Like A Flynn PAC run by former National Security Advisor retired Lieutenant General Mike Flynn.


Image by NIAID
Please Follow us on Gab, Minds, Telegram, Rumble, GETTR, Truth Social, Twitter

The Vires Law Group together with the Chris Byrd Law firm, and with the support of the Former Feds
Group Freedom Foundation, announce the submission of requests to the District Attorneys of twenty-two Texas counties to initiate criminal investigations of Dr. Anthony Fauci and other officials for alleged
crimes committed against citizens of Texas prior to and during the COVID-19 pandemic. The criminal
referral requests are being submitted to the District Attorneys for Angelina, Bexar, Brazos, Collin, Cooke,
Dallas, Fort Bend, Galveston, Guadalupe, Grayson, Gregg, Harris, Hays, Johnson, Lubbock,
Montgomery, Smith, Tarrant, Tom Green, Travis, and Wise counties. This effort to investigate Dr. Fauci
and other accused persons is supported by donations from individuals and organizations such as the Fight Like A Flynn PAC run by former National Security Advisor retired Lieutenant General Mike Flynn.

The requests made by attorneys Rodriguez, Miller, and Byrd ask the District Attorneys to make criminal
referrals to Attorney General Ken Paxton for investigation and charges, on behalf of the next-of-kin
relatives of 46 victims in Texas who have sought their assistance in requesting investigation into the deaths of their loved ones under COVID hospital protocols, intentional COVID-19 infection mismanagement, and suppression and denial of life-saving treatments in Texas hospitals, nursing homes, and other facilities.

The criminal referrals accuse Dr. Fauci, current and former federal officers, and hospital systems
providing care within Texas of committing crimes per Texas penal code, including:
? Capital Murder - Tex. Penal Code ?19.03(a)(7)
? Murder - Tex. Penal Code ?19.02(b)
? Manslaughter - Tex. Penal Code ?19.04
? Trafficking of Persons - Tex. Penal Code ?20A.02
? Participation in enterprise through racketeering or unlawful debt collection - Tex. Penal Code
?72.04 by Engaging in Organized Criminal Activity - Tex. Penal Code ?71.02
? Injury to a child, elderly individual, or disabled individual - Tex. Penal Code ?22.04
? Abandoning or endangering a child, elderly individual, or disabled individual - Tex. Penal Code
?22.041(c)
? Unlawful Restraint - Tex. Penal Code ?20.02.

In addition to Anthony Fauci, the following individuals and officers are Subjects of the requested
investigation:

Cliff Lane, Deputy Director, National Institute of Allergy and Infectious Diseases
Francis Collins, ex-Director, National Institutes of Health
Deborah Birx, ex-White House COVID Response Coordinator & former Director of DOD HIV
Research at Walter Reed Army Institute of Research
Rochelle Walensky, ex-Director, Centers for Disease Control and Prevention
Stephen Hahn, ex-Commissioner, Federal Drug Administration
Robert Redfield, ex-Director, Centers for Disease Control and Prevention
Peter Daszak, President, Eco-Health Alliance
Rick Bright, Director of the Biomedical Advanced Research and Development Authority
The Administrators and Healthcare Providers of hospital systems and facilities providing care to
patients in Texas, including but not limited to Baylor, Scott, & White Hospital System ("BSW")

The attorneys who extensively Researched and compiled the criminal referrals, along with many other
concerned citizens, believe that it is essential that the Texas Attorney General and his staff conduct a
thorough investigation to determine if the evidence contained in the filing together with further evidence
to be uncovered through investigation substantiates indictment and prosecution of the identified suspects for the alleged crimes. If the evidence provides probable cause that crimes have been committed, then it is expected that the State of Texas will prosecute them to the fullest extent of the law.

https://creativedestructionmedia.com/news/national/2024/03/13/texans-seek-justice-against-dr-fauci-medical-establishment/

#20523316 at 2024-03-05 23:58:58 (UTC+1)
Q Research General #25171: Stairway to Boomtown Edition

Moderna

USA Today acknowledges with Fauci is his having been "a co-reviewer of a vaccine platform Moderna is working to improve", as indicated by a 2019 Shareholder Letter. This refers to a review of vaccine technologies
Fauci coauthored that was published last year in the journal Nature Reviews Immunology.

https://web.archive.org/web/20200913054217/https:/www.modernatx.com/moderna-blog/moderna-2019-shareholder-letter

Although USA Today doesn't mention it, the same letter, under the subheading "Partnerships", mentions having $187 million in funding from grants, with a footnote reference. The footnote specifies that the grants are from the Biomedical Advanced Research and Development Authority (BARDA), Defense Advanced Research Projects Agency (DARPA), and the Bill and Melinda Gates Foundation.

BARDA operates under the Department of Health and Human Services. DARPA is a Research and development agency of the Department of Defense.
That both Fauci and Gates have close ties to Moderna is no secret.
A search immediately turned up a page published in March on the website of the NIAID, which operates under the National Institutes of Health (NIH), announcing the beginning of a phase one clinical trial for Moderna's COVID-19 vaccine. The webpage notes that Fauci's NIAID is "funding the trial."

Furthermore, Moderna's candidate vaccine "was developed by NIAID scientists and their collaborators" at Moderna.
The page quotes Fauci saying that the trial was "an important step" toward developing "a safe and effective vaccine to prevent infection with SARS-CoV-2".A page from Moderna's website listing the Bill & Melinda Gates Foundation as a "strategic collaborator", with the foundation having "entered a global health project framework agreement" in January 2016 "to advance mRNA-based development projects for various infectious disases."
https://www.flagshippioneering.com/companies/moderna
https://www.jeremyrhammond.com/2020/09/16/fauci-gates-moderna/
https://www.niaid.nih.gov/news-events/nih-clinical-trial-investigational-vaccine-covid-19-begins

DARPA
https://www.darpa.mil/
Defense Advanced Research Projects Agency
https://www.phe.gov/about/barda/Pages/default.aspx

#20414852 at 2024-02-15 00:07:11 (UTC+1)
Q Research General #25045: Angela Chaos Edition

>>20414849
ICAN is already deploying a legal strategy to ensure that individuals will never be infected with engineered viruses and bacteria without their express consent.

ICAN is also keeping a close eye on a new COVID-19 nasal vaccine, called CoviLiv, developed by Codagenix. It is described as "designed using the Codagenix platform technology that re-codes the genetic material of a virus - converting the virus from a disease-causing pathogen into a stable and safe, live-attenuated vaccine." No word yet on whether they anticipate this vaccine could spread from person-to-person, but they have just received funding from the Biomedical Advanced Research and Development Authority (BARDA).

Stay tuned for more on this issue as ICAN has instructed its legal team to dig further into these types of developing technologies that would permit involuntary, widespread delivery of pathogens that result in a complete and permanent revamping of our God-given immune systems without requiring any informed consent. ICAN has also, as noted, instructed its legal team to deploy a well-crafted strategy intended to ensure these technologies cannot be used to infect anyone without their consent, and it hopes to bring good news in the near future about that strategy.

See below for some of ICAN's other letters demanding answers from federal agencies:

https://icandecide.org/press-release/ican-uncovers-a-potential-next-level-threat-inhalable-self-spreading-vaccines-that-spread-like-a-virus/

2 of 2

#20414115 at 2024-02-14 22:07:36 (UTC+1)
Q Research General #25044: ? ? Edition

Pharmaceutical Companies are Abandoning mRNA Vaccines - Leaving Governments Holding the White Elephant

War spurs medical innovation. Ambulances to swiftly deliver the casualties of Napoleon's armies to field surgeons were the brainchild of Jean-Dominique Larrey. Florence Nightingale established professional nursing in the Crimea. The Kaiser's War brought the Thomas Splint, reducing mortality and amputation following limb fracture; 1939-45 spurred Florey and Chain's development of penicillin and McIndoe's reconstructive plastic surgery. All are now integral to civilian healthcare.

mRNA vaccines are offspring of George Bush's 'War on Terror'.

The idea of mRNA vaccines goes back to Robert Malone's discoveries of the late 1980s, but he was unable to pursue them and the patents passed to Merck, who spent the end of the old century expensively failing to develop a product. The idea might have remained in abeyance had it not been for 9/11 and the curious episode, immediately afterwards, when letters laced with anthrax spores were posted - allegedly by a disaffected U.S. Army scientist - to Senators and media outlets, killing five people and infecting 17 more.

A world already shaken by planes-turned-to-missiles awoke to bioterrorism. With modern molecular biology it isn't hard for a disaffected PhD student to insert genes for virulence or antibiotic resistance into a pathogen; it's a lot easier than building a nuclear bomb in your backyard. The bigger barriers are obtaining the pathogen in the first place and finding an effective distribution system. As then-Director of the Antibiotic Resistance Laboratory at the Public Health Laboratory Service (UKHSA's major predecessor) I wrote advice on which antibiotic to consider if some 'bad actor' modified anthrax or plague. My counterparts at Porton Down were more deeply involved.

Concerns extended to viruses. In 2018 a pharmaceutical company - seeking new smallpox vaccines - re-created the extinct horsepox virus using DNA chemistry alone. Given the right conditions, the reborn virus infected tissue culture, replicating itself. The potential to recreate smallpox became all too apparent. Many of us believe that the COVID-19 pandemic began with the escape of a virus manipulated by collaborating U.S. and Chinese scientists.

The U.S. response has been to lavishly fund its Biomedical Advanced Research and Development Authority (BARDA), Defence Advanced Research Projects Agency (DARPA) and Defence Threat Reduction Agency (DTRA). Please don't ask me how these interact and divide responsibilities; I never did understand. But they passed money to anyone with plausible product. By 2011, I'd moved to UEA and was consulting on antibiotic development for biotechs. We'd always review whether their prospective drug might cover some bioterrorism agent. If so, there was a chance of biodefence money.

DARPA alighted upon mRNA vaccines. Their beauty was that, if you sorted delivery, mRNA instability and toxicity, then you could adapt them for any pathogen. Think of the mRNA vaccine as a missile (lipid nanoparticle and mRNA modification to give stability) and payload (specific mRNA encoding the antigen). Once you have the missile you can fill it with an armour-piercing payload, or a high explosive, or shrapnel, gas or nuclear. Likewise with mRNA, different strands of mRNA cause the vaccinee to make different proteins, which elicits (in theory) the desired immune response. Bingo.

https://dailysceptic.org/2024/02/14/pharmaceutical-companies-are-abandoning-mrna-vaccines-leaving-governments-holding-the-white-elephant/

#20377641 at 2024-02-08 12:59:41 (UTC+1)
Q Research General #25000: Prep The Covfefe, Trump Speaks Bright And Early Edition

>>20377637
Additional Information:
About LAAB:

https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html#!

9 October 2020 21:30 BST


Two trials of AZD7442 will enroll over 6,000 adults for the prevention of COVID-19 with additional trials enrolling ~4,000 adults for the treatment of SARS-CoV-2 infections

US Government to invest ~$486m for development and supply of up to 100,000 doses and can acquire another one million doses

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to begin in the next weeks. The LAABs have been engineered with AstraZeneca's proprietary half-life extension technology to increase the durability of the therapy for six to 12 months following a single administration. The combination of two LAABs is also designed to reduce the risk of resistance developed by the SARS-CoV-2 virus.

The Company has received support of around $486m from the US Government for the development and supply of AZD7442 under an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

[1] Mark T. Esser, VP and Head of Microbial Sciences, AZD7442, Global Product Development Leader

4 of 4

#20307149 at 2024-01-26 18:30:34 (UTC+1)
Q Research General #24916: WRWY Texas! Edition

Department of Defense Inks $235.8 Million Contract for Anthrax Vaccines

Biopharmaceutical company Emergent BioSolutions (EBS) signed a massive $235.8 million contract with the Department of Defense to supply the U.S. military with its BioThrax anthrax vaccine.

Yahoo Finance reported the Biothrax anthrax vaccine is expected to be used by all branches of the U.S. military.

The Gateway Pundit previously reported that the FDA approved Emergent BioSolution's Cyfendus anthrax vaccine for adults 18-65 in July of last year.

Just months later after its approval, Emergent BioSolutions announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) "exercised an option valued on an existing deal to procure additional doses of its recently approved anthrax vaccine Cyfendus (AV7909)."

Per Yahoo Finance:

Emergent BioSolutions EBS signed an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract for a maximum value of up to $235.8 million with the U.S. Department of Defense (DoD) to supply its anthrax vaccine BioThrax.

The vaccine is intended for use by all branches of the United States military as pre-exposure prophylaxis (PrEP) for anthrax disease.

The procurement contract consists of a five-year base agreement ending on Sep 30, 2028, with an option to extend the contract for an additional five years to Sep 30, 2033.

Before the end of the initial five-year base period, the DoD should place a minimum guaranteed purchase order for $20.1 million worth of the vaccine product. For the following years, the annual order size should be at least $20 million for a total value of up to $235.8 million.

In recent months, the Federal governmet and state officials have been preparing for a possible anthrax outbreak.

Previously, The Gateway Pundit reported public safety, health, and emergency management agencies across Ohio came together recently to conduct a three-day anthrax attack simulation.

https://www.thegatewaypundit.com/2024/01/department-defense-inks-235-8-million-contract-anthrax/

#20257070 at 2024-01-17 11:28:57 (UTC+1)
Q Research General #24855: The Big Comfy Edition

>>20257069
It seems very unlikely that the above events in September and October of 2019-just a few months before SARS-CoV-2 was officially detected and announced-were just a coincidence. To be sure, most of the participants were probably unaware that a novel coronavirus was already spreading in Wuhan at the time they conducted these studies and seminars. Full knowledge was probably limited to a few intelligence and public health officials in China and the United States.

OCTOBER 29, 2019: Drs. Anthony Fauci and Rick Bright-director of the Biomedical Advanced Research and Development Authority (BARDA)-attend a conference at the Milken Institute to discuss the need for a universal flu vaccine. The moderator, New Yorker staff writer Michael Specter, repeatedly lamented that there wasn't sufficient motivation to invest the resources necessary to make the "disruptive" leap from traditional vaccine technology to new vaccine technology. Dr. Bright states that the most promising new technology to combat the flu or other viral pandemics is "nucleic acid based, and messenger RNA based sequences that can be rapidly shared around the world."

DECEMBER 12, 2019: A MATERIAL TRANSFER AGREEMENT (see pages 105-107) from NIAID/Moderna ("Provider") to Ralph Baric ("Research Recipient") is signed by Professor Ralph Baric at UNC Chapel Hill. The Agreement specifies the transfer of "mRNA coronavirus vaccine candidates developed and jointly owned by NIAID and Moderna" to Dr. Baric "to perform challenge studies with the mRNA vaccine."

?
The Agreement is signed by Ralph Baric on December 12, 2019-19 days BEFORE the Wuhan Municipal Health Commission informed the WHO China Country Office of "cases of pneumonia of unknown etiology detected in Wuhan City, Hubei Province of China on December 31, 2019, and 24 days BEFORE the genome of SARS-CoV-2 was published on January 5, 2020.

Here it is important to note Dr. Ralph Baric's remarkable history. Starting in 2013, Baric worked with scientists at the Wuhan Institute of Virology (WIV) to perform gain-of-function work on Bat SL-CoV-WIV1 and SHCO15 coronaviruses. His collaboration with Ge Xing-Ye and Shi Zhengli began shortly after they (along with Peter Daszak) discovered these two viruses in horseshoe bats in southern China. Xing-Ye, Zhengli, and Daszak published their discovery in Nature magazine in a 2013 paper titled Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. They were very excited about it, because for the first time in history, they found a wild bat coronavirus that would bind with a human ACE2 receptor-a protein (enzyme) on the surface of many cell types.

With this important discovery, Baric commenced work with his Chinese colleagues to fashion these two viruses into two new chimeric viruses that would infect the human respiratory tract. They reported their results in papers published in 2015 and 2016.

1). A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence (published in Nature Medicine)

2). SARS-like WIV1-CoV poised for human emergence (published in Proceedings of the National Academy of Sciences, or PNAS).

Note that Dr. Baric signs the Material Transfer Agreement "to perform challenge studies with NIAID/Moderna's mRNA vaccine" four years later.

Speaking of MODERNA: On Feb. 4, 2016, the company filed a patent for a proprietary genetic sequence (SEQ ID11652, nt 2751-2733) patented by Bancel S. et al. in Cambridge, Massachusetts.

As reported in the February 21, 2022 issue of Frontiers in Virology (MSH3 Homology and Potential Recombination Link to SARS-CoV-2 Furin Cleavage Site):

SARS-CoV-2 Spike Protein and MSH3

A peculiar feature of the nucleotide sequence encoding the PRRA furin cleavage site in the SARS-CoV-2 S protein is its two consecutive CGG codons. This arginine codon is rare in coronaviruses: relative synonymous codon usage (RSCU) of CGG in pangolin CoV is 0, in bat CoV 0.08, in SARS-CoV 0.19, in MERS-CoV 0.25, and in SARS-CoV-2 0.299 (8).

A BLAST search for the 12-nucleotide insertion led us to a 100% reverse match in a proprietary sequence (SEQ ID11652, nt 2751-2733) found in the US patent 9,587,003 filed on Feb. 4, 2016 [by Bancel S. et al. in Cambridge, Massachusetts].

#20019782 at 2023-12-03 18:30:13 (UTC+1)
Q Research General #24574: Return of the eBake Edition

U.S. Governmnent Inks $75 Million Contract for Recently Approved Anthrax Vaccines

The FDA approved Emergent Biosolution's Cyfendus for use following any confirmed or suspected exposure to anthrax, but it was also noted it must be administered with antibacterial drugs.

Now Emergent BioSolutions has announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has "exercised an option valued on an existing deal to procure additional doses of its recently approved anthrax vaccine Cyfendus (AV7909)."

The additional doses bought by BARDA will cost an additional $75 million.

In case you are unfamiliar with the office of BARDA, it is an office under the U.S. Department of Health and Human Services (HHS) office that is in charge of the procurement and Research of medical countermeasures, mostly against bioterrorism and emerging pandemics.

https://www.thegatewaypundit.com/2023/12/u-s-governmnent-inks-75-million-contract-recently/

#20019696 at 2023-12-03 18:07:45 (UTC+1)
Q Research General #24574: Return of the eBake Edition

U.S. Governmnent Inks $75 Million Contract for Recently Approved Anthrax Vaccines

https://www.thegatewaypundit.com/2023/12/u-s-governmnent-inks-75-million-contract-recently/

The Gateway Pundit reported in July that the FDA approved Emergent BioSolution's new anthrax vaccine for adults 18-65.

The FDA approved Emergent Biosolution's Cyfendus for use following any confirmed or suspected exposure to anthrax, but it was also noted it must be administered with antibacterial drugs.

Now Emergent BioSolutions has announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has "exercised an option valued on an existing deal to procure additional doses of its recently approved anthrax vaccine Cyfendus (AV7909)."

The additional doses bought by BARDA will cost an additional $75 million.

In case you are unfamiliar with the office of BARDA, it is an office under the U.S. Department of Health and Human Services (HHS) office that is in charge of the procurement and Research of medical countermeasures, mostly against bioterrorism and emerging pandemics.

$EBS
After Cyfendus' full approval, Emergent clinches $75M anthrax vaccine supply pact in US https://t.co/z3fo5KfVuS

- Bio/Tech Stock Focus (@MarcJacksonLA) November 28, 2023

The Gateway Pundit reported in October that public safety, health, and emergency management agencies across the state of Ohio conducted a three-day anthrax attack simulation.

WATCH:



Ohio isn't the only one concerned with a possible attack. Federal agencies have claimed if a bioterrorist attack were to occur, it's likely anthrax would be used in the attack.

Per the CDC's website, "If a bioterrorist attack were to happen, Bacillus anthracis, the bacteria that causes anthrax, would be one of the biological agents most likely to be used."

#19633249 at 2023-09-29 19:21:24 (UTC+1)
Q Research General #24110: NYC Goin Biblical, GOOSE DAY, Sheft?, RIP Tupac, 45 Cali Dreamin Edition

"Randomly" and "coincidentally" decided to look into this today. It has turned out to be a pretty interesting read.

CEPI and CEO Richard J. Hatchett
https://en.wikipedia.org/wiki/Coalition_for_Epidemic_Preparedness_Innovations

Quote: "In April 2017, Richard J. Hatchett, former director of the U.S. government's Biomedical Advanced Research and Development Authority (BARDA), became the full-time CEO.[15] Hatchett was also a member of the United States Homeland Security Council under George W. Bush, and the United States National Security Council, under Barack Obama.[16][17] Also in April 2017, CEPI opened an additional office in London, and in October 2017, a further office was opened in Washington, D.C.[18] Nature later stated, "It is by far the largest vaccine development initiative ever against viruses that are potential epidemic threats".[19]==

In October, 2017 they opened an office in Washington, DC!!

If you want to find a lot of boxes to check on DS connections this is a mother lode. Bill Gates, Davos, WEF, BARDA etc, etc.

#19467086 at 2023-08-31 18:45:19 (UTC+1)
Q Research General #23908: Parade In, Trail Blazing, Eyebrow Raising Edition

Judicial Watch: Pfizer Records Reveal 23-Person Study of COVID Vaccine Booster Safety and Effectiveness before Approval

Judicial Watch released 58 pages of records from the U.S. Food and Drug Administration (FDA) showing that a Pfizer study surveyed 23 people in 2021 to gauge reactions to its COVID vaccine booster before asking the FDA to approve it. The FDA indicated that this production of records "represents our complete response to your request; no additional productions are anticipated."

The records were obtained in response to a March 2022 lawsuit filed after the Department of Health and Human Services failed to respond to an August 2021 Freedom of Information Act (FOIA) request for records "submitted by Pfizer and BioNTech to the FDA, including BARDA, relating to 'booster' vaccinations for the SARS-CoV-2 virus" (Judicial Watch, Inc. v. U.S. Department of Health and Human Services (No. 1:22-cv-00730)).

Biomedical Advanced Research and Development Authority, BARDA, has been heavily involved with the development of the COVID-19 vaccine. According to its website:

The Biomedical Advanced Research and Development Authority (BARDA) provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks; pandemic influenza (PI), and emerging infectious diseases (EID).

BioNTech is a German pharmaceutical company that partnered with Pfizer in developing the original vaccine.

The records include a July study titled "Phase 1 Booster Safety and Immunogenicity Data up to 1 Month Post-Dose 3 of BNT162b2 30 ?g [micrograms] in Study C4591001" provided "preliminary safety and immunogenicity data" for a group that had received two vaccine shots and, seven to nine months later, a third (booster) shot:

This submission includes preliminary findings from a subset of younger (18 to 55 years of age) and older (65 to 85 years of age) participants in the Phase 1 part of Study C4591001 who completed the initial two-dose series of BNT162b2 30 ?g, given approximately 3 weeks apart, and then received a third dose (booster) of BNT162b2 30 ?g approximately 7 to 9 months after the second dose. Data were collected through the cutoff date of 13 May 2021.

The participants were evaluated for symptoms up to one month after the booster shot. The booster's immunogenicity, or how well a vaccine works over time, was evaluated seven days and one month after the booster:

SARS-CoV-2 50% neutralization titers were assessed in sera drawn before BNT162b2 Dose 1 (on Day 1); 7 days and 1 month after BNT162b2 Dose 2; before Dose 3; and 7 days and 1 month after Dose 3.

https://www.judicialwatch.org/pfizer-23-person-study/

https://www.judicialwatch.org/wp-content/uploads/2022/10/JW-v.-HHS-Pfizer-application-materials-00730.pdf

#19436165 at 2023-08-26 19:17:52 (UTC+1)
Q Research General #23869: HARRISON FLOYD - Say His Name! Edition

Biden Regime Seeks Additional Funding for New COVID-19 Vaccine "That Works" - Warns Everyone Will Get It "No Matter Whether They've Gotten It Before or Not"

The Gateway Pundit previously reported that InfoWars published insider information that alleges the TSA and US Border Patrol will be moving back to 2020-era COVID-19 mandates and restrictions starting in mid-September through mid-October, to include mask mandates on all flights. This is in addition to the confirmed mask-mandate reinstatement at Morris Brown College in Atlanta, GA, and Lionsgate Studios in Santa Monica, CA. Also, a school district in South Texas just outside of San Antonio closed down temporarily due to an 'uptick' in COVID cases.

That same week, WarRoom's Natalie Winters uncovered millions of dollars in funding, awarded primarily to the Department of Veteran's Affairs and DoD, to ramp up testing and other COVID-19 related.

This was just a week after the NIH appointed Dr. Jeanne Marrazzo, a staunch advocate for masks, lockdowns, and vaccine mandates, as the replacement for Dr. Fauci.

To further the suggestion that another lockdown scare is in the forecast, on Tuesday, the US Department of Health and Human Services announced funding of $1.4 billion to "support the development of a new generation of tools and technologies to protect against COVID-19 for years to come" according to a press release.

"Project NextGen is a key part of the Biden-Harris Administration's commitment to keeping people safe from COVID-19 variants," said HHS Secretary Xavier Becerra. "These awards are a catalyst for the program - kickstarting efforts to more quickly develop vaccines and continue to ensure availability of effective treatments."

Project NextGen, a $5 billion initiative led by ASPR's Biomedical Advanced Research and Development Authority (BARDA) in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), coordinates across the federal government and the private sector to advance innovative vaccines and therapeutics into clinical trials, regulatory review, and potential commercial availability for the American people. The project builds on a better understanding of COVID-19 - with HHS developing, using, and constantly re-evaluating the strengths and weaknesses of current vaccines and therapeutics for over three years.

Recipients of the awards include:

$1 billion to four BARDA Clinical Trial partners to support vaccine Phase IIb clinical trial studies: ICON Government and Public Health Solutions, Inc of Hinckley, Ohio; Pharm-Olam, LLC, of Houston, Texas; Technical Resources Intl (TRI), Inc, of Bethesda, Maryland; and Rho Federal Systems, Inc., Durham, North Carolina.
$326 million to Regeneron to support the development of a next-generation monoclonal antibody for COVID-19 prevention.
$100 million to Global Health Investment Corp. (GHIC), the non-profit organization managing the BARDA Ventures investment portfolio to expand investments in new technologies that will accelerate responses in the future.
$10 million to Johnson & Johnson Innovation (JLABS) for a competition through Blue Knight, a BARDA-JLABS partnership.

The press release claims that their partnership with Regeneron will help develop a "novel monoclonal antibody that will protect people who do not respond to or cannot take existing vaccines," despite their attempts to limit the distribution in Florida in 2021.

On Friday, Joe Biden announced that he plans to request more funding from Congress to develop a new COVID vaccine "that works."

"I signed off this morning on a proposal we have to present to the Congress a request for additional funding for a new vaccine that is necessary, that works," Biden told the reporters while vacationing for the nth times in Lake Tahoe.

Biden warned that everyone will get it despite their previous vaccination status.

"It will likely be recommended that everybody get it no matter whether they've gotten it before or not," he added.

https://www.thegatewaypundit.com/2023/08/here-we-go-biden-regime-seeks-additional-funding/

#19412318 at 2023-08-23 17:23:33 (UTC+1)
Q Research General #23840: Fire In The Hole Edition

Biden Administration Announces Massive $5 Billion COVID-19 Funding Called "Project NextGen"

This week, InfoWars published insider information that alleges the TSA and US Border Patrol will be moving back to 2020-era COVID-19 mandates and restrictions starting in mid-September through mid-October, to include mask mandates on all flights. This is in addition to the confirmed mask-mandate reinstatement at Morris Brown College in Atlanta, GA and Lionsgate Studios in Santa Monica, CA.

That same week, WarRoom's Natalie Winters uncovered millions of dollars in funding, awarded primarily for the Department of Veteran's Affairs, to ramp up testing and other COVID-19 related. This was just a week after the NIH appointed Dr. Jeanne Marrazzo, a staunch advocate for masks, lockdowns, and vaccine mandates, as the replacement for Dr. Fauci.

To further the suggestion that another lockdown scare is in the forecast, yesterday the US Department of Health and Human Services announced funding of $1.4 billion to "support the development of a new generation of tools and technologies to protect against COVID-19 for years to come" according to a press release:

The awards announced today follow extensive coordination with industry partners and include support for clinical trials that will enable the rapid development of even more effective and longer-lasting coronavirus vaccines, a new monoclonal antibody, and transformative technologies to streamline manufacturing processes.

"Project NextGen is a key part of the Biden-Harris Administration's commitment to keeping people safe from COVID-19 variants," said HHS Secretary Xavier Becerra. "These awards are a catalyst for the program - kickstarting efforts to more quickly develop vaccines and continue to ensure availability of effective treatments."

Project NextGen, a $5 billion initiative led by ASPR's Biomedical Advanced Research and Development Authority (BARDA) in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), coordinates across the federal government and the private sector to advance innovative vaccines and therapeutics into clinical trials, regulatory review, and potential commercial availability for the American people. The project builds on a better understanding of COVID-19 - with HHS developing, using, and constantly re-evaluating the strengths and weaknesses of current vaccines and therapeutics for over three years.

Recipients of the awards include:

https://www.thegatewaypundit.com/2023/08/biden-administration-announces-massive-5-billion-covid-19/

#19406448 at 2023-08-22 18:20:52 (UTC+1)
Q Research General #23833: It Was Always About Control Edition

HHS announces $1.5 billion in awards to partners to develop 'next generation COVID-19 vaccines'

HHS officials: COVID cases are spiking, which is expected to continue heading into the fall and emerging variants are being monitored



The Health and Human Services Department and the Biomedical Advanced Research and Development Authority on Tuesday announced a $1.5 billion initiative through Project NextGen for its partners to develop the "next generation" of COVID-19 vaccines and therapeutics.

Several new COVID-19 variants have emerged and HHS officials said the department is closely monitoring the situation as the vaccines are developed.

According to HHS, COVID cases are spiking, which is expected to continue heading into the fall.

HHS and BARDA officials expect to announce more grants for COVID vaccine development in the future.

https://justthenews.com/government/federal-agencies/hhs-announces-15-billion-grants-partners-develop-next-generation-covid

#19026686 at 2023-06-18 13:09:46 (UTC+1)
Q Research General #23363: Happy Father's Day Edition

DARPA aka the USgovt/US mil contracted pfizer/moderna/etc to craft the mrna gene editing technologies in 2013- posted and noted here many times.
>>18416942 (pb)
>>18402860 (pb)
>>18457428 (pb)
>>18457431 (pb)
>>18457444 (pb)
>>13710921 (pb)
>>13710809 (pb)

now lets tie DARPA to the Rockefeller Foundation which scenario'd a pandemic called 'Lock Step' in May 2010
>>19023021 (pb)
>>19023020 (pb)
>>19023041 (pb)
>>19023056 (pb)
>>19023080 (pb)

Here is Rick A. Bright, PhD
https://www.rockefellerfoundation.org/profile/dr-rick-bright/

Rick Bright is formerly the Chief Executive Officer of the Pandemic Prevention Institute (PPI) at The Rockefeller Foundation. Dr. Bright lead the development of the Foundation's pandemic data-to-action platform that integrates modern technology, data analytics and global partners to help the world detect, prevent, and mitigate pandemic threats to achieve containment as quickly as possible.

Prior to this role, he served as theDeputy Assistant Secretary for Preparedness and Response and the Director of the Biomedical Advanced Research and Development Authority(BARDA), in the U.S. Department of Health and Human Services. Dr. Bright has also gained extensive experience in the biotechnology industry where he served in senior leadership and executive management roles. He has held senior scientific leadership positions in non-governmental organizations where he championed innovative vaccine development and expanded vaccine manufacturing capacity to multiple developing countries. He also spent a decade in vaccine, therapeutics, and diagnostics development at the Centers for Disease Control and Prevention. For this work, Dr. Bright received the Charles C. Shepard Science Award for Scientific Excellence.

Dr. Bright sits on the Executive Board of the New York Academy of Sciences' International Science Reserve and serves as an international subject matter expert in biodefense, emergency preparedness and response, pharmaceutical innovation, vaccine, drug and diagnostics development. He also served as an advisor to the Biden Administration, World Health Organization, the Coalition for Epidemic Preparedness Innovations (CEPI) and the National Academies of Sciences, Engineering & Medicine Forum on Microbial Threats. Dr. Bright is a member of the Council on Foreign Relations and serves as a Sr. Fellow at the Foreign Policy Association.

Dr. Bright received a Ph.D. in Immunology and Molecular Pathogenesis from Emory University and a B.S. magna cum laude in Biology and Physical Sciences from Auburn University at Montgomery.

___

In July 2005, at the hearings before the Committee on Health, Education, Labor, and Pensions, the first CEO and Director of the center, Tara O'Toole, MD, MPH, has pointed to center's role as the "BioDARPA" (i.e. "Biomedical DARPA").
https://en.wikipedia.org/wiki/Biomedical_Advanced_Research_and_Development_Authority

#18446950 at 2023-03-04 23:34:00 (UTC+1)
Q Research General #22618: Into the Comfy Edition

Contract

https://www.hhs.gov/sites/default/files/moderna-covid-19-vaccine-contract.pdf


A.1 The U.S. Army Contracting Command - Aberdeen Proving Ground (ACC-APG), Natick Division has a
requirement for up to 500 million SARS-CoV-2 mRNA-1273 Vaccine doses (100m) in support of Joint Program
Executive Office - Chemical Biological Radiological Nuclear Defense (JPEO-CBRND), the Assistant Secretary for
Preparedness and Response (ASPR), and Biomedical Advanced Research and Development Authority (BARDA).
All doses of mRNA-1273 Vaccine referenced herein are 1001.tg doses. All doses will be delivered in a multi- dose
vial with a volume sufficient for 10 doses per vial.

FOB: Origin (Shipping Point)
PURCHASE REQUEST NUMBER: 0011534693
PROJECT: Operation Warp Speed
PSC CD: 6505

#18377390 at 2023-02-19 21:27:32 (UTC+1)
Q Research General #22528: DeSantis is a RINO who is trying to hide his past? Edition

https://aspr.hhs.gov/AboutASPR/ProgramOffices/BARDA/Pages/Project-Bioshield.aspx

Project Bioshield (related to BARDA)

Project BioShield was established to help incentivize private industry to develop vitally needed medical countermeasures by providing multi-year funding to support Advanced Research, clinical development, manufacture and procurement. Without this secure source of funding, companies do not have the incentive needed to develop the medical countermeasures that are critical to national security.

The Project BioShield Act was signed into law on July 21, 2004. Since its inception, the Biomedical Advanced Research and Development Authority (BARDA) within the HHS Administration for Strategic Preparedness and Response has managed the program and worked to develop the strong partnerships, clear direction, and market incentives needed to make the program a success. Project BioShield funding is used to address national security threats as identified by the Department of Homeland Security's Material Threat Determination process.

Overview of Key Accomplishments
Since its inception in 2006, BARDA has cultivated partnerships with partners in government as well as biotechnology and pharmaceutical companies to build a portfolio of cutting-edge medical countermeasures that address some of our most pressing health security threats, including anthrax, botulism, Ebola, smallpox, nerve agents, radiation, thermal or radiation burns, and antimicrobial resistance. Many of the products that have been supported under Project BioShield also received Advanced Research and development funding from BARDA.

picrel: Does timing of grants give approximate timing of outbreaks?
https://www.grants.gov/web/grants/search-grants.html?agencyCode=HHS-OS-ASPR

#18157868 at 2023-01-16 23:09:00 (UTC+1)
Q Research General #22264: Lurkers of the Kun, Unite! Edition

As of June, seven companies had been chosen for funding from Operation Warp Speed to expedite development and preparation for manufacturing their respective vaccine candidates: Johnson & Johnson (Janssen Pharmaceutical), AstraZeneca-University of Oxford, Pfizer-BioNTech, Moderna, Merck, Vaxart, and Inovio.[49][50] Funding from BARDA totaled more than $2 billion by the end of June, with the largest awards of $1.2 billion given to AstraZeneca and $483 million to Moderna.[49]
In June 2020, BARDA and the U.S. Department of Defenses signed a $143 million contract with SiO2 Materials Science to ramp up production of vials and syringes used for COVID drugs and vaccines.[51]

The Biomedical Advanced Research and Development Authority (BARDA) is a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases.[1]:?140? BARDA was established in 2006 through the Pandemic and All-Hazards Preparedness Act (PAHPA) and reports to the Office of the Assistant Secretary for Preparedness and Response (ASPR). The office manages Project BioShield, which funds the Research, development and stockpiling of vaccines and treatments that the government could use during public health emergencies such as chemical, biological, radiological or nuclear (CBRN) attacks.[1]:?140?
In addition to preparing and maintaining bioterrorism responses and countermeasures, HHS, through the ASPR and BARDA, prepares and maintains an integrated system of medical countermeasures for both known or unknown, and re-emerging or novel types of public health emergencies. These include diagnostic tools, therapeutics, such as antibiotics and antivirals, and preventative measures, such as vaccines.BARDA is an established, official interface between the U.S. federal government and the Biomedical industry.
? BARDA also participates in the governmental inter-agency Public Health Emergency Medical Countermeasures Enterprise (PHEMCE), providing coordination across the US federal government in developing and deploying such countermeasures.[1]:?267?
BARDA works with the Biomedical industry, using grants and other assistance, to promote Advanced Research, innovation and the development of medical devices, tests, vaccines and therapeutics. BARDA also procures and maintains stockpiles of materials, such as drugs, personal protective equipment (PPE) and vaccines, for the Strategic National Stockpile (SNS).

Operation Warp Speed, initially funded with about $10 billion from the CARES Act (Coronavirus Aid, Relief, and Economic Security) passed by the United States Congress on March 27, 2020,[1] was an interagency program that includes components of the Department of Health and Human Services, including the Centers for Disease Control and Prevention, Food and Drug Administration, the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA); the Department of Defense; private firms; and other federal agencies, including the Department of Agriculture, the Department of Energy, and the Department of Veterans Affairs.

Operation Warp Speed used BARDA as the financial interface between the U.S. federal government and the Biomedical industry.[20] The program was initially being funded with $10 billion,[1] with additional funds allocated through BARDA.[1] Funding was increased to about $18 billion by October 2020.[21]
Rick Bright, the BARDA director, was reassigned on or about April 22, 2020, following his resistance to (as he phrased it) "efforts to fund potentially dangerous drugs promoted by those with political connections".In May, new leadership was announced. Moncef Slaoui was named Operation Warp Speed's chief adviser.[1][9] Slaoui is a vaccine Researcher and, formerly, Chairman of Global Research and Development and Chairman of Global Vaccines at GlaxoSmithKline, where he led the development of five vaccines.[1] General Gustave F. Perna, who served as commanding general of Army Materiel Command, was named Operation Warp Speed chief operating officer.[1][23] Retired Lieutenant General Paul A. Ostrowski, who previously served as director of the Army Acquisition Corps, was the director of supply, production and distribution.[24][25] Army Major General Christopher J. Sharpsten was the deputy director.[26][27]
Alex Azar, Mark Esper, and Deborah Birx were on the board of directors of OWS, while Tony Fauci, Francis Collins, and Robert Redfield were nonvoting advisers.

https://en.wikipedia.org/wiki/Operation_Warp_Speed
https://en.wikipedia.org/wiki/Biomedical_Advanced_Research_and_Development_Authority

#17998999 at 2022-12-22 21:10:50 (UTC+1)
Q Research General #22053: The Fight for Arizona Election Trial: Lake v. Hobbs Day 2 Edition

>>17998930
>>17998609

PART 2

Trump's 2019 [pre-Covid19] "Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health" [PART 1 OF 2]

Issued on: September 19, 2019[BEFORE COVID 19]

continued from Part 1

Sec. 2. Policy. It is the policy of the United States to modernize the domestic influenza vaccine enterprise to be highly responsive, flexible, scalable, and more effective at preventing the spread of influenza viruses. This is a public health and national security priority, as influenza has the potential to significantly harm the United States and our interests, including through large-scale illness and death, disruption to military operations, and damage to the economy. This order directs actions to reduce the United States' reliance on egg-based influenza vaccine production; to expand domestic capacity of alternative methods that allow more agile and rapid responses to emerging influenza viruses; to advance the development of new, broadly protective vaccine candidates that provide more effective and longer lasting immunities; and to support the promotion of increased influenza vaccine immunization across recommended populations.

Sec. 3. National Influenza Vaccine Task Force. (a) There is hereby established a National Influenza Vaccine Task Force (Task Force). The Task Force shall identify actions to achieve the objectives identified in section 2 of this order and monitor and report on the implementation and results of those actions. The Task Force shall be co-chaired by the Secretary of Defense and the Secretary of Health and Human Services, or their designees.

(b) In addition to the Co-Chairs, the Task Force shall consist of a senior official from the following executive branch departments, agencies, and offices:

(i) the Department of Defense (DOD);

(ii) the Department of Justice;

(iii) the Department of Agriculture;

(iv) the Department of Veterans Affairs (VA);

(v) the Department of Homeland Security;

(vi) the United States Food and Drug Administration;

(vii) the Centers for Disease Control and Prevention;

(viii) the National Institutes of Health (NIH);

(ix) the Centers for Medicare and Medicaid Services (CMS); and

(x) the Biomedical Advanced Research and Development Authority (BARDA).

(c) The Co-Chairs may jointly invite additional Federal Government representatives, with the consent of the applicable executive department, agency, or office head, to attend meetings of the Task Force or to become members of the Task Force, as appropriate.

(d) The staffs of the Department of State, the Office of Management and Budget (OMB), the National Security Council, the Council of Economic Advisers, the Domestic Policy Council, the National Economic Council, and the Office of Science and Technology Policy (OSTP) may attend and participate in any Task Force meetings or discussions.

(e) The Task Force may consult with State, local, tribal, and territorial government officials and private sector representatives, as appropriate and consistent with applicable law.

(f) Within 120 days of the date of this order, the Task Force shall submit a report to the President, through the Assistant to the President for National Security Affairs, the Assistant to the President for Domestic Policy, the Director of the Office of Management and Budget, and the Director of the Office of Science and Technology Policy. The report shall include:

(i) a 5-year national plan (Plan) to promote the use of more agile and scalable vaccine manufacturing technologies and to accelerate development of vaccines that protect against many or all influenza viruses;

(ii) recommendations for encouraging non-profit, academic, and private-sector influenza vaccine innovation; and

(iii) recommendations for increasing influenza vaccination among the populations recommended by the CDC and for improving public understanding of influenza risk and informed influenza vaccine decision-making.

(g) Not later than June 1 of each of the 5 years following submission of the report described in subsection (f) of this section, the Task Force shall submit an update on implementation of the Plan and, as appropriate, new recommendations for achieving the policy objectives set forth in section 2 of this order.

[to be continued in PART 3]

https://trumpwhitehouse.archives.gov/presidential-actions/executive-order-modernizing-influenza-vaccines-united-states-promote-national-security-public-health/

#17941161 at 2022-12-14 17:14:41 (UTC+1)
Q Research General #21991: SBF is currently being held until at least February 8th Edition

Operation Warp Speed
Operation Warp Speed.png
Official seal of Operation Warp Speed
Active May 15, 2020 - February 24, 2021
(285 days)
Disbanded Transitioned to White House COVID-19 Response Team
Country United States
Allegiance United States
Part of U.S. Department of Defense
U.S. Department of Health and Human Services
Other various government agencies
Engagements Coronavirus disease 2019
Website Coronavirus: Operation Warp Speed
Commanders
Head Moncef Slaoui
Chief Operating Officer General Gustave F. Perna
Commander in Chief Donald Trump
Joe Biden
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
COVID-19 (disease) SARS-CoV-2 (virus)
Cases Deaths
show
Timeline
show
Locations
show
International response
hide
Medical response
Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation
Vaccines
History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports
Current vaccines
CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford-AstraZeneca Pfizer-BioNTech Sinopharm BIBP Sputnik V
show
Variants
show
Economic impact and recession
show
Impacts
virus icon COVID-19 portal
vte
Operation Warp Speed (OWS) was a public-private partnership initiated by the United States government to facilitate and accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.[1][2] The first news report of Operation Warp Speed was on April 29, 2020,[3][4][5] and the program was officially announced on May 15, 2020.[1] It was headed by Moncef Slaoui from May 2020 to January 2021 and by David A. Kessler from January to February 2021.[6] At the end of February 2021, Operation Warp Speed was transferred into the responsibilities of the White House COVID-19 Response Team.[7]
The program promoted mass production of multiple vaccines, and different types of vaccine technologies, based on preliminary evidence, allowing for faster distribution if clinical trials confirm one of the vaccines is safe and effective.[citation needed] The plan anticipated that some of these vaccines will not prove safe or effective, making the program more costly than typical vaccine development, but potentially leading to the availability of a viable vaccine several months earlier than typical timelines.[8]
Operation Warp Speed, initially funded with about $10 billion from the CARES Act (Coronavirus Aid, Relief, and Economic Security) passed by the United States Congress on March 27, 2020,[1] was an interagency program that includes components of the Department of Health and Human Services, including the Centers for Disease Control and Prevention, Food and Drug Administration, the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA); the Department of Defense; private firms; and other federal agencies, including the Department of Agriculture, the Department of Energy, and the Department of Veterans Affairs.[1]

#17806428 at 2022-11-25 01:54:52 (UTC+1)
Q Research General #21836: Let Gratitude Never End Edition

the top of the notables asking about Trump endorsing a covid vaccine, and not understanding why

the start
covid hits and is not a big deal, no more than the common cold
then all of a sudden it's killing all the old people so we need lockdowns
then the only way to remove lockdowns is to come up with a vaccine for the most at risk but it may take years
President Trump acts based off the information of the agencies responsible for such things, through a bill passed by congress. NOT an EO signed by President Trump to push/promote/mandate a covid vaccine.

"Operation Warp Speed, initially funded with about $10 billion from the CARES Act (Coronavirus Aid, Relief, and Economic Security) passed by the United States Congress on March 27, 2020,[1] was an interagency program that includes components of the Department of Health and Human Services, including the Centers for Disease Control and Prevention, Food and Drug Administration, the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA); the Department of Defense; private firms; and other federal agencies, including the Department of Agriculture, the Department of Energy, and the Department of Veterans Affairs" - https://en.wikipedia.org/wiki/Operation_Warp_Speed

What would happen if President Trump went against the recommendations of all of the above agencies?

fast forward

The inauguration of Joe Biden as the 46th president of the United States took place on Wednesday, January 20, 2021
Executive Order 13991 of January 20, 2021
Protecting the Federal Workforce and Requiring Mask-Wearing
Sec. 4. Safer Federal Workforce Task Force.
(ix) vaccine prioritization, distribution, and administration

Below is a briefing based on the information gathered from task force of EO 13991

https://www.whitehouse.gov/briefing-room/presidential-actions/2021/09/09/executive-order-on-requiring-coronavirus-disease-2019-vaccination-for-federal-employees/
SEPTEMBER 09, 2021
"I have determined that to promote the health and safety of the Federal workforce and the efficiency of the civil service, it is necessary to require COVID-19 vaccination for all Federal employees"

If you were scared of covid, Trump had a vaccine available under emergency use authorization and it was your choice to get it
Biden paved the way for mandates on his first day in office via EO and completed the federal worker vaccine mandate 9 months in

President Trump treated covid without a covid vaccine
Biden was on TV getting covid shot and boosters

Regret may cause some people to think irrationally, however the facts exist and they don't give a fuck about your opinion. President Trump never forced the vaccine on anyone. Biden EO'd vaccine requirements.

#17637705 at 2022-10-06 13:10:32 (UTC+1)
Q Research General #21627: Anons Do Battle in the Field of Digital Warfare and Lawfare Edition

US Buying $290M Worth Of Anti-Radiation Drugs for Use In "Nuclear Emergency"
The Biden regime is buying up $290 million in anti-radiation drugs for use in "nuclear emergencies" amid escalating tensions with Russia and heightened threats of a nuclear war.
FOR IMMEDIATE RELEASE
October 4, 2022
Contact HHS Press Office
202-821-9446
asprmedia@hhs.gov
www.hhs.gov/news
Twitter: @HHSgov
HHS purchases drug for use in radiological and nuclear emergencies
As part of long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies, the U.S. Department of Health and Human Services is purchasing a supply of the drug Nplate from Amgen USA Inc; Nplate is approved to treat blood cell injuries that accompany acute radiation syndrome in adult and pediatric patients (ARS).
Amgen, based in Thousands Oaks, California, developed Nplate for ARS with support from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR), as well as the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
BARDA is using its authority provided under the 2004 Project Bioshield Act and $290 million in Project BioShield designated funding to purchase this supply of the drug. Amgen will maintain this supply in vendor-managed inventory. This approach decreases life-cycle management costs for taxpayers because doses that near expiration can be rotated into the commercial market for rapid use prior to expiry and new doses can be added to the government supply.
https://www.zerohedge.com/geopolitical/us-buying-290m-worth-anti-radiation-drugs-use-nuclear-emergency

#17460832 at 2022-08-29 20:54:23 (UTC+1)
Q Research General #21401: FBI Buried & New Election Edition

Biden Admin. Announces $11M For Monkeypox Vaccine Production

The U.S. Department of Health and Human Services (HHS) will provide approximately $11 million to support the first U.S.-based fill and finish manufacturing of JYNNEOS - a vaccine approved to prevent smallpox and monkeypox - at Grand River Aseptic Manufacturing (GRAM) in Grand Rapids, Michigan.

The agreement between the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR), and GRAM aids the company in accelerating the fill and finish manufacturing qualification and production in its recently expanded facility. The funding will allow GRAM to purchase additional equipment necessary for JYNNEOS production and recruit and train additional staff to operate the line. With BARDA's support, vaccine production at the facility is expected to be underway later this year, months ahead of the 9-month schedule typical for this type of work.

"We continue to build on our efforts to secure and make safe and effective vaccines readily available," said HHS Secretary Xavier Becerra. "This new agreement solidifies a domestic manufacturing capability that will bring us more vaccine sooner to end this outbreak."

On August 18, Bavarian Nordic, maker of JYNNEOS, and GRAM announced an agreement to establish this first U.S.-based fill and finish capability for the JYNNEOS vaccine, an agreement facilitated by BARDA. Even prior to that agreement, Bavarian Nordic and GRAM had begun working together on the technology transfer to enable the opening of a U.S.-based line.

"Rapidly increasing the supply and safe delivery of monkeypox vaccine to at-risk Americans is a top priority," said Assistant Secretary for Preparedness and Response Dawn O'Connell. "BARDA's support helps ensure success in doubling the capacity available to fill and finish this vaccine, improves preparedness for smallpox bioterrorism, and strengthens the security of the U.S. supply chain. Production of JYNNEOS in the U.S. creates jobs and speeds the availability of the vaccine."

In July, to support the current monkeypox outbreak and future smallpox preparedness, BARDA placed orders for fill, finish, and delivery of 5 million vials of JYNNEOS from U.S. government-owned bulk vaccine stored in Denmark. In that contract, Bavarian Nordic agreed to complete a technology transfer that would allow a U.S.-based contract manufacturer to fill and finish 2.5 million vials of JYNNEOS.

The new manufacturing support at GRAM is the latest in ASPR's efforts to expand the capacity and capability in the U.S. to manufacture medical supplies, equipment, and the materials used to make medical supplies. These efforts enhance the U.S response to public health emergencies; the COVID-19 pandemic demonstrated the need to expand the U.S. industrial base for vaccine production. To date, ASPR has invested nearly $6.9 billion in manufacturing expansion to produce vaccines, glass vials, nitrile gloves, surgical gowns, test swabs, the raw materials needed for diagnostic tests, therapeutics and vaccines.

https://breaking911.com/biden-admin-announces-11m-for-monkeypox-vaccine-production/

#16743431 at 2022-07-16 11:44:49 (UTC+1)
Q Research General #21119: Early Morning Weekend Edition

>>16743022
>"said Dr. Rick Bright, CEO of the Pandemic Prevention Institute and former director of the Biomedical Advanced Research and Development Authority."

Funny/not funny how the article spells out BARDA - the Biomedical equivalent of DARPA - and his 2021 'disclosures' re: lack of efficacy associated with use of chloroquine and hydroxychloroquine as therapeutic treatments for COVID-19 or how he rec'd a 'whistleblower' settlement from the govt.

https://osc.gov/News/Pages/20-21-Settlement-Rick-Bright.aspx

#16743022 at 2022-07-16 08:43:04 (UTC+1)
Q Research General #21119: Early Morning Weekend Edition

Rockefeller Foundation "Pandemic Prevention Institute" CEO Rick Bright's has concerns for COVID-19 BA.5 Variant

Are you confused about BA.5 and the current state of the pandemic? Here's how the experts are thinking about it.

There's a gap between what's happening with the transmissible variant and the U.S. response, says Rick Bright, CEO of the Pandemic Prevention Institute.

"We're dropping our guard at the same time the virus is upping its game," said Dr. Rick Bright, CEO of the Pandemic Prevention Institute and former director of the Biomedical Advanced Research and Development Authority.

https://www.marketwatch.com/story/are-you-confused-about-ba-5-and-the-current-state-of-the-pandemic-heres-how-the-experts-are-thinking-about-it-11657889497?mod=home-page


Rick Arthur Bright is an American immunologist, vaccine Researcher, and public health official.

In May 2020, he filed a whistleblower complaint, alleging that the Trump administration ignored his early warnings about the COVID-19 pandemic and illegally retaliated against him by ousting him from his role and demoting him to a position at the National Institutes of Health.

On October 6, 2020, Bright resigned from the government.

On November 9 he was named a member of President-elect Joe Biden's coronavirus advisory board.

In March 2021 he was hired by the Rockefeller Foundation as Senior Vice President of Pandemic Prevention and Response. His assignment is to "lead the Foundation's work to collaborate with leading global public health emergency organizations and entities to develop a pandemic prevention institute that aims to avert future pandemics by identifying and responding to the earliest alerts of a disease outbreak and stopping it in the first 100 days."

https://en.wikipedia.org/wiki/Rick_Bright


Pandemic Prevention Institute at the The Rockefeller Foundation

https://www.rockefellerfoundation.org/pandemicpreventioninstitute/

#16431297 at 2022-06-11 19:10:12 (UTC+1)
Q Research General #20787: Wizard Edition

Biden Admin Orders 500,000 More Monkeypox Vaccines

The Biden administration has ordered an additional 500,000 more doses of the Jynneos vaccine for monkeypox, marking a big step up in the government's response amid rising cases in the United States and around the world.

Denmark-based biotech group Bavarian Nordic, the manufacturer of the vaccines, said that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has placed the order, to be delivered later this year.

"With the previous order from BARDA for 1.4 million doses of liquid-frozen JYNNEOS, awarded in 2020, this order will bring the total U.S. inventory of the vaccine to nearly 2 million doses," the company announced on Friday. Many of the 1.9 million doses are being held by the company until the U.S. government requests them.

The 500,000 vaccine doses will be manufactured using bulk materials that are owned by the United States under previous contracts with BARDA, and are currently stored with the company.

"The majority of this bulk, however, will be converted to approximately 13 million freeze-dried doses of JYNNEOS during 2023-2025," Barvarian Nordic said.

Dawn O'Connell, Assistant Secretary for Preparedness and Response, said on Friday that the U.S. government has a stockpile of 72,000 Jynneos doses, and will get 300,000 more doses from Bavarian Nordic over the next several weeks. She also confirmed that 500,000 more Jynneos doses from Bavarian Nordic will be delivered later this year.

"We have the vaccines and treatments we need to respond," she said.

As of late Friday, the United States has identified 49 monkeypox cases in 16 states and the District of Columbia. More than 1,470 cases have been found in about 30 other countries outside of Africa, where the virus is endemic, according to the Center for Disease Control and Prevention (CDC).

https://www.ntd.com/biden-admin-orders-500000-more-monkeypox-vaccines_792715.html

#16320737 at 2022-05-22 08:18:10 (UTC+1)
Q Research General #20646: Rolling in to Sunday Edition

Not "Monkeypox", VaxxPox™
Covid vaccines were the trojan horse and the foot in the door for globohomos latest "Monkeypox" false flag operation which will seek to exploit vaccine adverse events such as Bullous Pemphigoid (BC) in conjunction with the (ongoing) fraudulent misuse of PCR to help manufacture (((their))) latest global scamdemic.

Back in Dec 2019 a company named 'Global Security Plus' (with cooperation from US Indo- Pacific Command) held an Event-201-style tabletop exercise named 'Operation Pacific Elipse' which simulated a global smallpox outbreak and consequent international response, as did NTI (the Nuclear Threat Initiative) who released a paper back in March 2021 which also ran scenarios surrounding a global Monkeypox outbreak, that coincidently occurs within our current timeline (May 2022 - June 2022)

In 2011 a company named Siga Technologies partnered with BARDA (Biomedical Advanced Research and Development Authority: Government department) and awarded a 1 billion dollar no-bid contract to provide the U.S govt anti-smallpox drugs, and in Sept 2021 delivered up to $113,000,000 of their TPOXX® oral smallpox treatment.
The controlling shareholder of Siga Technologies is none other than billionaire Ronald Perelman (see:Jeffrey Epsteins little black book.)

>March 23rd 2022
https://www.instagram.com/p/CbbJtwmPciJ/

>Februrary 22nd 2022
https://www.instagram.com/p/CaQjoduvnEQ/

>Rare monkeypox outbreak in U.K., Europe and U.S.: What is it and should we worry?
https://www.npr.org/sections/goatsandsoda/2022/05/18/927043767/rare-monkeypox-outbreak-in-u-k-and-europe-what-is-it-and-should-we-worry

>Monkeypox contact tracing extended to Scotland
https://www.bbc.com/news/uk-scotland-61435476

>(Monkeypox) Diagnosis requires PCR tests
https://www.gavi.org/vaccineswork/five-things-you-need-know-about-monkeypox
>Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study
https://www.frontiersin.org/articles/10.3389/fmed.2022.841506/full

>Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report
https://www.sciencedirect.com/science/article/pii/S2049080122001807

>Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center
https://onlinelibrary.wiley.com/doi/10.1111/ijd.16086

>Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280592/

>Absolving COVID-19 Vaccination of Autoimmune Bullous Disease Onset
https://www.frontiersin.org/articles/10.3389/fimmu.2022.834316/full

>Global Security Plus - MULTIMEDIA FROM PACIFIC ECLIPSE, DEC 9-10, 2019
https://globalsecurityplus.org/multimedia-pacific-eclipse-dec-9-10-2019

>NTI - Strengthening Global Systems to Prevent and Respond to High-Consequence Biological Threats
https://www.nti.org/wp-content/uploads/2021/11/NTI_Paper_BIO-TTX_Final.pdf

>More than $1 billion in contract value awarded by the U.S. government
https://www.siga.com/about-siga/

>Epstein Little Black Book Ronald Perelman
https://epsteinsblackbook.com/pages/43

>Smallpox, Ronald Perelman, Siga Technologies Expos?
https://odysee.com/@ChadChaddington:d/Ron-Perelman,-Siga-Technologies-And-Smallpox-3:4

>MONKEYPOX, SMALLPOX UPDATES, PACIFIC ECLIPSE AND NTI NOVEMBER 2021 PAPER
https://www.bitchute.com/video/563SrdMX2jhE/
>PCR?
>We're going to have a million cases of non symptomatic people again aren't we?
Yep, and just to top it off, we're going to have a fuckload of symptomatic jabbies too that they can magically declare a positive "monkeypox case".
Vaxxpx™ is the gift that keeps on giving.

#15814978 at 2022-03-08 22:36:36 (UTC+1)
Q Research General #19998: March Madness Gets Madder Each Day Edition

>>15814811
cont…
Robert Kadlec: Accidental Bioweapon Tourist

Robert Kadlec describes himself as having been an "accidental tourist" regarding his introduction to biological warfare. An Air Force physician who had specialized in tropical diseases, Kadlec would later say his interest in the field began when he was assigned to be a special assistant for Chemical and Biological Warfare to the Joint Special Operations Command (JSOC), advising then-head of Special Operations Command Maj. Gen. Wayne Downing, on the eve of the first Gulf War.
https://www.nexusnewsfeed.com/article/human-rights/head-of-the-hydra-the-rise-of-robert-kadlec/

Wiki
In January 2018, Kadlec testified to the U.S. Congress that the US was dangerously unprepared for a pandemic.[7] Prior to the COVID-19 pandemic, Kadlec had heavily focused the office on preparing for a response to bioterror attacks, a choice that was later scruntinized.[8] From January through March 2020, Kadlec and his team focused on evacuating U.S. nationals from cruise ships and countries hard-hit by the pandemic; Kadlec's defenders said that this focus was necessary to protect Americans, while detractors criticized him for missing opportunities to prepare for pandemic COVID-19 in the United States.[8]
In April 2020, Kadlec demoted federal scientist Rick Bright, removing him from his position as head of the Biomedical Advanced Research and Development Authority (BARDA) and reassigning him to a lower post at the National Institutes of Health. The following month, Bright filed a wide-ranging whistleblower complaint against Kadlec and several Trump administration officials.[9][8] Bright asserted that Kadlec ousted him in retaliation for his "insistence" that the federal government focus resources on "safe and scientifically vetted" responses to the COVID-19 pandemic rather than "technologies that lack scientific merit" such as the use of hydroxychloroquine, which had been pushed by the Trump administration.[8] Bright also alleged that in January 2020, Kadlec had delayed acting to obtain face masks, testing swabs, and other materials for which there was later a shortage.[8] Supporters of Bright and supporters of Kadlec each accused the other "of preferential treatment for favored contractors and inappropriate spending decisions."[8] HHS denied that Bright had been retaliated against, but the Office of Special Counsel recommended Bright's reinstatement as BARDA chief,[8][9] finding a "substantial likelihood of wrongdoing" in his ouster.[9]
https://en.wikipedia.org/wiki/Robert_Kadlec

https://www.airuniversity.af.edu/Portals/10/CSDS/Books/battlefield_future2.pdf
http://dilyana.bg/the-pentagon-bio-weapons/

#15634682 at 2022-02-15 19:06:32 (UTC+1)
Q Research General #19769: Hillary Spies and Media hides Edition

Contracts For Feb. 14, 2022

ARMY

Eli Lilly and Co., Indianapolis, Indiana, was awarded a $1,080,000,000 firm-fixed-price contract for manufacture, distribution and storage of Bebtelovimab in support of the national emergency response to COVID-19. Bids were solicited via the internet with one received. Work will be performed in Indianapolis, Indiana, with an estimated completion date of Jan. 31, 2023. Health and Human Services Biomedical Advanced Research and Development Authority (HHS/BARDA) American Rescue Plan Act funds in the amount of $1,080,000,000 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity (W58P05-22-C-0012). (Awarded Feb. 10, 2022)
https://www.defense.gov/News/Contracts/Contract/Article/2934697/

#15620719 at 2022-02-14 00:13:41 (UTC+1)
Q Research General #19752: They Spied On The President Of The United States Edition

>>15620714
The Biomedical Advanced Research and Development Authority, or Barda, did announce in June 2021 that it would pay $1.2 billion for 1.7 million courses of Merck's investigational antiviral pill molnupiravir, but only if the FDA granted emergency-use authorization. That meant Merck had to put its own money at risk to expand manufacturing in advance, which may have reduced the supply that was available once the drug was authorized in December.

When the Delta variant slammed the South in July, GOP governors promoted the Regeneron and Eli Lilly monoclonal treatments. Supplies had to be rationed as demand surged. As the Delta wave crested in mid-September, the Pentagon and the Health and Human Services Department ordered 1.4 million more doses of Regeneron's antibody and 388,000 doses of Eli Lilly's.

Florida Gov. Ron DeSantis sought to circumvent the feds by ordering a monoclonal antibody treatment from GlaxoSmithKline and Vir. The antibody binds to a target on Covid-19 that is shared with the SARS virus, making it more difficult for variants to evade. It was authorized by the FDA in May, but the Biden administration then declined to add it to its meager treatment arsenal. This was a colossal mistake, since it was the only monoclonal treatment for infected patients that turned out to be effective against the Omicron variant.

The administration couldn't have anticipated that, but Operation Warp Speed's strategy was to diversify its bets expecting some to fail. The Biden team relied almost exclusively on Regeneron and Eli Lilly antibodies, even though scientists had warned that new variants might be able to evade them. The additional doses that Barda ordered in September were helpful for a couple of months until Omicron arrived.

Only in November did GSK and Vir announce a $1 billion contract with Barda. Around the same time Barda reached a $5.3 billion agreement with Pfizer for 10 million courses of its oral antiviral Paxlovid. Had it ordered these treatments earlier, much more supply would have been available this winter.

Why did the new administration abandon the successful Operation Warp Speed playbook? Most likely because progressives loathe pharmaceutical companies. Recall how congressional Democrats attacked Mr. Slaoui, a former GSK executive, without evidence, accusing him of profiting off his public service. Or maybe the Biden team believed their own cynical 2020 campaign line that Operation Warp Speed "lacks sound leadership, global vision, or a strategy."

Asked by New York Times columnist Ezra Klein last week whether the government should adopt OWS's strategy for other technologies, Mr. Klain replied: "I think we have to be careful about the level of government intervention in the economy and make sure that we're not putting our judgment in the place of private-sector thoughts and consumer demand and whatnot. I think vaccines are a very, very special case, a public good we wanted everyone to get."

He's right, but life-saving Covid-19 therapies are also a special case. At the same time, the Biden administration wants to spend hundreds of billions of dollars intervening in the economy to support green energy technologies that consumers largely don't want and are unlikely to do much public good.

https://www.wsj.com/articles/operation-warp-speed-slowly-gets-its-due-covid-deaths-vaccine-omicron-monoclonal-antibodies-biden-11643646972

#15605268 at 2022-02-12 00:01:30 (UTC+1)
Q Research General #19733: The People's Protest Edition

Contracts For Feb. 11, 2022
ARMY
AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, was awarded an $855,000,000 modification (P00005) to contract W911QY-20-C-0119 for the manufacture, distribution and storage of AZD7442, known as Evusheld, to treat COVID-19 in the general population. Work will be performed in various locations, with an estimated completion date of March 31, 2023. Health and Human Services Biomedical Advanced Research and Development Authority (HHS BARDA) Coronavirus Aid, Relief and Economics Security Act funds in the amount of $405,300,000; and HHS BARDA American Rescue Plan Act funds in the amount of $449,700,000, were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity.
https://www.defense.gov/News/Contracts/Contract/Article/2932911

#15458254 at 2022-01-25 17:17:26 (UTC+1)
Q Research General #19552: Listen Up F*ckers, Time to Start the Convoys and Take Amerca Back Edition

>>15458250
>Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health
Sec. 3. National Influenza Vaccine Task Force. (a) There is hereby established a National Influenza Vaccine Task Force (Task Force). The Task Force shall identify actions to achieve the objectives identified in section 2 of this order and monitor and report on the implementation and results of those actions. The Task Force shall be co-chaired by the Secretary of Defense and the Secretary of Health and Human Services, or their designees.
(b) In addition to the Co-Chairs, the Task Force shall consist of a senior official from the following executive branch departments, agencies, and offices:
(i) the Department of Defense (DOD);
(ii) the Department of Justice;
(iii) the Department of Agriculture;
(iv) the Department of Veterans Affairs (VA);
(v) the Department of Homeland Security;
(vi) the United States Food and Drug Administration;
(vii) the Centers for Disease Control and Prevention;
(viii) the National Institutes of Health (NIH);
(ix) the Centers for Medicare and Medicaid Services (CMS); and
(x) the Biomedical Advanced Research and Development Authority (BARDA).
(c) The Co-Chairs may jointly invite additional Federal Government representatives, with the consent of the applicable executive department, agency, or office head, to attend meetings of the Task Force or to become members of the Task Force, as appropriate.
(d) The staffs of the Department of State, the Office of Management and Budget (OMB), the National Security Council, the Council of Economic Advisers, the Domestic Policy Council, the National Economic Council, and the Office of Science and Technology Policy (OSTP) may attend and participate in any Task Force meetings or discussions.
(e) The Task Force may consult with State, local, tribal, and territorial government officials and private sector representatives, as appropriate and consistent with applicable law.
(f) Within 120 days of the date of this order, the Task Force shall submit a report to the President, through the Assistant to the President for National Security Affairs, the Assistant to the President for Domestic Policy, the Director of the Office of Management and Budget, and the Director of the Office of Science and Technology Policy. The report shall include:
(i) a 5-year national plan (Plan) to promote the use of more agile and scalable vaccine manufacturing technologies and to accelerate development of vaccines that protect against many or all influenza viruses;
(ii) recommendations for encouraging non-profit, academic, and private-sector influenza vaccine innovation; and
(iii) recommendations for increasing influenza vaccination among the populations recommended by the CDC and for improving public understanding of influenza risk and informed influenza vaccine decision-making.
(g) Not later than June 1 of each of the 5 years following submission of the report described in subsection (f) of this section, the Task Force shall submit an update on implementation of the Plan and, as appropriate, new recommendations for achieving the policy objectives set forth in section 2 of this order.

#15046358 at 2021-11-21 01:47:59 (UTC+1)
Q Research General #19036: Remove the liability protection [for vaccine developers] Edition

>>15045737 lb notable

Tembexa was approved on fast-track status last year as a small pox treatment - developed by company Chimerix.

Well, this drug was actually developed in tandem with BARDA. Per Wikipedia, "Biomedical Advanced Research and Development Authority (BARDA) is a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases."

Snippet from press release announcing Tembex approval on Chimerix website:

" Chimerix developed the TEMBEXA oral formulations as medical countermeasures for the treatment of smallpox under an ongoing collaboration with BARDA, part of the office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, under contract number HHSO100201100013C.

TEMBEXA's approval is based on efficacy data in two lethal orthopoxvirus animal models of human smallpox disease, the rabbitpox model (New Zealand White rabbits infected with rabbitpox virus) and the mousepox model (BALB/c mice infected with ectromelia virus). In the pivotal studies in each model, TEMBEXA treatment resulted in statistically significant survival benefit versus placebo following delayed treatment after animals were infected with a lethal viral dose. The FDA's 'Animal Rule' allows for testing of investigational drugs in animal models to support effectiveness in diseases which are not ethical or feasible to study in humans. The TEMBEXA U.S. Prescribing Information has a BOXED WARNING for increased risk for mortality when used for longer duration; see below for Important Safety Information."

Among possible side effects listed at the bottom of the release is PERMANENT loss of reproductive capacity in males.

#14949903 at 2021-11-08 11:38:53 (UTC+1)
Q Research General #18912: Big Bird now has Long-term Health Problems Edition

SIGA(c) "Human Bio Armor" is the company that
"announced the exercise of a procurement option under its 75A50118C00019 (19C) contract with Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services for the delivery of oral TPOXX® treatment courses valued at approximately $112.5 million to the U.S. government. "

TPOXX is used to treat small pox. monkey pox, and to create FUD.

But it is the SIGA mission as the very first defense pharma contractor to keep us all safe with their new "bio armor. "

https://www.siga.com/

And the premiere product is the only authorized treatment for smallpox.
Who do you think owns SIGA the sole existing FDA approved treatment for the treatment of the incredibly small pox/cowpox/chicken pox family of vile but virile virii.

https://www.siga.com/about-siga/#products

To be clear we are seeing something new.

The birth of a new industry sector: Defense Pharma

Awesome work here.

This is some high level shilling.

#14887962 at 2021-10-30 20:23:05 (UTC+1)
Q Research General #18832: Nothing Can Stop What is Comfy Edition

>>14887922
https://www.ebolaoutbreakmap.com/listings/marburg-vaccine/


Fauci Receives Funding For New Marburg Vaccines For You
October 23, 2021
The Washington, DC-based Sabin Vaccine Institute announced on October 21, 2021, the Biomedical Advanced Research and Development Authority (BARDA) had exercised the third contract option, valued at $34.5 million, to advance the development of vaccines against Ebola Sudan and Marburg viruses.

#14846302 at 2021-10-24 06:39:06 (UTC+1)
Q Research General #18779: Keeping the Kitchen Klean Edition

>>14846289
By the way, when I saw the reference to the Biomedical Advanced Research and Development Authority (BARDA), my immediate thought went to FunVax. That clip may have been a hoax, but it may have been some kind of predictive programming in a way. Dean Hamer was doing that type of work for the NIH. He is famous for writing "The God Gene" that was the inspiration for the FunVax mockumentary project.

#14846143 at 2021-10-24 05:49:07 (UTC+1)
Q Research General #18779: Keeping the Kitchen Klean Edition

Here's a department I just learned about while perusing the 21st Century Cures Act:

Biomedical Advanced Research and Development Authority
https://www.phe.gov/about/barda/Pages/default.aspx
They are under HHS and probably deserve some Research.

I found them mentioned in SEC. 3093, but there may be other mentions in this legislation.

H.R.34 - 21st Century Cures Act, signed into law December 13, 2016.
https://www.congress.gov/bill/114th-congress/house-bill/34

#14765415 at 2021-10-11 15:32:17 (UTC+1)
Q Research General #18675: Capitol Police Whistleblower Inside Job: And We Know Edition

https://www.usatoday.com/story/news/health/2021/10/11/covid-vaccinations-molnupiravir-antiviral-pill-cases/6083682001/

Molnupiravir is Thors Hammer?

Molnupiravir was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE).[3] In 2014, DRIVE began a screening project funded by the Defense Threat Reduction Agency to find an antiviral drug targeting Venezuelan equine encephalitis virus (VEEV), which led to the discovery of EIDD-1931.[7] When turned into the pro-drug EIDD-2801 (molnupiravir), the compound also showed activity against other RNA viruses including influenza, Ebola, chikungunya, and various coronaviruses.[7]

The name of the drug was inspired by that of Thor's hammer, Mj?lnir. The idea is that the drug will strike down the virus, like a mighty blow from the god of thunder. [6]
In May 2020, Rick Bright filed a whistleblower complaint, alleging that the Trump administration ignored his early warnings about the COVID-19 pandemic, pressured him to inappropriately fast-track unproven drugs, and illegally retaliated against him by removing him from his role as head of the Biomedical Advanced Research and Development Authority (BARDA) in April 2020.[13][14]

Among these complaints, Bright objected to providing additional federal funding to Ridgeback Biotherapeutics to further develop molnupiravir into a treatment for COVID-19. He argued that although the drug had shown potential against coronaviruses including SARS-CoV-2, it had already received substantial government support.[14] Bright also wanted to see more safety data for molnupiravir before final sign-off, due to the fact that some other nucleoside analogue drugs had caused birth defects in animal studies.[14][15]

https://en.wikipedia.org/wiki/Molnupiravir

#14751806 at 2021-10-09 12:47:52 (UTC+1)
Q Research General #18659: Dawn of a New Day Shift Edition

>>14751799
"Partners include the FDA, CDC, even BARDA (Biomedical Advanced Research and Development Authority), and that awful person named Bright, B-R-I-G-H-T, from BARDA. The
big government agencies, NIH (National Institutes of Health) and NIAID are there. They're all there working with Bill Gates and CEPI in 2016, '17, and is planning meetings, and BARDA remains on his planning board with Rick Bright.

Breggin explained that Rick Bright was "the key man in the deep state" who prevented President Trump from opening up repurposed drug treatments in America, which arguably led to hundreds of thousands of unnecessary deaths.

He explained that the reason the early treatments were shot down was that we were supposed to be in "the Decade of Vaccine."

"That's all it was ever about," he argued. "It was never about anything else."

Everything that's happening to us was developed and planned ahead of time. Now, people say, 'We don't understand,' and that's really, almost everybody thinks that there was no animal testing of the vaccines, there wasn't time, and blah, blah, blah. Animal testing of these vaccines go back to the early 2020s. What am I saying? 2008, 2010, you'll find it in the book. What they continually found is that any vaccine, including, because several of the studies were about RNA or DNA vaccines, that any coronavirus vaccine for SARS-CoV-because remember, they're creating SARS-CoVs in the lab, lots of them, all kinds, so they can experiment with the vaccines.

You know what they use? They use what Ginger calls, my wife calls "Frankenmice." You take a poor mouse and you develop it abnormally so that it has human lung epithelia, and then you can
see what happens to the mouse, how these things kill the mice. They find that, first of all, the mutations are so rapid, it's going to be a problem, but worse than that, the vaccines that they do
give to the mice end up making them susceptible to horrible outcomes, if they actually get COVID. They don't get very good protection, and when they get COVID, they get very, very
sick and many of them die."

#14733755 at 2021-10-06 18:09:21 (UTC+1)
Q Research General #18637: Audits, Rhinos, CRT, Vaccine Pick one Edition

VIDEO Emerges of Fauci and HHS Officials Plotting for 'A New Avian Flu Virus' to Enforce Universal Flu Vaccination

Alex Jones of Infowars made a special broadcast on Monday night regarding an explosive video of Fauci with HHS officials and other health experts discussing how to enforce Universal Flu Vaccination in a summit organized by Milken Institute in Washington, DC last October 2019.

Alex Jones highlighted three clips from the hour-long video of the summit from C-SPAN which proved the COVID-19 pandemic was planned and the Big Pharma worked with the UN and other corrupt government officials to develop and release the COVID-19 virus ahead of 'Great Reset'.

The first clip featured Michael Specter, a journalist from The New Yorker and also an adjunct professor of bioengineering at Stanford University, Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, and Rick Bright, the director of HHS Biomedical Advanced Research and Development Authority (BARDA).

In this video, they conceptualized having a new outbreak of novel avian flu virus from China so they can bypass the method of FDA approval and enforce mRNA vaccine to the masses.

Here's the transcript:

Michael Specter: Why don't we blow the system up? I mean obviously, we can't just turn off the spigot on the system. We have and then say, hey everyone in the world should get this new vaccine that we haven't given to anyone yet. But there must be some way that we grow vaccines mostly in eggs the way we did in 1947.

Fauci: In order to make the transition from getting out of the tried-and-true egg growing which we know gives us results that can be beneficial, I mean we've done well with that. There must be something that has to be much better. You have to prove that this works and then you've got to go through all of the clinical trials: phase 1, phase 2, phase 3, and then show that this particular product is going to be good over a period of years. That alone, if it works perfectly, it's going to take a decade.

Bright: There might be a need or even an urgent call for an entity of excitement out there that's completely disruptive, that's not beholden to bureaucratic strings and processes.

Fauci: So we really do have a problem of how the world perceives influenza and it's going to be very difficult to change that unless you do it from within and save.. I don't care what your perception is, we're going to address the problem in a disruptive and in an iterative way because she does need both.

Bright: But it is not too crazy to think that an outbreak of novel avian virus could occur in China somewhere. We could get the RNA sequence from that.. to a number of regional centers if not local, if not even in your home at some point, and print those vaccines on a patch of self-administer.

https://rumble.com/vndrmn-explosive-video-of-fauci-and-hhs-plotting-for-a-new-outbreak-to-enforce-mrn.html

https://www.thegatewaypundit.com/2021/10/explosive-video-emerges-fauci-hhs-officials-plotting-new-avian-flu-virus-enforce-universal-flu-vaccination-video/

https://www.thegatewaypundit.com/2021/10/explosive-video-emerges-fauci-hhs-officials-plotting-new-avian-flu-virus-enforce-universal-flu-vaccination-video/

#14707163 at 2021-10-02 19:35:35 (UTC+1)
Q Research General #18603: Work Together To Get Her Edition

>>14706432 pb
here is the article.

Molnupiravir - What Wrong With America? Why Is the American Government And Agencies Funding And Pushing Potentially Toxic Drugs To Treat COVID-19?

In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties.
https://cen.acs.org/pharmaceuticals/drug-development/emerging-antiviral-takes-aim-COVID-19/98/web/2020/

A previous company, Pharmasset, that had investigated the drug's active ingredient and because of toxicity issues, had abandoned it. Rumour has yet that in order to keep the mouth of executives at Pharmasset shut about what they knew about molnupiravir and other drugs, the company was bought at an inflated price.

All these claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.
https://www.science.org/news/2020/05/emails-offer-look-whistleblower-charges-cronyism-behind-potential-covid-19-
drug

On May 5, 2020, Bright filed a whistleblower complaint ("Complaint of Prohibited Personnel Practice and Other Prohibited Activity") against the HHS in the U.S. Office of Special Counsel, an independent agency that protects whistleblowers. The complaint included accompanying exhibits, only some of which have become public. https://context-cdn.washingtonpost.com/notes/prod/default/documents/800d4444-437b-4fcf-aff5-c2db665778b0 /note/b2f67b4a-526a-4566-80f3-1acb60be79f6.

https://www.thailandmedical.news/news/molnupiravir-what-wrong-with-america-why-is-the-american-government-and-agencies-funding-and-pushing-potentially-toxic-drugs-to-treat-covid-19

#14623383 at 2021-09-20 18:56:29 (UTC+1)
Q Research General #18498: EBake Booms Incoming Edition

Judicial Watch Sues HHS for Biodistribution Studies for the Pfizer, Moderna and Johnson & Johnson Vaccines

(Washington, DC) - Judicial Watch, the government watchdog group, announced today that it filed a Freedom of Information Act (FOIA) lawsuit against the Department of Health and Human Services (HHS) for biodistribution studies and related data for the Pfizer, Moderna, and Johnson & Johnson vaccines (Judicial Watch v. U.S. Department of Health and Human Services (No. 1:21-cv-02418)).

This lawsuit was filed after the Food and Drug Administration, the Centers for Disease Control and Prevention and the National Institute for Allergy and Infectious Disease failed to respond to a June 8, 2021, FOIA request for:

[A]ccess to biodistribution studies and related data for the Pfizer, Moderna, and Johnson & Johnson vaccines used to treat and/or prevent SARS-CoV-2 and/or COVID-19.

Similarly, HHS's Biomedical Advanced Research and Development Authority (BARDA) failed to respond to the same request sent on July 15, 2021, after the National Institute for Allergy and Infectious Disease advised Judicial Watch that BARDA "would be the appropriate federal agency to submit a request," to obtain the records if they existed.

Biodistribution is a method of tracking where compounds of interest travel in an experimental animal or human subject.

"The Biden administration should follow the law and release any biodistribution studies concerning the vaccines," said Judicial Watch President Tom Fitton. "Americans have a right to know as much as possible about the safety and efficacy of the COVID-19 vaccines."

https://www.judicialwatch.org/press-releases/jw-vaccines/

#14529173 at 2021-09-06 08:15:31 (UTC+1)
Q Research General #18379: EBake

Lead Scientist For COVID Vaccine Vial Maker Indicted For Stealing Technology For China.

https://thenationalpulse.com/breaking/covid-vaccine-vial-maker-Researcher-indicted/


A former lead scientist for Corning Inc. - a technology company manufacturing glass vials for COVID-19 vaccines - was indicted for stealing company technology for use in China, including Chinese Communist Party-sanctioned business ventures.

Corning's Wang Ji was indicted on charges of economic espionage, theft of trade secrets, and unlawful exports. Wang, who worked for the company from 1998 to 2019, was a lead scientist on a Corning project developing optical laser fibers to attack hostile drones, which counted $16 million in funding from the U.S. government's Defense Advanced Research Projects Agency (DARPA).

He allegedly stole files relevant to the project to set up a business using the same technology in China and was in negotiations with several Chinese Communist Party authorities in the city of Tianjian to set up the company.

The indictment follows Corning, which supplies pharmaceutical companies such as Pfizer, receiving hundreds of millions of dollars from the U.S. government to manufacture glass vials for COVID-19 vaccines. The Biomedical Advanced Research and Development Authority (BARDA) granted Corning $204 million and the company received another $57 million infusion from the federal government in March of 2021.

If convicted, Wang will face a maximum penalty of 20 years in prison and a maximum fine of $5 million.

#14525980 at 2021-09-05 18:00:37 (UTC+1)
Q Research General #18375: Recall Rinos, the Audits must flow Edition

Lead Scientist For COVID Vaccine Vial Maker Indicted For Stealing Technology For China.

A former lead scientist for Corning Inc. - a technology company manufacturing glass vials for COVID-19 vaccines - was indicted for stealing company technology for use in China, including Chinese Communist Party-sanctioned business ventures.

Corning's Wang Ji was indicted on charges of economic espionage, theft of trade secrets, and unlawful exports. Wang, who worked for the company from 1998 to 2019, was a lead scientist on a Corning project developing optical laser fibers to attack hostile drones, which counted $16 million in funding from the U.S. government's Defense Advanced Research Projects Agency (DARPA).

He allegedly stole files relevant to the project to set up a business using the same technology in China and was in negotiations with several Chinese Communist Party authorities in the city of Tianjian to set up the company.

The indictment follows Corning, which supplies pharmaceutical companies such as Pfizer, receiving hundreds of millions of dollars from the U.S. government to manufacture glass vials for COVID-19 vaccines. The Biomedical Advanced Research and Development Authority (BARDA) granted Corning $204 million and the company received another $57 million infusion from the federal government in March of 2021.

If convicted, Wang will face a maximum penalty of 20 years in prison and a maximum fine of $5 million.

https://thenationalpulse.com/breaking/covid-vaccine-vial-maker-Researcher-indicted/

#14497073 at 2021-08-31 14:10:47 (UTC+1)
Q Research General #18339: Breaking! Patriots Rumored To Seek Out New States, And Audit Them Edition

The mRNA Vaccine: Clinical Trial on Humans

As COVID-19 vaccines-including Moderna and Pfizer-NBioTech's mRNA "gene-therapy" jabs-continue to be promoted and mandated as the primary "treatment" against SARS-CoV-2, other alternative therapies have been around for just as long as the vaccines but have been heavily censored by government agencies. With substantial funding from the U.S. Defense Department's Advanced Research Projects Agency (DARPA) since 2011, mRNA vaccine technology took center stage as a treatment for COVID, with both mRNA "vaccines" receiving Emergency Use Authorization (EUA). Still, one element missing from the emerging treatment was clinical proof of its effectiveness.

Despite Years of Study, mRNA Vaccines Lacked Trial on Large Scale
A 2017 article published in Nature called "The 'anti-hype' vaccine" starts by remarking that the idea of "vaccines-on-demand" is an "alluring, yet misleadingly simple, concept," adding that "such a vaccine would enable rapid-response agents against pandemic threats." Ignored for years, using RNA as a starting point for immunotherapy "ticks many of the boxes for a vaccine-on-demand offering advantages in manufacture, flexibility, scalability, and cost of goods." Nonetheless, clinical validation faced challenging obstacles, "such as antigen discovery, product formulation, and delivery."

The first mRNA vaccine to be injected into humans was a prostate cancer product developed by CureVac. Despite $110 million in funding from Bill Gates and German billionaire Dietmar Hopp in 2015, the product failed to improve survival over the standard of care in patients with prostate cancer. With sustained interest across the board-including the commitment from DARPA, specifically its Biological Technology Office (BTO) in D.C.- the failure of Curevac's mRNA prostate vaccine didn't stop funding, and Research continued. At the time, Matt Hepburn, program manager at DARPA's BTO, whose primary focus is having "platforms in place that can respond quickly in the case of a pandemic," commented:

"We like to think of ourselves as [funders of] early-breakthrough, high-risk, things that would not normally be funded. If you were going to do a safe Biomedical Research program with incremental approaches to solving a problem, that would not be us. Our mindset, day, night, 24/7, is what do we need to do to be ready for the next pandemic."
https://www.youtube.com/watch?v=T4-DMKNT7xI

2013 mRNA Pre-Clinical Trial on Rats
mRNA vaccines had their first opportunity to halt a pandemic in 2013 during an outbreak of H7N9, a deadly strain of Asian lineage Avian Influenza A in China. With funding from DARPA and Biomedical Advanced Research and Development Authority (aka BARDA, which supports the application and delivery side as opposed to the development side), scientists at Novartis took a gene sequence deposited in GenBank by the Chinese Center for Disease Control and Prevention and endeavored to make a vaccine "based on the electronic sequence." Andrew Geall, who was managing Novartis's mRNA vaccine program at the time, said:

"We were lucky enough to be collaborating with Craig Venter's teams, so we made a vaccine in 8 days, put it in mice in 13 days, and showed that, indeed, it works."

Interestingly, Venter's companies, Synthetic Genomics (whose Research also focuses on synthetic biofuels and animal products, along with Bill Gates) and Synthetic Genomics Vaccines, began working on "next-generation synthetic RNA replicon platforms" to develop vaccines for livestock in 2017. The same year, Synthetic Genomics partnered with Duke Human Vaccine Institute on DARPA's recently funded Pandemic Prevention Platform (P3), which "aimed at establishing a system capable of halting viral pandemics within 60 days." An October 26, 2017 press release announced:

#14374149 at 2021-08-17 02:24:28 (UTC+1)
Q Research General #18185: Preliminary Arizona 2020 Election Audit Report Coming Soon Edition

Moderna

USA Today acknowledges with Fauci is his having been "a co-reviewer of a vaccine platform Moderna is working to improve", as indicated by a 2019 Shareholder Letter. This refers to a review of vaccine technologies Fauci coauthored that was published last year in the journal Nature Reviews Immunology.
https://web.archive.org/web/20200913054217/https:/www.modernatx.com/moderna-blog/moderna-2019-shareholder-letter

Although USA Today doesn't mention it, the same letter, under the subheading "Partnerships", mentions having $187 million in funding from grants, with a footnote reference. The footnote specifies that the grants are from the Biomedical Advanced Research and Development Authority (BARDA), Defense Advanced Research Projects Agency (DARPA), and the Bill and Melinda Gates Foundation.

BARDA operates under the Department of Health and Human Services. DARPA is a Research and development agency of the Department of Defense.

That both Fauci and Gates have close ties to Moderna is no secret. Having encountered the headline in a news feed, I knew it was false and so did a quick Google search to document its falsity. It took about ten seconds to fact check USA Today's "Fact Check".

My search immediately turned up a page published in March on the website of the NIAID, which operates under the National Institutes of Health (NIH), announcing the beginning of a phase one clinical trial for Moderna's COVID-19 vaccine. The webpage notes that Fauci's NIAID is "funding the trial."

Furthermore, Moderna's candidate vaccine "was developed by NIAID scientists and their collaborators" at Moderna.

The page quotes Fauci saying that the trial was "an important step" toward developing "a safe and effective vaccine to prevent infection with SARS-CoV-2".

Similarly, I was able to immediately pull up a page from Moderna's website listing the Bill & Melinda Gates Foundation as a "strategic collaborator", with the foundation having "entered a global health project framework agreement" in January 2016 "to advance mRNA-based development projects for various infectious disases."

https://www.flagshippioneering.com/companies/moderna

https://www.jeremyrhammond.com/2020/09/16/fauci-gates-moderna/

https://www.niaid.nih.gov/news-events/nih-clinical-trial-investigational-vaccine-covid-19-begins

https://www.darpa.mil/

https://www.phe.gov/about/barda/Pages/default.aspx

#13685166 at 2021-05-17 18:07:09 (UTC+1)
Q Research General #17330: Ebake 11 Re-orderedEdition

White House Visitor Logs Reveal Fauci/Klain Situation Room Meeting After Gain of Function Moratorium.

A National Pulse review of White House Visitor Logs from November 2014 reveals a meeting in the White House Situation Room, chaired by then-Ebola Czar Ron Klain. The meeting appears to have been coordinated by Dr. Anthony Fauci, and included several high-level U.S. government agency heads.

The high profile summit came just weeks after the Obama administration issued a moratorium on the same "gain of function" experiments that Dr. Fauci now claims were never directly funded by his government agency to take place at the Wuhan lab in China.

Fauci's insistence, however, is betrayed by new analysis of the sequence of events and examples of his own staff headlining gain of function events in Wuhan.

President Obama and other senior White House officials - potentially including then-Vice President Joe Biden - may also have been present.

The Situation Room Summit, 2014.

On the morning of November 17th, 2014, Dr. Anthony Fauci made his way to the Eisenhower Executive Office Building (EEOB), otherwise known as the Old Executive Office Building (OEOB). The meeting was confirmed in the White House logs by Department for Homeland Security administrator Drew Cramer.

At 10am, he met with the man who would become known 7 years later as Joe Biden's "prime minister," Ron Klain. Four others joined Dr. Fauci, including former Walmart executive-turned-Health and Human Services staffer Leslie Dach.

David J Horowitz, who headed the legal side of the Ebola crisis; the Center for Disease Control's Mitchell Wolfe; and the founding director of the Biomedical Advanced Research and Development Authority (BARDA), Robin Robinson, were all present.

BARDA is described as being "responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases."

Included on the roster for the Situation Room were then Centers for Disease Control Director Thomas Frieden and Rear Admiral Stephen Redd of the U.S. Public Health Service. In other words: a top team discussion.

Visiting government officials are, as a matter of routine, noted in the official records. White House employees, including the President and Vice President, are never logged in this manner.

https://thenationalpulse.com/exclusive/white-house-visitor-logs-fauci-klain-gain-of-function/

#13280393 at 2021-03-23 09:09:24 (UTC+1)
Q Research General #16823: The '[They] Want You Divided By [insert topic here]' Edition

>>13280234, >>13280336, >>13280343, >>13280357

niaid.nih.gov
Statement-Investigational AstraZeneca Vaccine Prevents COVID-19
March 22, 2021

Results from a large clinical trial in the United States and South America indicate that AstraZeneca's COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization. The independent Data and Safety Monitoring Board (DSMB) overseeing the trial identified no safety concerns related to the vaccine. The United Kingdom-based global biopharmaceutical company AstraZeneca developed the vaccine and led the trial as regulatory sponsor.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, provided funding support for the trial through the federal COVID-19 response.
The placebo-controlled trial began in August 2020. The analysis is based on results from 32,449 adult volunteer participants enrolled across 88 sites in the United States, Chile and Peru. One participant received a placebo for every two participants who received AZD1222, resulting in approximately 20,000 people receiving the investigational vaccine. The vaccine was administered as two doses of 5 x1010 viral particles four weeks apart.
AZD1222 demonstrated statistically significant vaccine efficacy of 78.9% in preventing symptomatic COVID-19 and 100% efficacy in preventing severe or critical disease and hospitalization.In participants 65 years and older, who comprised 20% of the trial population, vaccine efficacy against symptomatic COVID-19 was 79.9%.
The DSMB conducted a review of thrombotic events (blood clots) and cerebral venous sinus thrombosis (CVST) among participants and found no increased risk of these conditions in vaccinated participants.
Approximately 79% of participants were white, 22% were Hispanic, 8% were Black or African American, 4% were Native American, including American Indian/Alaska Native participants residing in the U.S., and 4% were Asian. Vaccine efficacy was consistent across ethnicity. Approximately 60% of participants of any age had underlying health conditions associated with an increased risk of developing severe COVID-19, such as diabetes, severe obesity or cardiac disease.
Authorization and guidelines for use of the vaccine in the United States will be determined by the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) after thorough review of the data by independent advisory committees. Today's results build on data from multiple clinical trials of AZD1222 conducted worldwide. The World Health Organization has recommended use of the vaccine for prevention of COVID-19 in adults and it is currently available for use in more than 70 countries. The European Commission has granted a conditional marketing authorization for the vaccine in the European Union.
The current trial defined symptomatic COVID-19 as having SARS-CoV-2 infection and at least one respiratory symptom (pneumonia, shortness of breath or low oxygen requiring supplemental oxygen) or at least two of the following symptoms: fever, new or worsening cough, muscle pain, fatigue, vomiting and/or diarrhea, and loss of smell and/or loss of taste. Severe or critical COVID-19 was defined as having SARS-CoV-2 infection and any of the following: clinical signs of severe systemic illness, respiratory failure (defined as needing high-flow oxygen, noninvasive ventilation, mechanical ventilation or extracorporeal membrane oxygenation, known as ECMO), evidence of shock, significant acute renal, hepatic or neurologic dysfunction, or admission to an intensive care unit or death.
cont…
https://www.niaid.nih.gov/news-events/statement-investigational-astrazeneca-vaccine-prevents-covid-19

#13280234 at 2021-03-23 07:42:16 (UTC+1)
Q Research General #16823: The '[They] Want You Divided By [insert topic here]' Edition

>>13280165
>AstraZeneca may have included 'outdated' data in US vaccine trials
dug a little on this.
really SMELLS -
look at all the doublespeak in the Reuters article.
looks like a smokescreen for deception.
WHAT IS REALLY BEING SAID???

anons dig

AstraZeneca may have given incomplete data from latest Covid trial: US agency
Reuters

The Data and Safety Monitoring Board has notified the drugmaker, NIAID and the Biomedical Advanced Research and Development Authority that it was concerned by the information released by AstraZeneca on the initial data from its clinical trial

British drugmaker AstraZeneca Plc may have provided an incomplete view of efficacy data on its Covid-19 vaccine from a large scale U.S. trial, the US National Institute of Allergy and Infectious Diseases (NIAID) said on Tuesday, in a fresh setback to the shot.

AstraZeneca said a day earlier that its Covid-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in the United States, Chile and Peru.

"The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," the U.S. agency said, referring to the independent Data Safety Monitoring Board (DSMB).

"We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible."what the hell does that mean?

The request cast doubts over the company's plan to seek US emergency use authorization for the vaccine in the coming weeks.

Authorization and guidelines for use of the vaccine in the United States will be determined by the Food and Drug Administration and Centers for Disease Control and Prevention after thorough review of the data by independent advisory committees, said the NIAID, part of the National Institutes of Health.

AstraZeneca did not immediately respond to a Reuters request for comment.

https://www.livemint.com/companies/news/astrazeneca-may-have-included-outdated-info-from-us-vaccine-trial-niaid-11616475263009.html

#11734735 at 2020-11-22 06:27:49 (UTC+1)
Q Research General #14979: Dominion-izing the Vote / D5 Edition

Fetal Stem Cells Being Used

Several COVID-19 vaccine frontrunners, including those being developed by Moderna, Oxford University/AstraZeneca, CanSino Biologics/Beijing Institute of Biotechnology, and Inovio Pharmaceuticals, are using a human fetal kidney cell line called HEK-293 to develop their trial vaccines. HEK-293 was originally derived from kidney tissue taken from a baby girl who was aborted in the Netherlands in 1972 and later developed into a cell line in a lab in 1973.

Additionally, Janssen, the pharmaceutical division of consumer product giant Johnson & Johnson, is using the human fetal cell line PER.C6 to develop its vaccine. The PER.C6 fetal cell line was derived from retinal tissue taken from an 18-week-old baby boy who was aborted in the Netherlands in 1985 and later converted into a fetal cell line in 1995.

The U.S. government has made grants totaling nearly $2 billion in support of the development of COVID-19 vaccines using fetal cell lines. Most of this funding has been awarded through the Biomedical Advanced Research and Development Authority (BARDA), a division within the U.S. Department of Health and Human Services (HHS).

BARDA has awarded a $1.2 billion grant for AstraZeneca to fund Research for the trial vaccine it is jointly developing with Oxford University. BARDA has also made grants for up to $483 million for Moderna's vaccine and $456 million for Janssen Research and Development, LLC of Johnson & Johnson. Inovio has also received an unspecified grant for developing its vaccine candidate from the Defense Advanced Research Projects Agency (DARPA) at the Department of Defense.

On June 1st, BARDA issued a $628 million task order under a preexisting government contract with Emergent BioSolutions Inc. to accelerate development and manufacturing capacity for COVID-19 vaccines and drug treatments. Emergent BioSolutions is currently working with Janssen of Johnson & Johnson to manufacture their trial vaccines. BARDA's funding for Emergent, however, was not awarded specifically for scaling up production of J&J's vaccine candidate.

Worse still, the U.S. Centers of Disease Control and Prevention (CDC) has been producing samples of the SARS-CoV2 virus for biotech and pharmaceutical companies to use for vaccine Research using fetal HEK-293T cells (a decedent cell line of HEK-293).

https://www.pop.org/which-covid-19-vaccines-are-being-developed-with-fetal-cell-lines-derived-from-aborted-babies/

#11557769 at 2020-11-09 15:34:19 (UTC+1)
Q Research General #14756: Bush Legal Team From The 2000 Election Edition

By Jack Davis
Published November 9, 2020 at 8:03am
A policymaker who helped to bring the nation Obamacare has been announced as a leader of the COVID-19 effort under presumptive President-elect Joe Biden.
Dr. Ezekiel Emanuel, an architect of the Affordable Care Act and a former special adviser for health policy in the Barack Obama White House, was named to Biden's Transition COVID-19 Advisory Board, according to Fox News.
While Biden has the edge in the election, President Donald Trump has challenged the results in a post-election battle that as of Monday showed no signs of abating. The Democrat was declared the election's winner Saturday by several media organizations and is now moving to begin his transition.
The COVID-19 board will be chaired by David Kessler, a former Food and Drug Administration commissioner; Dr. Vivek Murthy, an Obama-era surgeon general; and Dr. Marcella Nunez-Smith, an associate professor of internal medicine, public health and management at Yale University.
Beth Cameron, another former Obama official, and Rebecca Katz, who was on Biden's campaign advisory committee for the disease, were named advisers to the COVID-19 transition group.
Other members include Dr. Luciana Borio, who served in several senior leadership positions at the FDA; Rick Bright, who served as director of the Biomedical Advanced Research and Development Authority and was deputy assistant secretary for preparedness and response at the Department of Health and Human Services; Dr. Atul Gawande; Dr. Celine Gounder; Dr. Julie Morita; Michael Osterholm, who served as a science envoy for health security on behalf of the State Department and as a state epidemiologist for Minnesota; Loyce Pace, who served in leadership positions at LIVESTRONG Foundation and the American Cancer Society; Dr. Robert Rodriguez; and Dr. Eric Goosby.
Bright criticized the Trump administration's coronavirus response in May, Fox News noted.
"Without better planning, 2020 could be the darkest winter in modern history," he said then.
In a statement on the transition website, Biden said, "The advisory board will help shape my approach to managing the surge in reported infections; ensuring vaccines are safe, effective, and distributed efficiently, equitably, and free; and protecting at-risk populations."
In an interview with MarketWatch, Emanuel said a full reopening of the U.S. is not likely before next fall.
"It'll be closer to November, closer toward the end" of 2021, he said, adding that the opening would be keyed to the speed at which Americans are vaccinated.

https://www.westernjournal.com/biden-just-unveiled-covid-advisory-board-contains-worrying-name/?ff_source=site&ff_medium=protrumpnews&ff_campaign=can

#11556347 at 2020-11-09 13:07:40 (UTC+1)
Q Research General #14754: While The World Sleeps, Anons Save It Edition

Joe Biden's transition team announces new COVID-19 task force

Joe Biden's transition team announced Monday a new coronavirus task force.

"Dealing with the coronavirus pandemic is one of the most important battles our administration will face, and I will be informed by science and by experts," Biden said in a statement, citing that the number of infections were rising in over 40 U.S. states. "The advisory board will help shape my approach to managing the surge in reported infections; ensuring vaccines are safe, effective, and distributed efficiently, equitably, and free; and protecting at-risk populations."

The Transition COVID-19 advisory board will be led by co-chairs Dr. David Kessler, a professor of pediatrics and epidemiology and biostatistics at UCSF, Dr. Vivek Murthy, who served as the 19th Surgeon General of the United States from 2014-2017, and Dr. Marcella Nunez-Smith, an associate professor of internal medicine, public health, and management at Yale University and associate dean for health equity Research at the Yale School of Medicine.

Serving as advisers to the Transition on COVID-19 are Dr. Beth Cameron, vice president for global biological policy and programs at the Nuclear Threat Initiative and former senior director for global health security and biodefense on the White House National Security Council staff, and Dr. Rebecca Katz, professor and director of the Center for Global Health Science and Security at Georgetown University Medical Center. They will work closely with the Advisory Board.

Members of the task force also include:

- Luciana Borio, senior fellow for global health at the Council on Foreign Relations, and specializes in biodefense, emerging infectious diseases, medical product development, and complex public health emergencies. She also served as Assistant Commissioner for Counterterrorism Policy and Acting Chief Scientist at the Food and Drug Administration, and Director of FDA's Office of Counterterrorism and Emerging Threats.

- Rick Bright, an American immunologist, virologist, and former public health official, and former director of the Biomedical Advanced Research and Development Authority 2016-2020 and the Deputy Assistant Secretary for Preparedness and Response at the Department of Health and Human Services. He also previously served as an advisor to the World Health Organization and the United States Department of Defense.

- Ezekiel J. Emanuel, an oncologist and Vice Provost for Global Initiatives and chair of the Department of Medical Ethics and Health Policy at the University of Pennsylvania. From January 2009 to January 2011, he served as special advisor for health policy to the director of the White House Office of Management and Budget. Since 1997, he has served as chair of the Department of Bioethics at The Clinical Center of the National Institutes of Health.

- Atul Gawande, the Cyndy and John Fish Distinguished Professor of Surgery at Brigham and Women's Hospital, Samuel O. Thier Professor of Surgery at Harvard Medical School, and Professor of Health Policy and Management at Harvard T.H. Chan School of Public Health. He previously served as a senior adviser in the Department of Health and Human Services in the Clinton administration.

- Celine Gounder, Clinical Assistant Professor at the NYU Grossman School of Medicine and cares for patients at Bellevue Hospital Center. From 1998 to 2012, Dr. Gounder studied TB and HIV in South Africa, Lesotho, Malawi, Ethiopia and Brazil. She is a former Assistant Commissioner and Director of the Bureau of Tuberculosis Control at the NYC Department of Health and Mental Hygiene.

- Julie Morita, Executive Vice President of the Robert Wood Johnson Foundation. Morita helped lead the Chicago Department of Public Health for nearly two decades as medical director, chief medical officer and commissioner. She is a member of the American Academy of Pediatrics and has served on many state, local, and national health committees.

- Michael Osterholm, Regents Professor, McKnight Presidential Endowed Chair in Public Health and the director of the Center for Infectious Disease Research and Policy at the University of Minnesota. Dr. Osterholm previously served as a Science Envoy for Health Security on behalf of the State Department. From 1975 to 1999, he worked in the Minnesota Department of Health.

- Loyce Pace is the Executive Director and President of Global Health Council. nd health services worldwide.

- Robert Rodriguez graduated from Harvard Medical School and currently serves as a Professor of Emergency Medicine at the UCSF School of Medicine.

- Eric Goosby, Professor of Medicine at the UCSF School of Medicine. During the Clinton administration, Dr. Goosby was the founding director of the Ryan White CARE Act, the largest federally funded HIV/AIDS program.

Moar at: https://www.marketwatch.com/story/joe-bidens-transition-team-announces-new-covid-19-task-force-2020-11-09

#11556335 at 2020-11-09 13:06:07 (UTC+1)
Q Research General #14754: While The World Sleeps, Anons Save It Edition

==Biden unveils Transition COVID-19 Advisory Board to 'help shape' approach to coronavirus pandemic
Board includes former Obama surgeon general Vivek Murthy and ObamaCare architect Ezekiel Emanuel==

The board will be led by co-chairs Dr. David Kessler, who served in both the George H.W. Bush and Clinton administrations as FDA commissioner; Dr. Vivek Murthy, the surgeon general under the Obama administration; and Dr. Marcella Nunez-Smith, an associate professor of internal medicine, public health and management at Yale University. Also on the board: Dr. Ezekiel Emanuel, an architect of the Affordable Care Act and former special adviser for health policy during the Obama administration.

Other members include Dr. Luciana Borio, who served in several senior leadership positions at the FDA; Dr. Rick Bright, who served as director of the Biomedical Advanced Research and Development Authority and as the deputy assistant secretary for preparedness and response at the Department of Health and Human Services under the Trump administration; Dr. Atul Gawande; Dr. Celine Gounder; Dr. Julie Morita; Dr. Michael Osterholm who served as a Science Envoy for Health Security on behalf of the State Department, and as a state epidemiologist for Minnesota; Dr. Loyce Pace, who served in leadership positions at LIVESTRONG Foundation and the American Cancer Society; Dr Robert Rodriguez; and Dr. Eric Goosby.

Meanwhile, Biden is expected to push to restore the Obama-era White House National Security Council Directorate for Health Security and Biodefense, while re-engaging with the World Health Organization.

Trump, in April, announced that the U.S. would freeze funding to the WHO, and threatened to make the freeze permanent if the organization did not enact "major substantive reforms." The U.S. had been the top contributor to the agency to the tune of approximately $450 million a year. China meanwhile pays approximately $50 million a year – although Beijing had recently announced a $2 billion injection of funds.

Biden is also expected to re-launch the U.S. Agency for International Development's pathogen tracking program called "PREDICT," and will call on all governors to enact mask mandates.

https://archive.is/5P9VX

#11286621 at 2020-10-26 13:29:49 (UTC+1)
Q Research General #14417: George Trump Edition

>>11286479

I decided to see what type of therapeutics and homeopathic treatment was out there for small pox, and came across this:

Smallpox Preparedness and Response Updates from FDA

What's new
November 15, 2019: FDA In Brief: FDA issues final guidance for development of smallpox treatments as part of critical preparedness efforts - FDA issued final guidance, Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention (PDF, 127 KB), which is designed to assist drug manufacturers designing studies to appropriately establish the safety and efficacy of drugs to treat or prevent smallpox infection. Also see Guidance for industry below
September 24, 2019: FDA announced the approval of Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating, for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. This is the only currently FDA-approved vaccine for the prevention of monkeypox disease. Jynneos will be available for those determined to be at high risk of either smallpox or monkeypox infection. This vaccine is also part of the Strategic National Stockpile (SNS), the nation's largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency that is severe enough to cause local supplies to be depleted. The availability of this vaccine in the SNS will help ensure that the vaccine is accessible in the U.S. if needed.

https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/smallpox-preparedness-and-response-updates-fda

BioFactura's Smallpox Biodefense Therapeutic Awarded $67M BARDA Contract

BioFactura, Inc. today announced a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $67.4 million for the Advanced development of its Smallpox Biodefense Therapeutic as a potential medical countermeasure (MCM) for the treatment of smallpox.

This product has the potential to fulfill an unmet need in preparedness for a second anti-viral therapeutic with a different mechanism of action to the current stockpile to guard against potential host resistance.

This contract for the development of the Smallpox Biodefense Therapeutic consists of a base phase, valued at approximately $9.5 million, and three option phases over a total of 5 years. Under the base period-of-performance, work will focus on the development of manufacturing processes for the drug components, final product formulation, analytical method development, stability studies and regulatory activities to support formal engagement with the FDA. In addition to the base, the contract also includes U.S. Government options that may be activated to support process optimization and clinical manufacturing, additional non-clinical development studies to support an Investigational New Drug filing, and a first-in-humans Phase 1 clinical study.

https://globalbiodefense.com/2019/09/26/biofacturas-smallpox-biodefense-therapeutic-awarded-67m-barda-contract/

#11248458 at 2020-10-24 04:45:39 (UTC+1)
Q Research General #14369 Comfy Friday Edition

>>11248428

continued:


Rick Bright, the former director of the Department of Health and Human Services' Biomedical Advanced Research and Development Authority, and claimed whistleblower, has been all over the mainstream news as of late projecting the "darkest winter in modern history."

Using this term was no accident, and in fact was meant as propaganda to frighten and alarm the populace that the second wave of the virus will happen and if we are to look back at the table top exercise it will happen because of a cooler than normal summer and a harsh winter that will keep the Atlantic Seaboard in a winter long lockdown.

The authorities are already preparing us for the possibility by indicating that not only are we seeing a "lockdown" of the sun due to sunspot inactivity but that also there are plans to continue to dim the sun in an effort to curb global warming.

Coincidentally here have been some unbelievably cold temperatures happening in the United States for the month of May as temperatures have dropped because of a Polar vortex over the Northeast- meanwhile Fairbanks Alaska clocked in at 82 degrees in the Pacific Northwest last week.

How is it there are such anomalous cold events on an ever rapidly warming planet?

While many of us have grown a bit tired of a lockdown - scientists have now determined that the sun is on lock down and the dears of global warming should be calmed as cooler temperatures are coming to the planet and possibly areas of the world that will be in famine.
The sun has entered into what is called "lockdown" which some scientists are warning could produce freezing weather, earthquakes, and famine in the near future. According to a report from the New York Post, The sun is currently in a period of "solar minimum," meaning activity on its surface has fallen dramatically.

It is no accident that scientist are calling it "lockdown" these are buzzwords that they want to make sure we hear - loud and clear.

Scientists believe we are about to enter the deepest period of "recession" for the sun that has ever been recorded as sunspots have virtually disappeared. Astronomer Dr. Tony Phillips recently stated: "Solar Minimum is underway and it's a deep one." "Sunspot counts suggest it is one of the deepest of the past century.

The sun's magnetic field has become weak, allowing extra cosmic rays into the solar system." "Excess cosmic rays pose a health hazard to astronauts and polar air travelers, affect the electro-chemistry of Earth's upper atmosphere, and may help trigger lightning."

According to the report, NASA scientists fear this event could produce be a repeat of the Dalton Minimum, which took place between 1790 and 1830 and lead to periods of brutal cold, crop loss, famine, earthquakes and powerful volcanic eruptions.

History showed that temperatures plummeted by up to 2 degrees Celsius (3.6 degrees Fahrenheit) over 20 years, devastating the world's food production. On April 10, 1815, the second-largest volcanic eruption in 2,000 years took place at Mount Tambora in Indonesia, killing at least 71,000 people.

The event also led to the so-called "Year Without a Summer" in 1816 - also nicknamed "eighteen hundred and froze to death" - when there was snow in July. Thus far in 2020, the sun has been "blank" with no sunspots 76 percent of the time, a rate surpassed only once before in the Space Age.

Last year the sun was 77 percent blank.

There is also the ever looming report of sun dimming projects that are meant to cool the planet through geoengineering.

Engineered snow storms are a major part of the ongoing climate engineering assault on our biosphere. Massive fluctuations of temperatures and conditions accompany such unnatural events. It is now becoming apparent that many so called natural weather anomalies are not natural any longer.

The way to tell if the weather has been engineered is to monitor temperature spikes and how unnatural occurrences such has softball sized hail and snow are falling during days that are above freezing are happening around the country.
How can there be so much snow after such high temperatures? Are we to think it should be snowing at temperatures in the 40s not far away from the forecast temperatures of 85 degrees or more in Chicago and areas even further north?

It is like the country is having microclimates as temperatures can top the 80's in one part of the area and have snow an hour's drive away. Weather modification patents are everywhere now and stratospheric aerosol injections are now part of a CIA program to cool the earth.

continued:

#11073730 at 2020-10-14 22:46:18 (UTC+1)
Q Research General #14162: Dem Peach Mint Debacle Goes All In Edition

FDA approves first Ebola treatment

The U.S. Food and Drug Administration (FDA) on Wednesday approved the world's first successful treatment for the Ebola virus, a major step against one of the world's deadliest pathogen.

The FDA gave its formal blessing to Inmazeb, a mixture of three monoclonal antibodies produced by the American pharmaceutical company Regeneron, after a trial among 382 adult and pediatric patients in the Democratic Republic of the Congo.

The new treatment is a breakthrough, but not one that completely eliminates the threat of a virus that can kill as many as nine in ten of those who contract it if they are not treated.

The mortality rates among patients who received the drug was substantially lower than those who were treated for the virus without the drug. About a third of those receiving the drug died, compared to just over half of those who did not.

The drug's development was funded by a public-private partnership between Regeneron and the Biomedical Advanced Research and Development Authority. The National Institutes of Health and Congo's Health Ministry helped administer the study.

"The approval of the first-ever therapeutic for Ebola is a momentous global health achievement that would have never occurred without American leadership," Health and Human Services Secretary Alex Azar said in a statement Wednesday.

The Ebola virus has infected humans almost a dozen times in Congo in modern history. An outbreak in Equateur Province, along the Congo River, had infected more than 100 people by mid-September, according to the World Health Organization. That conflagration erupted just as Congo's worst-ever epidemic, in two eastern provinces along the borders with Uganda and Rwanda, came under control.

Global health officials got that outbreak under control in part with the help of an American-developed vaccine, also the first of its kind.

Both the treatment and the vaccine were developed in the wake of the world's worst-known Ebola outbreak, which struck three West African countries in 2014 and 2015. More than 11,300 people died in that epidemic.

The new drug is meant to treat the most common form of the Ebola virus, the Zaire strain that was first identified in 1976, before the DRC changed its name. Zaire ebolavirus has infected far more people than the other four known strains of Ebola, and it kills a substantially higher percentage of its victims.

https://thehill.com/policy/healthcare/521097-fda-approves-first-ebola-treatment

#10906746 at 2020-10-03 22:18:38 (UTC+1)
Q Research General #13958: As Always, Anons Know Edition

Regeneron: Wikipedia Excerpts

https://en.wikipedia.org/wiki/Regeneron_Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988.[4] Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.

Company history

Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.

On March 26, 2012, Bloomberg announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72% more than the leading brands. The new drug targets the PCSK9 gene.[5][citation needed]

In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron,[6] with $640 million upfront, $750 million for proof of concept data and $650 million from the development of REGN2810.[7] REGN2810 was later named cemiplimab. In 2019, Regeneron Pharmaceuticals was announced the 7th best stock of the 2010s, with a total return of 1,457%.[8]

Regeneron Pharmaceuticals was home to the two highest-paid pharmaceutical executives as of 2020.[9]

During the COVID-19 pandemic, in early 2020, Regeneron made a deal with the US-government Biomedical Advanced Research and Development Authority that the government would fund 80% of the costs for Regeneron to develop and manufacture Coronavirus disease 2019 treatments, and Regeneron would retain the right to set prices and control production. This deal was criticized in the New York Times. Such deals are not unusual for routine drug development in the American pharmaceutical market.[9]

In May 2020 Regeneron announced it would repurchase around $5 billion of its shares, held directly by Sanofi. Prior to the transaction Sanofi held 23.2 million Regeneron shares.[10]

As of September 2020, Regeneron is evaluating an artificial "antibody cocktail", REGN-COV2, for its potential both to treat people with COVID-19 and to prevent SARS-CoV-2 coronavirus infection.[11][12][13]

#10523875 at 2020-09-04 07:51:14 (UTC+1)
Q Research General #13468: I Have No Idea What I'm Doing Edition

National Academy of Medicine held workshop on "tackling issues of access and hesitancy" on vaccines in August - COVID and vaccine confidence were keynote speeches

https://www.nationalacademies.org/event/05-28-2020/the-critical-public-health-value-of-vaccines-tackling-issues-of-access-and-hesitancy-a-workshop
https://www.youtube.com/watch?v=rjWp9_Tx87M&list=PLGTMA6Qkejfi6eXu5XGcdKlfe4dEsfVlt

The National Academy of Medicine (NAM) held an virtual event on August 17-20, 2020 named "The Critical Public Health Value of Vaccines - Tackling Issues of Access and Hesitancy". The event was conducted under the Forum of Microbial Threats of the National Academies of Sciences, Engineering, and Medicine. Note that Victor Dzau is the President of NAM and is a key stakeholder in Event 201. Dzau also serves as a member of China's CDC.

Panelists stated that doctors will be used to help increase vaccine confidence. One of the speeches was from Dorit Reiss, a pro-vax law Professor, who stated that the law could be used to promote compliance and access to vaccinations. https://www.youtube.com/watch?v=n96-yE6k_R8


Sponsors of the Forum:
? Biomedical Advanced Research and Development Authority
? U.S. Agency for International Development
? U.S. Centers for Disease Control and Prevention
? U.S. Department of Homeland Security
? U.S. Department of Veterans Affairs
? U.S. Food and Drug Administration
? U.S. National Institutes of Health
? Uniformed Services University of the Health Sciences
? American Society of Tropical Medicine and Hygiene
? EcoHealth Alliance
? Infectious Diseases Society of America
? Johnson & Johnson
? Merck & Co., Inc.
? Sanofi Pasteur


Event keynote speeches:
The Global Impact of COVID-19 on Vaccination Uptake and Access
ANN LINDSTRAND
EPI Coordinator, World Health Organization, Department of Immunization and Biologicals

The Global State of Vaccine Confidence: How Do We Enhance the Uptake of Vaccines?
SAAD B. OMER
Director, Yale Institute for Global Health


Event moderators:
- Matthew Zahn, Orange County Health Care Agency, Workshop Co-Chair
- Noni MacDonald, Dalhousie University
- Alison Buttenheim, University of Pennsylvania
- Chandy C. John, Indiana University School of Medicine
- Rafael Obregon, UNICEF, Paraguay
- Kent Kester, Sanofi Pasteur (Vice-Chair of the Forum on Microbial Threats)
- Alison Buttenheim (University of Pennsylvania)
- Amanda Cohn, U.S. Centers for Disease Control and Prevention


Planning committee included:
Amanda Cohn, M.D.
Executive Secretariat, Advisory Committee on Immunization Practices
Acting Chief Medical Officer, National Center for Immunization and Respiratory Diseases
U.S. Centers for Disease Control and Prevention

Walter Orenstein, M.D.
Professor, Emory University
Associate Director, Emory Vaccine Center
Director, Emory Vaccine Policy and Development

Heidi Larson, M.A., Ph.D. (Co-Chair)
Professor of Anthropology, Risk and Decision Science
London School of Hygiene & Tropical Medicine
Director, The Vaccine Confidence Project


Agenda:
>Session I: Improving Access and Closing the Global Immunization Gap
Objectives:
? Assess the current state of vaccine-preventable diseases globally, delineating the key barriers to dissemination and uptake of vaccines.
? Examine evidence-based strategies to improve access to vaccines and increase immunization coverage, globally and locally.

>Session II: Assessing Global and Local Drivers of Vaccine Hesitancy
Objectives:
?Examine trends in hesitant attitudes toward vaccination and the impact on declining immunization rates.
?Evaluate the complex determinants and drivers of vaccine uptake, including sociocultural factors that influence perceptions, attitudes, and behaviors towards vaccination.
?Explore methods to monitor and measure vaccine hesitancy to better address concerns, and to sustain confidence in vaccination.

>Session III: Employing a Systems Approach to Building Confidence and Increasing Uptake
Objectives:
?Explore opportunities in Research, communication, legislation, and technology in influencing vaccine behavior, improving access, and building confidence in immunization practices.
?Discuss how community-based approaches and strategies can effectively and ethically be employed to reduce vaccine hesitancy and increase vaccine confidence.

Session IV: Moving Forward: Optimizing the Utilization of Vaccines
Objectives:
?Discuss the impact of vaccines in mitigating the effects of emerging threats during an outbreak.
?Discuss approaches to strengthen public trust in science and public health programs.
?Synthesize priority actions that could ensure that immunization programs reach the last mile.

>>10523161 (pb) on Walter Orenstein

#10100149 at 2020-07-28 12:22:22 (UTC+1)
Q Research #12926: Almost an E-Bake Edition

Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine

Today, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate donated to the Strategic National Stockpile to be used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation in a clinical trial was not feasible. The agency determined that the legal criteria for issuing an EUA are no longer met. Based on its ongoing analysis of the EUA and emerging scientific data, the FDA determined that chloroquine and hydroxychloroquine are unlikely to be effective in treating COVID-19 for the authorized uses in the EUA. Additionally, in light of ongoing serious cardiac adverse events and other potential serious side effects, the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks for the authorized use. This is the statutory standard for issuance of an EUA. The Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services originally requested the EUA covering chloroquine and hydroxychloroquine, and the FDA granted the EUA on March 28, 2020 based on the science and data available at the time. Today, in consultation with the FDA, BARDA sent a letter to the FDA requesting revocation of the EUA based on up to date science and data.

"We've made clear throughout the public health emergency that our actions will be guided by science and that our decisions may evolve as we learn more about the SARS-CoV-2 virus, review the latest data, and consider the balance of risks versus benefits of treatments for COVID-19," said FDA Deputy Commissioner for Medical and Scientific Affairs Anand Shah, M.D. "The FDA always underpins its decision-making with the most trustworthy, high-quality, up-to-date evidence available. We will continue to examine all of the emergency use authorizations the FDA has issued and make changes, as appropriate, based on emerging evidence."

The FDA has a responsibility to regularly review the appropriateness of an EUA, and as such, the agency will review emerging information associated with the emergency uses for the authorized products. Recent results from a large randomized clinical trial in hospitalized patients, a population similar to the population for which chloroquine and hydroxychloroquine were authorized for emergency use, demonstrated that hydroxychloroquine showed no benefit on mortality or in speeding recovery. This outcome was consistent with other new data, including data showing that the suggested dosing regimens for chloroquine and hydroxychloroquine are unlikely to kill or inhibit the virus that causes COVID-19. The totality of scientific evidence currently available indicate a lack of benefit.

"While additional clinical trials continue to evaluate the potential benefit of these drugs in treating or preventing COVID-19, we determined the emergency use authorization was no longer appropriate. This action was taken following a rigorous assessment by scientists in our Center for Drug Evaluation and Research," said Patrizia Cavazzoni, M.D., acting director of the FDA's Center for Drug Evaluation. "We remain committed to using every tool at our disposal in collaboration with innovators and Researchers to provide sick patients timely access to appropriate new therapies. Our decisions will always be based on objective and rigorous evaluation of the scientific data.This will never change."

Chloroquine and hydroxychloroquine are both FDA-approved to treat or prevent malaria. Hydroxychloroquine is also approved to treat autoimmune conditions such as chronic discoid lupus erythematosus, systemic lupus erythematosus in adults, and rheumatoid arthritis. Both drugs have been prescribed for years to help patients with these debilitating, or even deadly, diseases, and FDA has determined that these drugs are safe and effective when used for these diseases in accordance with their FDA-approved labeling. Of note, FDA approved products may be prescribed by physicians for off-label uses if they determine it is appropriate for treating their patients, including during COVID.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and

#10055945 at 2020-07-23 17:30:42 (UTC+1)
Q Research General #12869: Pics Up! Make Em Count! Edition

NIH leadership details unprecedented initiative to ramp up testing technologies for COVID-19

https://www.nih.gov/news-events/news-releases/nih-leadership-details-unprecedented-initiative-ramp-testing-technologies-covid-19?utm_source=dlvr.it&utm_medium=twitter

In a paper in the New England Journal of Medicine(link is external), scientific leaders from the National Institutes of Health set forth a framework to increase significantly the number, quality and type of daily tests for detecting SARS-CoV-2, the virus that causes COVID-19, and help reduce inequities for underserved populations that have been disproportionally affected by the disease. The authors describe the current testing landscape and explain the urgent need for nationwide deployment of low-complexity, point-of-care molecular diagnostics with rapid results. To fill this urgent need, the Rapid Acceleration of Diagnostics (RADx) program was established in just five days following the announcement of $1.5 billion in federal stimulus funding in April 2020. RADx covers the entire life cycle of the target testing technologies, is tightly focused on timelines and outcomes, receives applications from small and large companies and is expressly focused on health disparities. While based at NIH, RADx is closely coordinating with the Office of the Assistant Secretary for Health, the Biomedical Advanced Research and Development Authority, and the Department of Defense.

Current testing methods to diagnose COVID-19 detect either viral RNA or viral antigens. These tests are highly sensitive and specific when conducted in centralized laboratories with standardized protocols, but require a large amount of lab space, complex equipment, regulatory approvals for the laboratory operations and skilled technicians. Results may take hours to days, and samples often need transport to a central laboratory, furthering delays. During that time someone who is unknowingly carrying the virus may go on to infect others, instead of being quickly isolated. These issues highlight the need for reliable, rapid, point-of-care testing diagnostics.

RADx includes four major components to enable approximately 6 million daily tests in the United States by December 2020, many times the current daily testing rate. In the near term, RADx confronts the pandemic by expanding testing capacity by fall 2020 as the nation faces the beginning of seasonal flu. In the slightly longer-term RADx aims to produce additional innovative diagnostic technologies and strategies for making testing available to diverse, vulnerable and underserved populations.

#10053754 at 2020-07-23 12:10:13 (UTC+1)
Q Research General #12866: "Mayor Wheeler protest fail" Edition

>>10053634
>>10053698
>http://homenewshere.com/news/state/article_fa5aa8cb-2744-5b54-b243-212ee611df4d.html

Thermo Fisher Scientific Reports Second Quarter 2020 Results

By Thermo Fisher Scientific Jul 22, 2020 Updated 23 hrs ago

WALTHAM, Mass., July 22, 2020 /PRNewswire/ – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2020.

Second Quarter 2020 Highlights

Second quarter revenue increased 10% to $6.92 billion.
Second quarter GAAP diluted earnings per share (EPS) increased 5% to $2.90.
Second quarter adjusted EPS increased 28% to $3.89.
Leveraged our industry-leading scale and expertise to meet strong global demand for COVID-19 products and services. Highlights in the second quarter included:
Generated approximately $1.3 billion of COVID-related revenue
Received expansion of emergency use authorization (EUA) to run our PCR test on additional instruments and consumables for greater workflow flexibility
Designed and built a new facility in Lenexa, Kansas, to manufacture highly specialized viral transport media (VTM) for sample collection under a U.S. government contract
Formed a collaboration with WuXi Diagnostics and Mayo Clinicto develop a total antibodies serology test
Secured a multi-year pharma services contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support accelerated vaccine development and production.

>https://www.prnewswire.com/news-releases/wuxi-diagnostics-to-open-its-first-Research-facility-in-the-us-300921555.html
WuXi Diagnostics
About WuXi Diagnostics

WuXi Diagnostics is a joint venture formed in 2018 betweenWuXi AppTec Groupand Mayo Clinic. The company's mission is to build an innovative model that enables diagnostic product innovation, generates clinical insights, benefits the health of mankind through precision diagnosis and treatment, and ultimately fulfills the vision of "every disease can be precisely diagnosed." For more information, please visit?www.wuxidiagnostics.com/en.

SOURCE WuXi Diagnostics

WuXi AppTec Group
>https://www.wuxiapptec.com/about/history
WuXi Apptec history
2000
WuXi PharmaTech was registered in the city of Wuxi, Jiangsu and operated in Shanghai
2001
WuXi started synthetic chemistry services
2003
WuXi started manufacturing process development services
2004
WuXi started manufacturing services for Research and development
2005
WuXi started bio-analytical services
2006
WuXi started antibody discovery and process development services
2007
WuXi started toxicology and formulation services
The Tianjin site of WuXi was put into operation and it was among the leading R&D bases of chemical medicines in China then
WuXi PharmaTech traded on the New York Stock Exchange under the ticker symbol "NYSE:WX"
WuXi set up "Life Science and Chemistry Awards", aiming to stimulate early-stage innovation and promote excellence in life sciences and clinical Research
2008
WuXi PharmaTech acquired AppTec Laboratory Services, with locations in Minnesota, Pennsylvania and Georgia. The Company has been renamed WuXi AppTec since then.

#9979890 at 2020-07-16 16:16:57 (UTC+1)
Q Research General #12771: Iceland Plays Screams, Anons Be Like............ Edition

J&J says in talks with Japan, Gates Foundation to lock in deals on COVID-19 vaccine

Johnson & Johnson Inc is in talks with the government of Japan and the Bill and Melinda Gates Foundation about locking up allocations of its potential COVID-19 vaccine in advance of it producing any of the medicines, Johnson & Johnson's chief financial officer Joseph Wolk told Reuters in an interview. It has already agreed to provide an allocation to the United States as part of its funding agreement with U.S. government agency Biomedical Advanced Research and Development Authority (BARDA). The Bill and Melinda Gates Foundation would focus on allocating any vaccine it acquired to developing countries, Wolk added. Reuters previously reported that J&J is also in talks with the European Union.
https://www.reuters.com/article/us-health-coronavirus-johnson-johnson-va/exclusive-jj-says-in-talks-with-japan-gates-foundation-to-lock-in-deals-on-covid-19-vaccine-idUSKCN24H2FB

#9822013 at 2020-07-02 05:55:06 (UTC+1)
Q Research General #12571: Open Up Our Country Up NOW! Edition

Genetically Engineered Cow Plasma Therapy for COVID-19 Will Be Tested on Humans

SAb Biotherapeutics (SAB), a biopharmaceutical company based in Sioux Falls, South Dakota has announced that human testing will begin on a new experimental therapy for people infected with COVID-19. In vitro data has demonstrated that its COVID-19 immunotherapy candidate derived from cattle, known as SAB-185, has highly potent neutralizing antibodies to the SARS-CoV-2 virus that is four times higher than the most potent human convalescent plasma serum (plasma from a recovering COVID-19 patient) sample.

SAB-185 is an immunotherapy candidate for COVID-19 that was created based on the assumption that the antibodies generated after a a patient gets infected and recovers can assist other patients who get infected or be used as a prophylactic therapy to prevent future coronavirus infections. Instead of relying on human plasma donations from patients who have recovered from COVID-19, SAB-185 uses genetically engineered cattle to produce antibodies in large quantities.

The process of developing SAB-185 involves injecting cattle with a COVID-19 vaccine every 28 days to trigger an immune response in order to produce antibodies that have the ability to fight against the SARS-CoV-2 virus.

Dr. Eddie Sullivan, CEO and co-founder of SAb Biotherapeutics said, "The cows then produce a specifically targeted high-neutralizing antibody that can be used in patients."

SAb Biotherapeutics said that SAB-185 is developed from the original SARS-CoV-2 strain from Wuhan, China. However, laboratory success has been demonstrated against a mutated strain known as the Munich strain and company officials say that that SAB-185 has the potential to be useful when the virus mutates.6

In order for cattle to produce COVID-19 antibodies that may be useful in treating humans infected with COVID-19, SAb Biotherapeutics took skin cells from a cow, removed the genes that are responsible for creating cow antibodies and inserted an engineered artificial human chromosome that produces human antibodies instead.7 Thereafter, scientists put the DNA from those cells into a cow egg, created an embryo, and then implanted the embryo into a cow to start a pregnancy. Over the past two decades, Sab Biotherapeutics have produced hundreds of genetically identical cows that produce COVID-19 antibodies.

According to SAb Biotherapeutics, cows are used to produce antibodies not just because they have more blood than smaller animals engineered to synthesize human versions of the proteins, but their blood can also contain twice as many antibodies per milliliter as human blood and that makes it an economically viable product. Dr. William Klimstra, immunologist at the University of Pittsburgh said, "Essentially, the cows are used as a giant bioreactor."

Researchers believe that cows can produce antibodies that mimic the manner in which the human body fights viruses. The journal Science Magazine stated:

Most companies trying to produce antibodies to combat COVID-19 have pinned their hopes on mass-producing identical copies of a single version, a so-called monoclonal antibody that homes in on and attaches tightly to a particular section of a virus. Instead of making just one antibody variety, the cows fashion polyclonal antibodies, a range of the molecules that recognize several parts of the virus.

Some experts are skeptical about using cows to produce COVID-19 antibodies for use in humans. Dr. Manish Sagar, associate professor of medicine and microbiology at Boston University Medical Centers said that he will remain skeptical "until I see further proof that production of antibodies in cows is a lot more feasible and economically viable."

Currently, there are no antibody therapies generated in cows approved for use in the United States.

SAb Biotherapeutics had already been working in partnership with the U.S. Department of Defense (DoD) to prepare its human polyclonal antibody platform for rapid responses to new infectious diseases when the COVID-19 pandemic was declared by the WHO and CDC in March 2020.

The company was awarded expanded scope on their Rapid Response contract for their SAB-185 candidate to treat COVID-19 from the DoD Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO - CBRND) Joint Project Lead for Enabling Biotechnologies (JPL-EB). The funding of $9.4 million is supported by the Biomedical Advanced Research Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services.

https://thevaccinereaction.org/2020/06/genetically-engineered-cow-plasma-therapy-for-covid-19-will-be-tested-on-humans/

#9635478 at 2020-06-16 19:34:37 (UTC+1)
Q Research General #12333: Rallies Are On! Coronavirus? Edition

FDA Moves to Prohibit Hydroxychloroquine Use

Update (1810ET): Hours after the FDA revoked its EUA on hydroxychloroquine, the agency dealt another blow to the COVID-19 treatment - warning not to combine the incredibly inexpensive anti-malarial with the incredibly expensive remdesivir; Gilead Sciences' yet-to-be-priced experimental treatment.

The agency, based on data from a recent non-clinical study, said the co-administration may result in reduced antiviral activity of remdesivir. It also added it had no such evidence from a clinical setting and that it continues to evaluate all data related to remdesivir.

* * *

FDA said it was no longer reasonable to believe that oral formulations of hydroxychloroquine and chloroquine may be effective in treating the illness caused by the novel coronavirus. -Reuters

Meanwhile, has anyone found the missing zinc?

The Food and Drug Administration said in a Monday letter that it has revoked its authorization for the emergency use authorization (EUA) governing the use of hydroxychloroquine and chloroquine for the treatment of COVID-19.

The decision - a response to a request by a Health and Human Services official to revoke the EUA - cites "new information, including clinical trial data results," which have led the Biomedical Advanced Research and Development Authority (BARDA) "to conclude that this drug may not be effective to treat COVID-19 [Coronavirus Disease 2019] and that the drug's potential benefits for such use do not outweigh its known and potential risks."

"Earlier observations of decreased viral shedding with HCQ or CQ treatment have not been consistently replicated and recent data from a randomized controlled trial assessing probability of negative conversion showed no difference between HCQ and standard of care alone," wrote FDA chief scientists Denise Hinton.

Of significant note, none of the studies cited include the use of zinc - which has been widely cited as the 'key' which HCQ provides a tunnel into cells to halt virus replication.

In fact, the FDA's letter doesn't include the word 'zinc' or its symbol, Zn.

The FDA issued the EUA in March, allowing COVID-19 patients to be treated with anti-malarial drugs from a federal stockpile.

Given all of the conflicting information on HCQ from government officials - as well as a retracted Lancet study which found HCQ did more harm than good, people aren't buying this; below are a sample of comments from MarketWatch's report on the EUA revocation.

If you haven't realized that all these agencies that are suppose to protect us from unsafe and unethical practices of big corporation have been captured by those very corporations, then you are not paying attention. The Pharmaceutical/Vaccine Industry can't make a fortune selling the world their poorly tested Covid-19 Vaccine if an existing medicine costing pennies is being used to successfully treat the virus. -Andrew Vela

Or this one:

moar

https://www.zerohedge.com/political/fda-revokes-emergency-authorization-hydroxychloroquine

#9622412 at 2020-06-15 17:53:23 (UTC+1)
Q Research General #12316: Past Proves Future Edition

FDA Withdraws Emergency Authorization For Hydroxychloroquine After HHS Official Makes Request

The Food and Drug Administration said in a Monday letter that it has revoked its authorization for the emergency use authorization (EUA) governing the use of hydroxychloroquine and chloroquine for the treatment of COVID-19.

The decision - a response to a request by a Health and Human Services official to revoke the EUA - cites "new information, including clinical trial data results," which have led the Biomedical Advanced Research and Development Authority (BARDA) "to conclude that this drug may not be effective to treat COVID-19 [Coronavirus Disease 2019] and that the drug's potential benefits for such use do not outweigh its known and potential risks."

"Earlier observations of decreased viral shedding with HCQ or CQ treatment have not been consistently replicated and recent data from a randomized controlled trial assessing probability of negative conversion showed no difference between HCQ and standard of care alone," wrote FDA chief scientists Denise Hinton.

Of significant note, none of the studies cited include the use of zinc - which has been widely cited as the 'key' which HCQ provides a tunnel into cells to halt virus replication.

In fact, the FDA's letter doesn't include the word 'zinc' or its symbol, Zn.

The FDA issued the EUA in March, allowing COVID-19 patients to be treated with anti-malarial drugs from a federal stockpile.

Given all of the conflicting information on HCQ from government officials - as well as a retracted Lancet study which found HCQ did more harm than good, people aren't buying this; below are a sample of comments from MarketWatch's report on the EUA revocation.

If you haven't realized that all these agencies that are suppose to protect us from unsafe and unethical practices of big corporation have been captured by those very corporations, then you are not paying attention. The Pharmaceutical/Vaccine Industry can't make a fortune selling the world their poorly tested Covid-19 Vaccine if an existing medicine costing pennies is being used to successfully treat the virus. -Andrew Vela

Or this one:

This is purely a political move. Looks like the FDA has been infiltrated by the globalist cabal who want Trump gone, too. I'm no Trump fan, but I'm even lesser of a fan of bureaucrats who put politics ahead of lives. -Orange Sanders

https://www.zerohedge.com/political/fda-revokes-emergency-authorization-hydroxychloroquine

FDA removes CURE as second wave starts being staged out of China

#9622246 at 2020-06-15 17:39:31 (UTC+1)
Q Research General #12315: Patriots Give New Meaning to Watch the Water Edition

>>9621489

Breaking Hydroxychloroquine news. Many media reporting this.

The Food and Drug Administration has revoked its emergency use authorization for the drugs hydroxychloroquine and chloroquine for the treatment of Covid-19.

Hydroxychloroquine was frequently touted by President Donald Trump, and he has claimed to have used it himself.
After reviewing the current Research available on the drugs, the FDA determined that the drugs do not meet "the statutory criteria" for emergency use authorization as they are unlikely to be effective in treating Covid-19 based on the latest scientific evidence, the agency noted on its website on Monday.
"FDA has concluded that, based on this new information and other information discussed in the attached memorandum, it is no longer reasonable to believe that oral formulations of HCQ and CQ may be effective in treating COVID-19, nor is it reasonable to believe that the known and potential benefits of these products outweigh their known and potential risks," FDA chief scientist Denise Hinton wrote in a letter to Gary Disbrow of the Biomedical Advanced Research and Development Authority (BARDA) on Monday. Hydroxychloroquine and chloroquine have been tied to serious cardiac events as well as other side effects among Covid-19 patients.
"Accordingly, FDA revokes the EUA for emergency use of HCQ and CQ to treat COVID-19," Hinton wrote in the letter, using abbreviations for hydroxychloroquine and chloroquine. "As of the date of this letter, the oral formulations of HCQ and CQ are no longer authorized by FDA to treat COVID-19."

https://www.cnn.com/2020/06/15/politics/fda-hydroxychloroquine-coronavirus/index.html

#9272566 at 2020-05-22 03:34:41 (UTC+1)
Q Research General #11867: Qresearch Breads. Now With Moar Pepes Edition

>>9272480
Trump Administration's Operation Warp Speed Accelerates AstraZeneca COVID-19 Vaccine to be Available Beginning in October

https://www.hhs.gov/about/news/2020/05/21/trump-administration-accelerates-astrazeneca-covid-19-vaccine-to-be-available-beginning-in-october.html

Responding to President Trump's call to develop 300 million doses of SARS-CoV-2 vaccine by January under Operation Warp Speed, the U.S. Department of Health and Human Services (HHS) and AstraZeneca are collaborating to make available at least 300 million doses of a coronavirus vaccine called AZD1222, with the first doses delivered as early as October 2020.

The agreement between AstraZeneca and the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS office of the Assistant Secretary for Preparedness and Response, will accelerate the development and manufacturing of the company's investigational vaccine to begin Phase 3 clinical studies this summer with approximately 30,000 volunteers in the United States.

Under this public-private partnership, BARDA can provide up to $1.2 billion to support, in parallel, Advanced clinical studies, vaccine manufacturing technology transfer, process development, scaled-up manufacturing, and other development activities. Emergency use authorization or licensure of this vaccine from the U.S. Food and Drug Administration (FDA) would be required to make the vaccine available. Early milestones enable BARDA and AstraZeneca to determine how the program progresses forward.

"This contract with AstraZeneca is a major milestone in Operation Warp Speed's work toward a safe, effective, widely available vaccine by 2021," said HHS Secretary Alex Azar. "Getting a vaccine to the American public as soon as possible is one part of President Trump's multi-faceted strategy for safely reopening our country and bringing life back to normal, which is essential to Americans' physical and mental well-being in so many ways. The Trump Administration is making multiple major investments in developing and manufacturing promising vaccines long before they're approved so that a successful vaccine will reach the American people without a day wasted."

#9272480 at 2020-05-22 03:26:39 (UTC+1)
Q Research General #11867: Qresearch Breads. Now With Moar Pepes Edition

Astra Zeneca secures capacity for a billion doses of any potential Covid-19 vaccine

https://aboutmanchester.co.uk/astra-zeneca-secures-capacity-for-a-billion-doses-of-any-potential-covid-19-vaccine/

AstraZeneca has announced that it now has secured the the capacity to manufacture 1bn doses of the potential coronavirus vaccine being developed at Oxford University

The Company has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020. It aims to conclude further agreements supported by several parallel supply chains, which will expand capacity further over the next months to ensure the delivery of a globally accessible vaccine.

AstraZeneca today received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in the fall. The development programme includes a Phase III clinical trial with 30,000 participants and a paediatric trial.

In addition, the Company is engaging with international organisations such as the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance and the World Health Organisation (WHO), for the fair allocation and distribution of the potential vaccine around the world. AstraZeneca is also in discussions with governments around the world to increase access. Furthermore, AstraZeneca is in discussions with the Serum Institute of India and other potential partners to increase production and distribution.

AstraZeneca recently joined forces with the UK Government to support Oxford University's potential vaccine and has progressed rapidly in its efforts to expand access around the world. The Company will supply 100m doses to the UK and is thankful for the Government's commitment and overall work on vaccines.

#9271061 at 2020-05-22 01:20:59 (UTC+1)
Q Research General #11865: Baking Bad Edition

ABC News
'Science by press release':
Sudden rise of vaccine developer Moderna rankles some in scientific establishment
May 21, 2020, 3:31 PM EDT

The company has been embraced by a Trump administration desperate for good news in the fight against COVID-19. In April, Moderna received $483 million from the Biomedical Advanced Research and Development Authority (BARDA), the government agency charged with overseeing the rapid production of a vaccine. And last week, one of its board members, Moncef Slaoui, was appointed the nation's new "vaccine czar," leading him to resign from his position at the company and announce plans to divest more than $12 million of equity holdings amid concerns about potential conflicts of interest.

But while the announcement of favorable preliminary results has generated widespread excitement and put the company at the forefront of the race for the most sought-after vaccine in more than a century, some in the typically staid and sober scientific establishment have begun to question the company's decision to publicize preliminary results by press release with no supporting data.


https://www.yahoo.com/gma/science-press-release-sudden-rise-vaccine-developer-moderna-193102158–abc-news-topstories.html

#9235628 at 2020-05-19 08:20:35 (UTC+1)
Q Research General #11820: The 'The Chopping Block: Fake News Is Next!' Edition

Amid rumors China is asshoe, Trump rethinks decade old cabal policy letting strategic enemies make all the medicine. A war of words broke out as some in the D caucas fear Master Xi might be displeased.

Trump admin taps startup to build nation's first stockpile of key drug ingredients

The $354 million project is designed to shore up the drug supply chain and reduce the country's dependence on foreign manufacturers.


Seeking to secure the nation's supply of critical medications, the Trump administration has signed a $354 million contract that would create the nation's first strategic stockpile of key ingredients needed to make medicines.

The agreement was signed Monday with Phlow Corp., a generic drug maker based in Virginia. According to a news release to be made public Tuesday, the project will use federal funds from the Biomedical Advanced Research and Development Authority under the Department of Health and Human Services.


The goal is twofold: to enable the U.S. to manufacture essential drugs at risk of shortage and to create a reserve of active pharmaceutical ingredients to reduce the dependence on foreign suppliers.

Phlow's CEO, Dr. Eric Edwards, told NBC News that the company had been in discussions with the administration back in November but that the project was fast-tracked once COVID-19 hit.

"We said: 'We have a short-term and long-term solution. We know that there are certain key essential generic medicines that are going to go into shortage if this thing starts spreading,'" Edwards said. "There were drugs that were already on the FDA drug shortage list long before COVID-19 and we already saw what was happening with PPE, and we knew this was going to be as bad or even worse."

"PPE" is short for personal protective equipment used by medical personnel.

Cont@
https://www.nbcnews.com/news/us-news/trump-admin-taps-startup-build-nation-s-first-stockpile-key-n1210011

#9211077 at 2020-05-17 15:10:20 (UTC+1)
Q Research General #11789: Sunday Morning Futures Edition

https://www.bnnbloomberg.ca/trump-aide-accuses-china-of-using-air-travelers-to-seed-virus-1.1437516

The Trump administration stepped up its campaign of blaming China for the deadly coronavirus pandemic, with a top aide suggesting Beijing sent airline passengers to spread the infection worldwide.
"The virus was spawned in Wuhan province, patient zero was in November," White House trade adviser Peter Navarro said on ABC's "This Week."
"The Chinese, behind the shield of the World Health Organization, for two months hid the virus from the world and then sent hundreds of thousands of Chinese on aircraft to Milan, New York and around the world to seed that."
Milan and New York went on to become hotspots for the pandemic.
Navarro's comments add to the almost daily barrage of U.S. attacks on China, including suggestions that the virus escaped from a laboratory in the central city of Wuhan.
As recently as last week, Secretary of State Michael Pompeo ratcheted up his criticism, asserting China covered up the origins of the virus.
"They could have kept it in Wuhan," Navarro said. "Instead, it became a pandemic. That's why I say the Chinese did that to Americans and they are responsible."
'Out of Control'
On Thursday, Trump said that while he still suspects the outbreak may be connected to the Wuhan virology lab, he said it was unlikely the Chinese deliberately unleashed the pathogen. "I think more likely it got out of control," he said.
Navarro also dismissed complaints offered by whistle-blower Rick Bright, who had served as the director of the Biomedical Advanced Research and Development Authority until the end of last month.

#9193651 at 2020-05-16 01:07:42 (UTC+1)
Q Research General #11767: Discovery Launched Edition

1/6
Dr. Anthony S. Fauci Testified Before the Energy and Commerce Committee in 2018

On June 15, 2018 Dr. Anthony S. Fauci testified before the U.S. House Energy and Commerce Committee regarding preparedness in the event of biological attack, pandemics and emerging infectious disease. Here are some interesting quotes.

"NIH coordinates its biodefense Research with partners in industry, academia, and the Federal Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) to ensure that promising countermeasures for biological, chemical, and radiological public health threats can proceed to Advanced development. Since fiscal year 2012, NIH has supported the early development of more than 20 candidate MCMs for high-priority threats, and ultimately transitioned support for those candidate MCMs to the Biomedical Advanced Research and Development Authority (BARDA) for Advanced development, with the goal of Food and Drug Administration (FDA) approval, licensure, clearance, or authorization, and for potential inclusion in the Strategic National Stockpile. NIH funding for emerging infectious disease, including biodefense, Research was approximately $2.6 billion in FY 2017."

"…NIAID has supported development of broad-spectrum antiviral agents such as BCX4430 (galidesivir), which has demonstrated activity against Ebola and other RNA viruses…"

"NIAID has moved strategically toward a MCM Research paradigm that features broader, more flexible platform technologies. This effort is yielding significant scientific advances that help protect against multiple emerging public health threats, whether man-made or naturally occurring. Together with academia, industry, and PHEMCE partners, NIAID remains committed to meeting public health emergency needs by advancing high-priority Research toward development of MCMs for radiological/nuclear, chemical, and biological threats, including emerging and re-emerging infectious diseases."

See more of Dr. Fauci's written testimony here.
v v v
https://docs.house.gov/meetings/IF/IF02/20180615/108422/HHRG-115-IF02-Wstate-FauciA-20180615.pdf

To see Dr. Rick Bright's June 15, 2018 written testimony and other Energy and Commerce Committee documentation look here.
v v v
>>9178062 (PB)
>>9178081 (PB)
>>9178097 (PB)
>>9178127 (PB)
>>9178190 (PB)
>>9178238 (PB)
>>9178269 (PB)
>>9178296 (PB)

#9189057 at 2020-05-15 20:00:27 (UTC+1)
Q Research General #11761: Cures Already Exist Edition

President Trump Says Production Will Begin Even Before Final Approvals

14 coronavirus vaccine candidates are being evaluated
130 therapies are in trials with 450 others in the planning stages
Half the country has lifted stay-at-home orders

President Trump said Friday the possible candidates for a coronavirus vaccine have been narrowed to 14 and manufacture will begin before final Food and Drug Administration approvals are given. Trump said he's hoping a viable vaccine will be available before the end of the year.

In addition to vaccine development, some 130 therapies for COVID-19 are undergoing trials, with 450 others in the planning stages.

By early afternoon Friday, the virus had killed more than 86,200 Americans.

"When a vaccine is ready the U.S. government will deploy every soldier and plane available to deploy it," Trump pledged in an announcement in the Rose Garden.

Trump characterized the $10 billion search for a coronavirus vaccine as the "most aggressive in history" and likened it to the Mahnattan Project, which saw the development of the atomic bomb during World War II.

"Tremendous strides are being made," Trump said.

Trump hailed Americans for continuing to take precautions against the pandemic, adding that whether or not a vaccine is developed, America has to get back to work.

"Vaccine or no vaccine, we're back. We're starting the process," he said.

Trump noted the U.S. now is conducting 350,000 coronavirus tests a day.

The announcement came as states began easing stay-at-home orders with half the country already open for business.

Economic experts have warned Americans likely won't feel comfortable returning to business as usual until effective treatments and a vaccine against COVID-19 are developed, with medical experts warning reopening the economy too rapidly will lead to a spike in cases and deaths.

Infectious disease expert Dr. Anthony Fauci said earlier this week it was unlikely a vaccine would be available in time for schools to start in the fall while Dr. Richard Bright, former head of the Biomedical Advanced Research and Development Authority, said Thursday even if a vaccine were available, the U.S. is ill-equipped to distribute it.

Trump told Fox Business Thursday he is prepared to use the military to distribute the vaccine once it is available.

"You know, it's a massive job to give this vaccine. Our military is now being mobilized so at the end of the year we're going to be able to give it to a lot of people very, very rapidly," Trump said.

https://www.ibtimes.com/coronavirus-vaccine-president-trump-says-production-will-begin-even-final-approvals-2977072

#9178062 at 2020-05-15 01:44:48 (UTC+1)
Q Research General #11747: NARA Please Edition

1/7
Dr. Rick Bright: His and His Colleagues' Preparedness Resposibility

This is Dr. Rick Bright's June 15, 2018 "Written Testimony" given before the "House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations". The testiomomy concerns "The State of U.S. Public Biopreparedness: Responding to Biological Attacks, Pandemics, and Emerging Infectious Disease Outbreaks". It is titled "Statement of Rick Bright, Ph.D Director, Biomedical Advanced Research and Development Authority Deputy Assistant Secretary For Preparedness and Response."

Dr. Bright wrote, "I am Dr. Rick Bright, the Director of the Biomedical Advanced Research and Development Authority (BARDA) and the Deputy Assistant Secretary for Preparedness and Response (ASPR) at the Department of Health and Human Services (HHS)." Anon highly recommends that all Anons read this written testimony. The big takeaway from this testimony is that Dr. Bright identifies the individuals who are responsible for emergency preparedness. In this 2018 testimony he identifies the Assistant Secretary for Preparedness and Response (ASPR), who is his boss, and himself as Deputy ASPR and Director of the Biomedical Advanced Research and Development Authority (BARDA) as the people responcible for preparedness. He uses words such as stockpile, vaccines, "…equipement and other materiel to respond to 21st century health security threats, as well as the flexible response capabilities needed to handle the unexpected." According to Dr. Bright's 2018 testimony, ASPR and BARDA have been responsible for preparing for these emergencies for 10 years. This Anon can only wonder what they have been spending 10 years of budgets on. Dr. Bright also testifies that ASPR and BARDA coordinate federal, state and local training and preparedness. Anon thinks it is deceitful for Dr. Bright to realize, in January of 2020, that preparedness is woefully lacking and then blame others, after testifying on June 15, 2018 that he and his colleagues were doing their jobs. How can he blame the current administration because he woke up one day in January and thought oh shit we're not ready.
PDF warning. Anon will post all 10 PDF pages for Anons who don't like to click on PDF.
https://docs.house.gov/meetings/IF/IF02/20180615/108422/HHRG-115-IF02-Wstate-BrightR-20180615.pdf

Anon was highlighting the important stuff and then decided it is all important. Sorry for so much yellow.

#9171749 at 2020-05-14 17:54:57 (UTC+1)
Q Research General #11739: When do you attack the King? Edition

'Whistleblowing' Vaccine Expert Rick Bright Testifies To House

Rick Bright, the top federal vaccine official who claims he was ousted from his position for speaking out, is expected to criticize the administration's response to the COVID-19 pandemic and warn of dark days to come during a House hearing on Thursday.

Bright will publicly advise the federal government to ramp up its response, a week after filing a whistleblower complaint alleging he was fired from his job leading the Biomedical Advanced Research and Development Authority (BARDA) for opposing the use of hydrochloroquine (which has been "touted" - to use the media's new favorite word - by President Trump as a potential COVID-19 treatment).

In his complaint, Bright claims he was excluded from an HHS meeting on the coronavirus in late January after he "pressed for urgent access to funding, personnel, and clinical specimens, including viruses," to develop treatments for the coronavirus should it spread outside of Asia.

Bright alleges it "became increasingly clear" in late January that "HHS leadership was doing nothing to prepare for the imminent mask shortage."

Bright claims he "resisted efforts to fall into line with the Administration's directive to promote the broad use of chloroquine and hydroxychloroquine and to award lucrative contracts for these and other drugs even though they lacked scientific merit and had not received prior scientific vetting."

He adds that "even as HHS leadership began to acknowledge the imminent shortages in critical medical supplies, they failed to recognize the magnitude of the problem, and they failed to take the necessary urgent action."

President Trump had a few things to say, of course:

The Hill reports that Bright is expected to warn the House Energy and Commerce Subcommittee on Health of "unprecedented illness and fatalities" if the U.S. coronavirus response does not improve.



"Our window of opportunity is closing," Bright is expected to testify, according to his prepared remarks provided to CNN.

"Without clear planning and implementation… 2020 will be (the) darkest winter in modern history."

https://youtu.be/WneNXuDAJnE

https://www.zerohedge.com/political/watch-live-whistleblowing-vaccine-expert-rick-bright-testifies-house

#9168750 at 2020-05-14 14:38:40 (UTC+1)
Q Research General #11735: Suicide Weekend Approaches Edition

thick as a brick rick bright right there through it all:
From 2006 to 2008, Bright returned to working in the private sector of the biotechnology industry at Novavax in Maryland, where he was vice president of their global influenza programs as well as of their vaccine Research and development. During this time, he participated in World Health Organization committees on vaccine development and pandemic preparedness.

In 2003, Bright rejoined the CDC as an immunologist/virologist in their Disease Control and Prevention, Influenza Division, Strain Surveillance Branch in Atlanta, Georgia, where he worked on their influenza antiviral drug program and focused on avian influenza. He held that position until 2006.

In February 2008, Bright worked at the non-profit PATH on a Bill & Melinda Gates Foundation grant funded project as the director in vaccine manufacturing capacity building in Viet Nam. He was also the scientific director of the influenza vaccine project as well as the global vaccine development program, a position he held until October 2010.

In 2010, Bright joined the U.S. Department of Health and Human Services (HHS) governmental agency Biomedical Advanced Research and Development Authority (BARDA). He was the program lead of BARDA International Programs, then in June 2011 became acting chief of the influenza antiviral drug Advanced development program, a position he held until December 2011. From June 2011 to December 2015, he was both deputy director and acting director of BARDA's Influenza and Emerging Diseases Division, eventually serving as director of the division from December 2014 to November 2016. From February 2016 to November 2016, he was an incident commander in the ASPR/BARDA Zika Response.

On November 15, 2016, President Obama appointed Bright to the position of Director of BARDA. Bright succeeded founding director Robin Robinson. In addition to his role as Director of BARDA, Bright was also Deputy Assistant Secretary for Preparedness and Response in the Office of the Assistant Secretary for Preparedness and Response (ASPR).>>9168707

#9148915 at 2020-05-13 01:51:18 (UTC+1)
Q Research General #11710: Sydney Powell's Open Letter Edition

'How much should Gilead Sciences charge for its now-authorized COVID-19 therapy remdesivir? Up to $4,460 per patient, an influential pricing watchdog figures.

While Gilead has yet to present a marketing plan for the first coronavirus treatment to have shown clinical benefits in a well-designed randomized study, the Institute for Clinical and Economic Review (ICER)-which routinely weighs in on drug costs-says the drug is cost-effective at $4,460 per course of treatment.

Even at $1,000 per patient, less than a quarter of ICER's fair price, Gilead could rake in $1 billion in sales this year-at least theoretically. The company's now bolstering supply with the aim to treat 1 million patients by the end of the year, Jefferies analyst Michael Yee said in a Sunday note.

For now, Gilead is donating remdesivir to the U.S. government for allocation, and it's pledged to continue giving doses away until its current supply chain is exhausted. That's about 1.5 million doses, the company said. It hasn't detailed its plans for supplying the drug after that, whether in the U.S. or beyond, and hasn't offered any hints on pricing.

A revenue haul of $1 billion may seem like a lot, but Yee noted that it's dwarfed by the $6 trillion the U.S. government is doling out to prop up the economy. Plus, the federal Biomedical Advanced Research and Development Authority (BARDA) has committed up to $483 million to fund the development and manufacturing of Moderna's mRNA vaccine candidate even ahead of clinical results, among other vaccine projects.

Moreover, a $1,000 tag is "pretty reasonable" given the global context of modern drug pricing, Yee said. "The fact that ICER is typically conservative in all their analyses, and yet they can justify up to $4,500, seems pretty interesting," he added.

Drugmakers aren't obligated to follow ICER's pricing limits, and they often find themselves at odds with each other. But in an open letter in late March, O'Day promised the company will "work to ensure affordability and access" to remdesivir. …'
https://www.fiercepharma.com/marketing/gilead-s-covid-19-therapy-remdesivir-worth-4-460-per-course-says-pricing-watchdog

#9145243 at 2020-05-12 21:46:18 (UTC+1)
Q Research General #11705: Cameras Off = Masks Off Edition

Biomedical Advanced Research and Development Authority (BARDA)

You have heard of DARPA. Well, here is BARDA

https://experimentalvaccines.org/2015/10/21/barda-genome-hygiene-authority-or-vaccination-police-force/

(2011-2016 agenda)

#9047586 at 2020-05-06 04:52:25 (UTC+1)
Q Research General #11581: Dr Shiva and THE ADRENOCHROME Edition

>>9047537
>>9047558
>>THE PRESIDENT: No, no, but you talk about his great gifts."

Oh Shit! Here it is.
This is something..




" Exclusive
Director of U.S. agency key to vaccine development leaves role suddenly amid coronavirus pandemic

By Nicholas Florko @NicholasFlorko

April 21, 2020

Rick Bright
Rick Bright
HHS

WASHINGTON - Rick Bright, one of the nation's leading vaccine development experts and the director of the Biomedical Advanced Research and Development Authority, is no longer leading the organization, officials told STAT.

The shakeup at the agency, known as BARDA, couldn't come at a more inopportune time for the office, which invests in drugs, devices, and other technologies that help address infectious disease outbreaks and which has been at the center of the government's coronavirus pandemic response.

Bright, whose departure was confirmed by three industry sources and two current Trump administration sources, will instead move into a narrower role at the National Institutes of Health. Gary Disbrow, Bright's former deputy at BARDA, will serve as the acting director of the office, an HHS spokesperson confirmed to STAT.

BARDA was expected to play an even larger role in the coming months; Congress more than tripled BARDA's budget in the most recent coronavirus stimulus package. Already, the office has a role in some of the splashiest Covid-19 projects, including partnerships with Johnson & Johnson and Moderna Therapeutics, both of which are developing potential Covid-19 treatments.:"

#9041984 at 2020-05-05 20:05:00 (UTC+1)
Q Research General #11574: Cinco de Cinco, Knowledge Is Power Edition

>>9041423
(CQ/HCQ) Effective on (SARS-CoV-2)? [Who] Knew? = Discovery Phase of Whistleblower Lawsuit Would Answer, Right?

(Rick Bright) & (Katz, Marshall & Banks) - Double-Down
Formally Filed Whistleblower Complaint
(APnews - May 5, 2020)
Whistleblower: Trump official ignored warning on drug, virus

WASHINGTON (AP) - A government scientist was ousted after the Trump administration ignored his dire warnings about COVID-19 and a malaria drug President Donald Trump was pushing for the coronavirus despite scant evidence it helped, according to a whistleblower complaint Tuesday.

Rick Bright, former director of the Biomedical Advanced Research and Development Authority, filed the complaint Tuesday with the Office of Special Counsel, a government agency responsible for whistleblower complaints.
—
(whistleblower complaint on scribd.com below)
(excerpt)
As detailed below, despite Dr. Bright's efforts to ensure that the U.S. government dedicated the appropriate resources and expert personnel to combat this deadly virus, HHS political leadership leveled baseless criticisms against him for his proactive efforts to invest early in vaccine development as well as in critical supplies such as masks, respirators, and swabs, which were in short supply and would be necessary to combat COVID-19. Thereafter, HHS political leadership retaliated against Dr. Bright for his objections and resistance to funding potentially dangerous drugs promoted by those with political connections and by the Administration itself. Specifically, as detailed in the attached emails and other documentary evidence, Dr. Bright opposed the broad use of chloroquine and hydroxychloroquine as lacking scientific merit, even though the Administration promoted it as a panacea and demanded that New York and New Jersey be "flooded" with these drugs, which were imported from factories in Pakistan and India that had not been inspected by the FDA.
—
Either the evidence shows: CDC HHS, NIH etc… had clinical PROOF (CQ/HCQ) was effective on (SARS-CoV & SARS-CoV-2) or they didn't.

How do you introduce evidence?
Discovery Phase of Legal Proceedings.

Just food for thought.

https://apnews.com/68ff635c752d056a3f6242fa555b163b
https://www.scribd.com/document/460034740/Dr-Rick-Bright-s-whistleblower-complaint#from_embed?campaign=VigLink&ad_group=xxc1xx&source=hp_affiliate&medium=affiliate

#9041173 at 2020-05-05 19:01:20 (UTC+1)
Q Research General #11573: The Mask Of Choice WW Edition

>>9041125
breaking news
HHS official Rick Bright says he was ousted after raising concern about coronavirus drug Trump had touted
David Jackson
John Fritze
USA TODAY
https://www.usatoday.com/story/news/politics/2020/05/05/rick-bright-files-whistleblower-complaint-against-trump-administration/3023905001/

WASHINGTON - A vaccine expert who said he was ousted after raising concerns about a drug President Donald Trump touted as a potential treatment for coronavirus filed a whistleblower complaint Tuesday alleging longstanding political influence at the Department of Health and Human Services.
Rick Bright, who until recently served as director of the HHS Biomedical Advanced Research and Development Authority, also said he raised alarms about the coronavirus - and the need to ramp up production of face masks and other personal protective equipment - with White House officials as far back as January.
Bright says in the report that he resisted widespread use of hydroxychloroquine, which Trump had repeatedly touted, because the claims of its benefit lacked "scientific merit." In his report, Bright said he pushed back against the drug "even though the administration promoted it as a panacea and demanded that New York and New Jersey be 'flooded' with these drugs."

The Biomedical Advanced Research and Development Authority is designed to aid in securing the nation from chemical, biological, radiological, and nuclear threats, as well as from influenza and diseases, according to HHS. Bright was removed from his role and assigned to a job at the National Institutes of Health last month.
HHS and White House officials did not immediately respond to a request for comment.

The report argues that "HHS political leadership retaliated against Dr. Bright for his objections and resistance to funding potentially dangerous drugs promoted by those with political connections and by the administration itself."
Bright's attorneys argue in the report that tension with HHS leadership dated to non-Covid contracts earlier in Trump administration. Bright said he resisted efforts to extend a contract with a company whose CEO, he was told, was a friend of Jared Kushner, the president's son-in-law and a senior adviser at the White House.

Bright also claims in the report that he met with White House officials as far back as February 8, 2020 to warn about the coronavirus and that he emphasized the need to "secure N95 masks and to ramp up mask production," as well as other equipment.
Trump said late last month that he didn't know about Bright or his accusations.
"I have never heard of him," the president said. "I don't know who he is."

#9041125 at 2020-05-05 18:57:08 (UTC+1)
Q Research General #11573: The Mask Of Choice WW Edition

Ousted vaccine director files whistleblower complaint alleging coronavirus warnings were ignored
By Kaitlan Collins, Jeremy Diamond and Kevin Liptak, CNN

Updated 2:38 PM ET, Tue May 5, 2020
https://www.cnn.com/2020/05/05/politics/rick-bright-complaint/index.html


Dr. Rick Bright, the ousted director of the office involved in developing a coronavirus vaccine, formally filed an extensive whistleblower complaint Tuesday alleging his early warnings about the coronavirus were ignored and that his caution at a treatment favored by President Donald Trump led to his removal.
Bright had led the Biomedical Advanced Research and Development Authority since 2016 until last month, when was reassigned to a narrower position at the National Institutes of Health.
In his whistleblower complaint, Bright says he raised concerns about US preparedness for coronavirus starting in January but was met with "indifference which then developed into hostility" by leaders at the Department of Health and Human Services.
His attorneys argue that Bright's removal from his post amounts to a violation of the Whistleblower Protection Act, claiming that Bright "has engaged in numerous instances of protected activity."



In the complaint, he says he is seeking reinstatement as BARDA's director and asking for a full investigation.

He claims leaders at the agency were surprised by his concerns and responded slowly to the outbreak.
He alleges old disputes with HHS leadership were exacerbated by clashes over the coronavirus and that he was eventually excluded from participating in meetings about the virus.
"Dr. Bright pressed for urgent access to funding, personnel and clinical specimens, including viruses, which he emphasized were all critically necessary to begin development of lifesaving medicines needed in the likely event that the virus spread outside of Southeast Asia," the complaint reads. "Secretary Azar and Dr. Kadlec responded with surprise at Dr. Bright's dire predictions and urgency."

Later, Bright claims he was cut out of critical meetings for raising early alarm about the virus.
"It was obvious that Dr. Bright's persistent demands for urgent action to respond to the pandemic had caused a 'shit storm' and a 'commotion' and were unwelcome in the office of the HHS Secretary," the complaint reads. "As a result, HHS leadership excluded Dr. Bright and BARDA from these recurring meetings and from the critical discussions about addressing the COVID-19 pandemic

#8995974 at 2020-05-02 03:57:28 (UTC+1)
Q Research General #11514: Bring On The Night Edition

>>8995872
https://www.msn.com/en-us/health/medical/houston-Researchers-test-lung-inhalant-that-could-protect-healthcare-workers-from-covid-19/ar-BB11Be6X?fbclid=IwAR3Vv-ddg_QIQqGtdirUkqMjXcOPlDfZRB4OULgFz1LdR3Tw0HCio_VY1h0

Houston Researchers test lung inhalant that could protect healthcare workers from COVID-19
By Gwendolyn Wu, Staff writer 3/23/2020
Health official says US missed some chances to slow virus
Sam Lloyd, actor on 'Scrubs,' dies at 56
Houston Chronicle logoHouston Researchers test lung inhalant that could protect healthcare workers from COVID-19
A Houston company is developing a drug that could protect people in close contact with patients who have COVID-19 from contracting the illness caused by the new coronavirus.

a man cooking in a kitchen: Dr. Brenton Scott, chief operating officer of Houston-based Pulmotect, works in the company's lab.© Courtesy Of Pulmotect Dr. Brenton Scott, chief operating officer of Houston-based Pulmotect, works in the company's lab.
The drug, delivered as an aerosol known as PUL-042, was created by biopharmaceutical company Pulmotect, MD Anderson Cancer Center and Texas A&M, which have worked together to develop the drug for more than a decade. While PUL-042 has been tested on mice and had limited human trials in the United Kingdom, it is still at least a year away from approval by the Food and Drug Administration.


But if approved, it could provide short-term immunization for doctors, nurses and people in close proximity to COVID-19 patients until a proper vaccine is developed.

CORONAVIRUS UPDATES: Stay informed with accurate reporting you can trust

"Our lungs are the front line of defense against noxious pathogens," said Colin Broom, Pulmotect's chief executive. "Normally we can fight those off. But an overwhelming infection that you get from this virus? You just can't fight that."

Pulmotect and its Research partners are among the many drug companies and scientists racing to find vaccines and treatment for COVID-19, the illness caused by the new coronavirus. The virus can cause severe pneumonia in patients, who may experience fevers, dry coughs and difficulty breathing, along with possible gastrointestinal symptoms, according to Baylor University Researchers.

Pulmotect's drug works by stimulating a thin layer of tissue that lines the inside of the lungs and training it to be hostile to invading pathogens. It differs from most vaccines because its effect is almost immediate, but temporary, while vaccines can take weeks to develop antibodies that can fight infections, but last for years, if not lifetimes.

Someone taking the PUL-042 would have to inhale it twice a week to maintain its effectiveness, said Dr. Burton Dickey, chair of pulmonary medicine at MD Anderson Cancer Center and one of the leading Researchers.

On HoustonChronicle.com: Is the vaccine to thwart the new coronavirus stored in a Houston freezer?


AdChoices
The company has successfully tested the drug on some of the world's most vicious viruses in mice, including strains of SARS and MERS, two other coronaviruses. Researchers said it acts like "Clorox," killing bacteria, viruses and microorganisms that cause illness.

"You'd expect it to work against any virus," Dickey said, " but this provides proof it works against highly virulent coronaviruses."

What's next
The aerosol has moved to clinical trials in the United Kingdom, examining how safe the drug is for smokers who have respiratory issues. Like other vaccines and drugs that could treat COVID-19, two things are keeping PUL-042 from becoming consumer-ready: money and federal approval.

Researchers have asked the FDA to approve the drug in time to address the global pandemic. Broom said they have also turned to the National Institute of Allergy and Infection Diseases and the U.S. Biomedical Advanced Research and Development Authority in hopes they can fast-track their drug into clinical trials in the United States.

CORONAVIRUS: Stay informed with accurate reporting you can trust

Approval from one of those federal agencies could mean a grant to study how it would work with people who could be exposed to the new coronavirus. The company, which has raised $28 million over the last 13 years, is also chasing down any private investor that would fund another round of studies.

Researchers estimated the trial could be completed within the year with just $5 million in funding, if not sooner given the jump in cases worldwide.

"At the rate cases are happening," Dickey said, "you could be seeing in a few weeks if it's effective."

Pulmotect had originally pitched itself to the FDA as a drug that could help cancer patients who are more susceptible to respiratory infections. It's possible, Broom and Dickey said, that as the public health crisis grows, federal officials will support funding the drug as a part of the fight against the new coronavirus.

#8974895 at 2020-04-30 19:24:31 (UTC+1)
Q Research General #11488: G to the Y, We got this! Edition

Dr. Fauci Introduces "Operation Warp Speed" - A 'Manhattan Project'-Style Program To Find A Vaccine: Live Updates

Update (1412ET): In addition to cranking out more courses of remdesivir, the White House is launching a new federal effort to direct the search for a coronavirus vaccine - a "Manhattan Project"-type effort purportedly inspired by a WSJ story about a group of leading scientists working with the administration - Dr. Tony Fauci confirmed on Thursday.

The plan is to have 100 million doses of a workable vaccine ready by January.

Here's Reuters with the details on 'OWS':

The Trump administration is planning to speed up development of a coronavirus vaccine with the goal of having 100 million doses ready by the end of 2020, a senior administration official said on Wednesday.

Executives and other experts have previously suggested that clinical trials to guarantee a vaccine is safe and effective could take a minimum of 12 to 18 months.

Several agencies within the Department of Health and Human Services announced plans earlier in April to partner with more than 15 drug companies as well as European regulators in an effort to spur development of vaccines and treatments for the disease.

The latest Trump administration efforts to speed vaccine development were originally reported by Bloomberg News, citing people familiar with the matter.
Called "Operation Warp Speed," the project will join private pharmaceutical companies with government agencies and the military in trying to cut the development time for a vaccine by as much as eight months.

It said a White House meeting on the project was scheduled for Wednesday.

Last month, President Donald Trump directed Health and Human Services (HHS) Secretary Alex Azar to speed development of a vaccine, and administration officials have been meeting on the effort for three to four weeks, the report added.

The administration's initiative comes a week after HHS said it had replaced Rick Bright as director of a key U.S. agency charged with developing drugs and vaccines for COVID-19.

Bright has said he was ousted as director of the Biomedical Advanced Research and Development Authority, or BARDA, because he resisted the administration's efforts to push malaria drugs hydroxychloroquine and chloroquine touted by Trump to treat the coronavirus even though their effectiveness has not been demonstrated and there are concerns about heart damage.

Lawyers for Bright, an expert in vaccines and therapeutics who served as an adviser to the World Health Organization, have said he will file a whistleblower's complaint with two government offices over his removal.

Under Bright's leadership, BARDA recently announced nearly $1 billion in support of vaccine manufacturing efforts by Moderna and Johnson & Johnson. The agency had a total of $5 billion set aside for vaccine development.

The program, which was first detailed in a series of leaks last night, aims to speed up the timeline for a mass produced vaccine.

Of course, it's a moonshot - and some critics are complaining that the only thing it accomplishes is wasting more taxpayer dollars on backstopping drug companies that are already racing to find a vaccine. Moreover, certified geniuses like Bill Gates insist it will take up to 2 years to find a vaccine.

https://www.zerohedge.com/geopolitical/airbus-reports-abysmal-earnings-russian-mafia-busted-trafficking-ventilators-live

#8940895 at 2020-04-27 22:34:01 (UTC+1)
Q Research General #11444 Even the Left Has Noticed ~ Fake News in Full Panic Edition

New York clinical trial quietly tests heartburn remedy against coronavirus

By Brendan BorrellApr. 26, 2020 , 12:00 PM

Science's COVID-19 reporting is supported by the Pulitzer Center.

The fast-growing list of possible treatments for the novel coronavirus includes an unlikely candidate: famotidine, the active compound in the over-the-counter heartburn drug Pepcid. On 7 April, the first COVID-19 patients at Northwell Health in the New York City area began to receive famotidine intravenously, at nine times the heartburn dose. Unlike other drugs the 23-hospital system is testing, including Regeneron's sarilumab and Gilead Sciences's remdesivir, Northwell kept the famotidine study under wraps to secure a Research stockpile before other hospitals, or even the federal government, started to buy it. "If we talked about this to the wrong people or too soon, the drug supply would be gone," says Kevin Tracey, a former neurosurgeon in charge of the hospital system's Research.

As of Saturday, 187 COVID-19 patients in critical status, including many on ventilators, have been enrolled in the trial, which aims for a total of 1174 people. Reports from China and molecular modeling results suggest the drug, which seems to bind to a key enzyme in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), could make a difference. But the hype surrounding hydroxychloroquine and chloroquine-the unproven antimalarial drugs touted by President Donald Trump and some physicians and scientists-has made Tracey wary of sparking premature enthusiasm. He is tight-lipped about famotidine's prospects, at least until interim results from the first 391 patients are in. "If it does work, we'll know in a few weeks," he says.

A globe-trotting infectious disease doctor named Michael Callahan was the first to call attention to the drug in the United States. Callahan, who is based at Massachusetts General Hospital and has extensive connections in the biodefense world, has spent time in disease hot zones around the world, including the 2003 outbreak of another coronavirus disease, SARS, in Hong Kong. In mid-January, he was in Nanjing, China, working on an avian flu project. As the COVID-19 epidemic began to explode in Wuhan, he followed his Chinese colleagues to the increasingly desperate city.

The virus was killing as many as one out of five patients older than 80. Patients of all ages with hypertension and chronic obstructive pulmonary disease were faring poorly. Callahan and his Chinese colleagues got curious about why many of the survivors tended to be poor. "Why are these elderly peasants not dying?" he asks.

In reviewing 6212 COVID-19 patient records, the doctors noticed that many survivors had been suffering from chronic heartburn and were on famotidine rather than more-expensive omeprazole (Prilosec), the medicine of choice both in the United States and among wealthier Chinese. Hospitalized COVID-19 patients on famotidine appeared to be dying at a rate of about 14% compared with 27% for those not on the drug, although the analysis was crude and the result was not statistically significant.

...

"If it does work, we'll know in a few weeks," says Northwell Health's Kevin Tracey, who leads the famotidine study. NORTHWELL HEALTH

With both the tantalizing Chinese data and the modeling pointing toward famotidine, a low-cost, generally safe drug, Callahan contacted Tracey about running a double-blind randomized study. COVID-19 patients with decreased kidney function would be excluded because high doses of famotidine can cause heart problems in them.

After getting FDA approval, Northwell used its own funds to launch the effort. Just getting half of the needed famotidine in sterile vials took weeks, because the injectable version is not widely used. On 14 April, the U.S. Biomedical Advanced Research and Development Authority (BARDA), which operates under Kadlec, gave Alchem a $20.7 million contract for the trial, most of which paid Northwell's costs.

The study's draft protocol was aimed only at evaluating famotidine's efficacy, but Trump's "game-changer" antimalarial drug was rapidly becoming the standard of care for hospitalized COVID-19 patients. That meant investigators would only be able to recruit enough subjects for a trial that tested a combination of famotidine and hydroxychloroquine. Those patients would be compared with a hydroxychloroquine-only arm and a historic control arm made up of hundreds of patients treated earlier in the outbreak. "Is it good science? No," Tracey says. "It's the real world."

Michael Callahan during a medical evacuation of COVID-19 patients from a cruise ship MICHAEL CALLAHAN

...

https://www.sciencemag.org/news/2020/04/new-york-clinical-trial-quietly-tests-heartburn-remedy-against-coronavirus

https://en.wikipedia.org/wiki/Famotidine

#8940648 at 2020-04-27 22:14:48 (UTC+1)
Q Research General #11443: Stay Strong POTUS. WRWY Edition

New York clinical trial quietly tests heartburn remedy against coronavirus
By Brendan BorrellApr. 26, 2020 , 12:00 PM

Science's COVID-19 reporting is supported by the Pulitzer Center.

The fast-growing list of possible treatments for the novel coronavirus includes an unlikely candidate: famotidine, the active compound in the over-the-counter heartburn drug Pepcid. On 7 April, the first COVID-19 patients at Northwell Health in the New York City area began to receive famotidine intravenously, at nine times the heartburn dose. Unlike other drugs the 23-hospital system is testing, including Regeneron's sarilumab and Gilead Sciences's remdesivir, Northwell kept the famotidine study under wraps to secure a Research stockpile before other hospitals, or even the federal government, started to buy it. "If we talked about this to the wrong people or too soon, the drug supply would be gone," says Kevin Tracey, a former neurosurgeon in charge of the hospital system's Research.

As of Saturday, 187 COVID-19 patients in critical status, including many on ventilators, have been enrolled in the trial, which aims for a total of 1174 people. Reports from China and molecular modeling results suggest the drug, which seems to bind to a key enzyme in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), could make a difference. But the hype surrounding hydroxychloroquine and chloroquine-the unproven antimalarial drugs touted by President Donald Trump and some physicians and scientists-has made Tracey wary of sparking premature enthusiasm. He is tight-lipped about famotidine's prospects, at least until interim results from the first 391 patients are in. "If it does work, we'll know in a few weeks," he says.

A globe-trotting infectious disease doctor named Michael Callahan was the first to call attention to the drug in the United States. Callahan, who is based at Massachusetts General Hospital and has extensive connections in the biodefense world, has spent time in disease hot zones around the world, including the 2003 outbreak of another coronavirus disease, SARS, in Hong Kong. In mid-January, he was in Nanjing, China, working on an avian flu project. As the COVID-19 epidemic began to explode in Wuhan, he followed his Chinese colleagues to the increasingly desperate city.

The virus was killing as many as one out of five patients older than 80. Patients of all ages with hypertension and chronic obstructive pulmonary disease were faring poorly. Callahan and his Chinese colleagues got curious about why many of the survivors tended to be poor. "Why are these elderly peasants not dying?" he asks.
In reviewing 6212 COVID-19 patient records, the doctors noticed that many survivors had been suffering from chronic heartburn and were on famotidine rather than more-expensive omeprazole (Prilosec), the medicine of choice both in the United States and among wealthier Chinese. Hospitalized COVID-19 patients on famotidine appeared to be dying at a rate of about 14% compared with 27% for those not on the drug, although the analysis was crude and the result was not statistically significant.
…
"If it does work, we'll know in a few weeks," says Northwell Health's Kevin Tracey, who leads the famotidine study. NORTHWELL HEALTH
With both the tantalizing Chinese data and the modeling pointing toward famotidine, a low-cost, generally safe drug, Callahan contacted Tracey about running a double-blind randomized study. COVID-19 patients with decreased kidney function would be excluded because high doses of famotidine can cause heart problems in them.

After getting FDA approval, Northwell used its own funds to launch the effort. Just getting half of the needed famotidine in sterile vials took weeks, because the injectable version is not widely used. On 14 April, the U.S. Biomedical Advanced Research and Development Authority (BARDA), which operates under Kadlec, gave Alchem a $20.7 million contract for the trial, most of which paid Northwell's costs.
The study's draft protocol was aimed only at evaluating famotidine's efficacy, but Trump's "game-changer" antimalarial drug was rapidly becoming the standard of care for hospitalized COVID-19 patients. That meant investigators would only be able to recruit enough subjects for a trial that tested a combination of famotidine and hydroxychloroquine. Those patients would be compared with a hydroxychloroquine-only arm and a historic control arm made up of hundreds of patients treated earlier in the outbreak. "Is it good science? No," Tracey says. "It's the real world."
Michael Callahan during a medical evacuation of COVID-19 patients from a cruise ship MICHAEL CALLAHAN
…

https://www.sciencemag.org/news/2020/04/new-york-clinical-trial-quietly-tests-heartburn-remedy-against-coronavirus
https://en.wikipedia.org/wiki/Famotidine

#8903974 at 2020-04-24 02:36:13 (UTC+1)
Q Research General #11396: Undiscovered Stars Learned. Missions Forward Edition

>>8903695
>NYT Story About Ousted HHS Director Rick Bright Starts To Crumble Almost Instantly
—
This is the FDA doc from (Mar 28, 2020) that the [MSM isn't talking about.
* (Dr Rick Bright) requested an ([E]mergency [U]se [A]uthorization) for (chloroquine phosphate and hydroxychloroquine sulfate) to treat COVID-19.

It certainly contradicts characterizations, in the MSM, of his situation.
(Mar 28, 2020) - He requested emergency use of (Chloroquine) type drugs for CV-19.
—
(header of letter replying to Dr Bright)&(1st page cap)

March 28, 2020
Dr. Rick Bright, Ph.D.
Director
Biomedical Advanced Research and Development Authority (BARDA) Office of Assistant Secretary for Preparedness and Response (ASPR) U.S. Department of Health and Human Services (HHS)
330 Independence Ave, S.W.
Room 640G
Washington, D.C. 20201

Re: Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease

https://www.fda.gov/media/136534/download

#8903048 at 2020-04-24 01:04:40 (UTC+1)
Q Research General #11395: Morning Sun Brings Heat. Full Moon Coming Edition

>>8902871

Former US Federal Vaccine Agency Chief Files Whistleblower Complaint For 'Retaliatory' Demotion
(sputniknews April 23 2020)
https://sputniknews.com/us/202004231079072670-former-us-federal-vaccine-agency-chief-files-whistleblower-complaint-for-retaliatory-demotion/

Dr. Rick Bright, who was removed on Tuesday from his positions as both the Director of the Biomedical Advanced Research and Development Authority (BARDA) and as the HHS Deputy Assistant Secretary for Preparedness and Response, has alleged that his demotion to a "less impactful" position was inspired by White House politics.

The former leader of the US federal vaccine agency, Dr. Rick Bright, is planning to file a whistleblower complaint with the US Department of Health and Human Services (HHS) attorney general and the Office of Special Counsel over "retaliatory treatment" he suffered following his criticism of US President Donald Trump's promotion of hydroxychloroquine as a cure for the COVID-19 disease, attorneys said in statement.

"We will soon be filing a whistleblower complaint with both the Office of Special Counsel and the HHS Inspector General on behalf of Dr. Rick Bright detailing the retaliatory treatment to which he was subjected by HHS political leadership after raising science-based concerns about White House pressure on treatment and vaccines related to the COVID-19 pandemic," the statement read.

Bright's lawyers, Debra S. Katz and Lisa J. Banks, said that the HHS is currently making "demonstrably false statements" about the health expert in a bid to "deflect attention from its retaliatory removal of him" from office.

"Dr. Bright was sidelined for one reason only – because he resisted efforts to provide unfettered access to potentially dangerous drugs, including chloroquine, a drug promoted by the Administration as a panacea, but which is untested and possibly deadly when used improperly," the attorneys stated.
Katz and Banks said that documents supporting Bright's concerns about the untested drug will soon be released to the public.

The attorneys noted that Bright desires to return to his position at BARDA to concentrate on the fight against the ongoing coronavirus pandemic ravaging the country.

Trump had previously repeatedly suggested that taking hydroxychloroquine and azithromycin together was an effective treatment to cure COVID-19, claiming that his suggestion could "have a real chance to be one of the biggest game changers in the history of medicine".

On Wednesday, Bright stated in a press release that he was removed from office over his call to resist the adoption of untested drug treatments promoted by the US president and his advisers.


other articles linked in story:
US Federal Vaccine Agency Leader Suggests His Demotion Was Political (April 22)
https://sputniknews.com/us/202004221079060801-us-federal-vaccine-agency-leader-suggests-his-demotion-was-political/

CIA Warns Workforce Against Anti-Malaria Drug Promoted by Trump for COVID-19 - Report (April 14)
https://sputniknews.com/us/202004141078954774-cia-warns-workforce-against-anti-malaria-drug-promoted-by-trump-for-covid-19—report-/

#8898643 at 2020-04-23 18:30:39 (UTC+1)
Q Research General #11390: Liberty and Freedom Ride Edition

HERE WE GO... Bitter Doctor Hires Christine Blasey Ford Attorney Debra Katz to Represent Him in His Upcoming Whistleblower Complaint Against Trump

Earlier today US health official Dr. Rick Bright told reporters he was ousted because he insisted on limiting the use of a drug President Donald Trump has pushed as a Covid-19 treatment despite little clinical evidence it works.

Rick Bright was abruptly pushed out of his position as the director of the Biomedical Advanced Research and Development Authority on Tuesday and given a smaller role at the National Institutes of Health.

Bright told reporters when leaving the drugs Trump has touted, hydroxychloroquine and chloroquine, "clearly lack scientific merit"
Dr. Bright was very upset about the use of hydroxychloroquine to treat coronavirus despite its record of success.

And now, just hours later, Dr. Bright has hired two far left hack attorneys Debra Katz and Lisa Banks to represent him.

Dr. Bright is ready to file a whistleblower complaint.

What BS.

The government is littered with these bitter anti-Trump hacks.

https://postnewsd2.blogspot.com/2020/04/here-we-go-bitter-doctor-hires.html

#8893768 at 2020-04-23 07:28:28 (UTC+1)
Q Research General #11385: Wew lads, the shills are scurred.. Edition

Bright should have been arrested instead of moved for undermining the administration.
China China China.



https://www.who.int/blueprint/about/Rick-Bright/en/

https://www.foxnews.com/politics/hhs-doctor-says-he-was-removed-after-disagreeing-with-white-house-over-coronavirus

"Dr. Rick Bright said in a statement that he believed his transfer Tuesday to a role with fewer responsibilities at the National Institutes of Health (NIH) was in response to his call for the federal government to "invest the billions of dollars allocated by Congress to address the COVID-19 pandemic into safe and scientifically vetted solutions, and not in drugs, vaccines and other technologies that lack scientific merit."

Bright, represented by the law firm Katz, Marshall & Banks – whose famous clients included Christine Blasey Ford, who accused future Supreme Court Justice Brett Kavanaugh of sexual assault in 2018 – had led the Biomedical Advanced Research and Development Authority (BARDA), a small but important agency during a pandemic, since 2016 after working in its Influenza and Emerging Infectious Diseases Division. The unit, part of the Department of Health and Human Services (HHS), has been tasked with countering chemical, biological and radiological threats, as well as infectious diseases.

"I am speaking out because to combat this deadly virus, science – not politics or cronyism – has to lead the way," Bright said in his statement.

#8891018 at 2020-04-23 01:38:41 (UTC+1)
Q Research General #11381: Fake News, (You) Were the One Duped, Projection 101 Edition

Director of key federal vaccine agency says his departure was retaliation

(CNN)The director of the office involved in developing a coronavirus vaccine says he was abruptly dismissed from his post in part because he resisted efforts to widen the availability of a coronavirus treatment pushed by President Donald Trump.

Dr. Rick Bright had led BARDA, the Biomedical Advanced Research and Development Authority, since 2016 until Tuesday, when was reassigned to a narrower position. He also announced he will file a whistleblower complaint with the Department of Health and Human Services' inspector general.

"I believe this transfer was in response to my insistence that the government invest the billions of dollars allocated by Congress to address the Covid-19 pandemic into safe and scientifically vetted solutions, and not in drugs, vaccines and other technologies that lack scientific merit," Bright said in a lengthy statement issued Wednesday. "I am speaking out because to combat this deadly virus, science – not politics or cronyism – has to lead the way."

He cited "clashes with political leadership" as a reason for his sidelining, as well as his resistance to "efforts to fund potentially dangerous drugs promoted by those with political connections."

Bright clashed directly with Health and Human Services Secretary Alex Azar and Bob Kadlec, the assistant secretary for preparedness and response, two people familiar with the situation told CNN. A senior HHS official denied Bright and Azar clashed.
One source said the "political leadership" Bright referred to in his statement is Azar.
Bright previously did not respond to repeated requests for comment on his departure by CNN. The Department of Health and Human Services did not immediately respond to CNN's request for comment on Bright's statement.

Bright said he "limited the broad use of chloroquine and hydroxychloroquine, promoted by the administration as a panacea, but which clearly lack scientific merit."
Trump repeatedly promoted that therapeutic treatment for coronavirus, touting its possible effects at White House briefings as recently as April 13.
Asked to weigh in on Bright's departure at Wednesday's press briefing, the President claimed he hadn't heard of him.
"I've never heard of him. When did this happen?" Trump asked, then added, "I never heard of him. Guy says he was pushed out of a job, maybe he was, maybe he wasn't."

A spokesperson for the Department of Health and Human Services confirmed Bright's move in a statement to CNN Tuesday and said he will now lead a new government project: a public-private partnership on vaccine development and treatment.

"On April 17, the National Institutes of Health (NIH) announced a new public-private partnership – the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership – to accelerate the development of COVID-19 vaccine and treatment options. At the same time, given the simultaneous importance of accelerating the development of diagnostic tests for COVID-19, Dr. Rick Bright will transfer the skills he has applied as Director of the Biomedical Advanced Research and Development Authority (BARDA) to the National Institutes of Health, as part of a bold plan to accelerate the development and deployment of novel point-of-care testing platforms," the HHS statement said.
Bright had been with the agency as its influenza and Emerging Infectious Diseases Division director since 2010 before he was tapped to lead it in late 2016.

BARDA is a small, but powerful agency with remarkable purchasing power. Though little-known, it is especially critical during a pandemic, which is why Bright's abrupt departure surprised his colleagues.

Bright was removed from his position but is not resigning, the source familiar said. He said Wednesday he will request that the HHS inspector general "investigate the manner in which this administration has politicized the work of BARDA and has pressured me and other conscientious scientists to fund companies with political connections as well as efforts that lack scientific merit."

He has not yet filed the request, according to the source, but intends to do so in the next day or so.

His lawyers said in the statement that that they will request a stay of the termination and that Bright "be permitted to remain in his position" pending the investigation's findings.

https://www.cnn.com/2020/04/22/politics/rick-bright-barda-trump-coronavirus/index.html

#8890678 at 2020-04-23 01:09:35 (UTC+1)
Q Research General #11381: Fake News, (You) Were the One Duped, Projection 101 Edition

Top vaccine expert says he was fired for resisting Trump on hydroxychloroquine

A senior US government doctor who worked on the search for a coronavirus vaccine has claimed he was fired after resisting Donald Trump's push to use the unproven drug hydroxychloroquine as a treatment, the New York Times reported on Wednesday.
Trump stops hyping hydroxychloroquine after study shows no benefit
Read more
Rick Bright was this week ousted as director of the US health department's Biomedical Advanced Research and Development Authority, or Barda, and as the deputy assistant secretary for preparedness and response.

In a stunningly candid statement, Bright highlighted his refusal to embrace hydroxychloroquine, a malaria drug relentlessly promoted by the president and Fox News despite a lack of scientific studies.
"Specifically, and contrary to misguided directives, I limited the broad use of chloroquine and hydroxychloroquine, promoted by the administration as a panacea, but which clearly lack scientific merit," Bright said.
"While I am prepared to look at all options and to think 'outside the box' for effective treatments, I rightly resisted efforts to provide an unproven drug on demand to the American public."
Asked about Bright at the White House coronavirus briefing on Wednesday, Trump said: "I never heard of him. If a guy says he was pushed out of a job, maybe he was, maybe he wasn't. You'd have to hear the other side. I don't know who he is."

https://www.theguardian.com/world/2020/apr/22/rick-bright-trump-hydroxychloroquine-coronavirus

#8890622 at 2020-04-23 01:04:30 (UTC+1)
Q Research General #11381: Fake News, (You) Were the One Duped, Projection 101 Edition

Re-post:
w/ added - [Schiff] Dis-Info Tweet - Maggie H Fake News Reference.

Here we go again.
Dr. Rick Bright = Another [Whistleblower Op]

(LawandCrime - Apr 22, 2020)
Another Whistleblower: Christine Blasey Ford's Lawyers Are Representing Demoted Doctor Who 'Resisted' Hydroxychloroquine Push

It looks like President Donald Trump has a new whistleblower complaint controversy on his hands.

At the beginning of the week, Dr. Rick Bright was the director of the Department of Health and Human Services (DHS) Biomedical Advanced Research and Development Authority (BARDA), a key vaccine-related agency in the federal government's fight against the novel Coronavirus (COVID-19) pandemic.
-
Yes, you read that right.
Rep'd by: (Katz, Marshall & Banks)

https://lawandcrime.com/covid-19-pandemic/another-whistleblower-christine-blasey-fords-lawyers-are-representing-demoted-doctor-who-resisted-hydroxychloroquine-push/
https://www.kmblegal.com
https://bio2019.zerista.com/profile/member/309211
https://twitter.com/RepAdamSchiff/status/1253081364666159104

#8890365 at 2020-04-23 00:40:25 (UTC+1)
Q Research General #11380 KEK WILLS IT - BEERS AT THE PARADE! Edition

Here we go again.
Rick Bright = Another [Whistleblower Op]

(LawandCrime - Apr 22, 2020)
Another Whistleblower: Christine Blasey Ford's Lawyers Are Representing Demoted Doctor Who 'Resisted' Hydroxychloroquine Push

It looks like President Donald Trump has a new whistleblower complaint controversy on his hands.

At the beginning of the week, Dr. Rick Bright was the director of the Department of Health and Human Services (DHS) Biomedical Advanced Research and Development Authority (BARDA), a key vaccine-related agency in the federal government's fight against the novel Coronavirus (COVID-19) pandemic.
—
Yes, you read that right.
Rep'd by: (Katz, Marshall & Banks)

https://lawandcrime.com/covid-19-pandemic/another-whistleblower-christine-blasey-fords-lawyers-are-representing-demoted-doctor-who-resisted-hydroxychloroquine-push/
https://www.kmblegal.com
https://bio2019.zerista.com/profile/member/309211

#8889247 at 2020-04-22 23:12:40 (UTC+1)
Q Research General #11379: Race To Eights, We Here Edition

Coronavirus vaccine official says he was dismissed for questioning a drug which Trump has hailed as a 'game changer'

Rick Bright, the former director of the Biomedical Advanced Research and Development Authority, which was involved in work on a coronavirus vaccine and treatments, said Wednesday he was removed from his post for resisting efforts to promote hydroxychloroquine as a treatment for coronavirus.

Bright was moved to a narrower role this week. In a statement to the New York Times, Bright said his resistance towards pushing the anti-malaria drug, which Trump has hailed as a "game changer," led to clashes with political leadership at the Department of Health and Human Services, which BARDA is under.

More than 800,000 coronavirus cases have been confirmed in the United States, with nearly 45,000 reported deaths. Worldwide, more than 2.5 million infections and 175,000 deaths have been reported.

Here are some significant developments:

"Our Country is starting to OPEN FOR BUSINESS again," President Trump tweeted Wednesday, and Treasury Secretary Steven Mnuchin predicted most if not all of the U.S. economy will have reopened by late summer. Several states are beginning to ease restrictions and closures, although some health experts and local lawmakers have cautioned that it may be too early to do so safely.
Global markets rebounded Wednesday following a wild, two-day slide in the price of oil that had unnerved investors and sent major indexes due south.
As several states rush to reopen businesses, the sudden relaxation of restrictions will supply new targets for the coronavirus, according to experts, math models and the basic rules that govern infectious diseases.
Scientists hypothesize that a mysterious blood-clotting complication could be responsible for some bizarre and sometimes fatal cases of covid-19. "While we understand that there is a clot, we don't yet understand why there is a clot," one physician said. "We don't know. And therefore, we are scared."
The World Bank estimated that remittances sent to families in low- and middle-income countries would fall by some 20 percent to $445 billion as a result of the pandemic - a severe loss for many of the world's most economically vulnerable populations.
A $484 billion deal to replenish a small-business loan program passed the Senate and is expected to be approved by the House on Thursday.
President Trump signed an executive order Wednesday restricting certain categories of immigrants from entering the United States, but the measures contain broad exceptions and are significantly more limited that the sweeping closure he described earlier in the week.

https://www.washingtonpost.com/world/2020/04/22/coronavirus-latest-news/

#8887223 at 2020-04-22 21:00:37 (UTC+1)
Q Research General #11376: Californication Edition

>>8887079
>>8887079
> Biomedical Advanced Research and Development Authority (BARDA)

#8887079 at 2020-04-22 20:47:27 (UTC+1)
Q Research General #11376: Californication Edition

>>8886896

>https://www.msn.com/en-us/news/politics/rick-bright-director-of-key-trump-administration-vaccine-agency-suddenly-departs/ar-BB130fPR

The director of the agency responsible for leading the charge on the production and purchase of vaccines in the Trump administration is no longer leading the agency as of Tuesday, CNN has confirmed.


Dr. Rick Bright had led the Biomedical Advanced Research and Development Authority, which has been central to the response to the coronavirus outbreak, since 2016. An acting director has taken over in his position, though the reason behind Bright's sudden departure is still unclear.


The move was first reported by STAT News.
A spokesperson for the Department of Health and Human Services confirmed Bright's move in a statement to CNN and said he will now lead a new government project: a public-private partnership on vaccine development and treatment.
"On April 17, the National Institutes of Health (NIH) announced a new public-private partnership – the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership – to accelerate the development of COVID-19 vaccine and treatment options. At the same time, given the simultaneous importance of accelerating the development of diagnostic tests for COVID-19, Dr. Rick Bright will transfer the skills he has applied as Director of the Biomedical Advanced Research and Development Authority (BARDA) to the National Institutes of Health, as part of a bold plan to accelerate the development and deployment of novel point-of-care testing platforms," the HHS statement said.

The spokesperson added: "Dr. Bright brings extensive experience and expertise in facilitating powerful public-private partnerships that advance the health and well-being of the American people. Gary Disbrow with the Office of the Assistant Secretary for Preparedness and Response will serve as the acting director of BARDA."

Bright had been with the agency as its influenza and Emerging Infectious Diseases Division director since 2010 before he was tapped to lead it in late 2016.

#8877998 at 2020-04-21 23:05:19 (UTC+1)
Q Research General #11365: Meme Fodder MSM Meltdown Edition

Director of U.S. agency key to vaccine development leaves role suddenly amid coronavirus pandemic
WASHINGTON - Rick Bright, one of the nation's leading vaccine development experts and the director of the Biomedical Advanced Research and Development Authority, is no longer leading the organization, officials told STAT.

The shakeup at the agency, known as BARDA, couldn't come at a more inopportune time for the office, which invests in drugs, devices, and other technologies that help address infectious disease outbreaks and which has been at the center of the government's coronavirus pandemic response.

Bright, whose departure was confirmed by three industry sources and two current Trump administration sources, will instead move into a narrower role at the National Institutes of Health. Gary Disbrow, Bright's former deputy at BARDA, will serve as the acting director of the office, an HHS spokesperson confirmed to STAT.


BARDA was expected to play an even larger role in the coming months; Congress more than tripled BARDA's budget in the most recent coronavirus stimulus package. Already, the office has a role in some of the splashiest Covid-19 projects, including partnerships with Johnson & Johnson and Moderna Therapeutics, both of which are developing potential Covid-19 treatments.

BARDA has been plagued with management issues virtually since its creation in 2006, with much of the criticism aimed at a contracting department that some say is unresponsive to industry partners. The office has only had two permanent directors since its creation in 2006. Bright has led the organization since 2016.

The BARDA director position is not a Senate-confirmed position. It reports directly to the HHS assistant secretary for preparedness and response.

None of the sources articulated the reason for Bright's departure, though several mentioned recent chafing between Bright and Bob Kadlec, the current HHS assistant secretary for preparedness and response.

An HHS spokesperson confirmed that Bright will begin working out of NIH. An NIH spokesperson later clarified that Bright will work on diagnostics.

"Dr. Rick Bright will transfer the skills he has applied as Director of the [BARDA] to the [NIH]. ... Dr. Bright brings extensive experience and expertise in facilitating powerful public-private partnerships that advance the health and well-being of the American people," the HHS spokesperson said.

Bright did not immediately respond to requests for comment.

Bright's career has largely centered around vaccine and drug development. His work at the Centers for Disease Control and Prevention focused on influenza viruses, antiviral drugs and tests. He has also worked in the biotechnology industry and served as an advisor to the World Health Organization. Before becoming BARDA director, he led the agency's Influenza and Emerging Infectious Diseases Division.

https://www.statnews.com/2020/04/21/rick-bright-out-at-barda/

#8877916 at 2020-04-21 23:00:19 (UTC+1)
Q Research General 11364: Barr's Governor Beatdown Edition

Director of U.S. agency key to vaccine development leaves role suddenly amid coronavirus pandemic

WASHINGTON - Rick Bright, one of the nation's leading vaccine development experts and the director of the Biomedical Advanced Research and Development Authority, is no longer leading the organization, officials told STAT.

The shakeup at the agency, known as BARDA, couldn't come at a more inopportune time for the office, which invests in drugs, devices, and other technologies that help address infectious disease outbreaks and which has been at the center of the government's coronavirus pandemic response.

Bright, whose departure was confirmed by three industry sources and two current Trump administration sources, will instead move into a narrower role at the National Institutes of Health. Gary Disbrow, Bright's former deputy at BARDA, will serve as the acting director of the office, an HHS spokesperson confirmed to STAT.

https://www.statnews.com/2020/04/21/rick-bright-out-at-barda/

#8850761 at 2020-04-19 16:02:37 (UTC+1)
Q Research General #11330: Patriot's Day Edition

Did we see this? Potus EO from Sept 19, 2019 on Mondernizing flu vaccines in the US, with discussion on pandemics

https://www.whitehouse.gov/presidential-actions/executive-order-modernizing-influenza-vaccines-united-states-promote-national-security-public-health/

Secretary of Defense: Mark Esper (https://en.wikipedia.org/wiki/Mark_Esper)
Secretary of Health and Human services: Alex Azar (https://en.wikipedia.org/wiki/Alex_Azar)


(b) In addition to the Co-Chairs, the Task Force shall consist of a senior official from the following executive branch departments, agencies, and offices:

(i) the Department of Defense (DOD);

(ii) the Department of Justice;

(iii) the Department of Agriculture;

(iv) the Department of Veterans Affairs (VA);

(v) the Department of Homeland Security;

(vi) the United States Food and Drug Administration;

(vii) the Centers for Disease Control and Prevention;

(viii) the National Institutes of Health (NIH);

(ix) the Centers for Medicare and Medicaid Services (CMS); and

(x) the Biomedical Advanced Research and Development Authority (BARDA).

#8637093 at 2020-03-31 18:18:13 (UTC+1)
Q Research General #11059: WHO's News Now? Edition

US Gov't Partners with Johnson & Johnson To Prep for 1 Billion Coronavirus Vaccine Doses

Pharmaceutical giant Johnson & Johnson is partnering with the U.S. government to produce up to 1 billion doses of a coronavirus vaccine for use around the world by the end of next year.
Asked on NBC's "Today" on Monday how quickly the first vaccines could be available, CEO Alex Gorsky replied, "This is like a moonshot for us."

"What would usually take five to seven years, we expect to be able to accomplish in five to seven months," he said.

The company is working directly with the Biomedical Advanced Research and Development Authority at the Department of Health and Human Services.

"We have a candidate that has a high degree of probability of being successful against the COVID-19 virus," Gorsky said.

"Now we also, very important, we've got the production capabilities to be able to ramp up production of this in a relatively short period of time so it can become available."

Gorsky said he anticipates starting human testing in September and having interim study results by early next year.

The Johnson & Johnson leader said the company plans to start production of the vaccine even before it has the study's results.
"Literally within the next few days and weeks, we're going to start ramping up production of these vaccines as well, and we should be able to have several hundred million doses available by the middle of next year. Our goal is to have a billion prepared by the end of 2021," he said.
Forbes reported that Johnson & Johnson entered into the $1 billion deal with the federal government to develop the vaccine late last week.

Under the terms of the agreement, the government will pay $456 million and Johnson & Johnson will cover the rest of the cost for the vaccine's Research, development and testing.
"Today" co-host Savannah Guthrie highlighted that Johnson & Johnson and other companies entering into these agreements with the government are taking a risk by producing the vaccine before even knowing if it's effective.
"Look, that's what we have to do in this case," Gorsky replied.

"We're going to do everything possible to make sure we have a safe, effective, vaccine available in the kind of quantities that can really make a difference," he said.
Johnson & Johnson's chief scientific officer, Dr. Paul Stoffels, also confirmed to Reuters that going to production before the vaccine is approved "is the only option for us to get it on time."

Gorsky said his company is doing everything possible to try to accelerate the process to get a vaccine to the public.

http://www.yourdestinationnow.com/2020/03/us-govt-partners-with-johnson-johnson.html

#8458762 at 2020-03-18 05:02:16 (UTC+1)
Q Research General #10830: Boomerang Suicide Edition

CoronaVirus Timeline
>>8457311 (pb)
>- The REAL first case was November 17, 2019

Great timeline, but it leaves out a critical early event.
Sep 18, 2019, 60 days before the first case in Wuhan.
Trump signed Executive Order 13887

```Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health```
https://www.federalregister.gov/documents/2019/09/24/2019-20804/modernizing-influenza-vaccines-in-the-united-states-to-promote-national-security-and-public-health

Section 1: Findings
1a:
…This situation is called an influenza pandemic (pandemic). Unlike seasonal influenza, a pandemic has the potential to spread rapidly around the globe…
1c: …vaccines must be reformulated…in the event of a pandemic
1d: …current domestic enterprise for manufacturing influenza vaccines has critical shortcomings…
1e: …[current] approach is insufficient to meet the response needs in the event of a pandemic, which can emerge rapidly and with little warning…

Section 2: Policy
…This order directs actions to reduce the United States' reliance on egg-based influenza vaccine production; to expand domestic capacity of alternative methods that allow more agile and rapid responses to emerging influenza viruses; to advance the development of new, broadly protective vaccine candidates that provide more effective and longer lasting immunities…

Sec. 3. National Influenza Vaccine Task Force
…The Task Force shall be co-chaired by the Secretary of Defense and the Secretary of Health…
Plus a senior official from each of the following.
(i) DoD
(ii) DoJ
(iii) Dept of Agr
(iv) Dept of VA
(v) Dept of Homeland Sec
(vi) FDA
(vii) CDC
(viii) NIH
(ix) Centers for Medicare and Medicaid Services (CMS)
(x) Biomedical Advanced Research and Development Authority (BARDA).

```VACCINE PRODUCTION TO BE DONE DOMESTICALLY```
```DOD CONTROL, NOT CDC```
```TASK FORCE ALREADY IN PLACE```
```RED TAPE REMOVED, NOT SUBJECT TO CDC OR FDA OVERSIGHT```

#8321361 at 2020-03-05 03:17:41 (UTC+1)
Q Research General #10653 MSM, All Your Breaking News Stories are Belong to Us! Edition

A detailed guide to the coronavirus drugs and vaccines in development

In the months since the novel coronavirus rose from a regional crisis to a global threat, drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic. Some are repurposing old antivirals. Some are mobilizing tried-and-true technologies, and others are pressing forward with futuristic approaches to human medicine. Here's a guide to some of the most talked-about efforts to treat or prevent coronavirus infection, with details on the science, history, and timeline for each endeavor.

Gilead Sciences Approach: Treatment Stage: Phase 3
Gilead's remdesivir, an intravenous treatment, has already been used to treat one infected patient in the U.S. and will soon be deployed in a pair of large, late-stage studies in Asia. Later this month, Gilead will recruit about 1,000 patients diagnosed with the coronavirus to determine whether multiple doses of remdesivir can reverse the infection. The primary goals are reducing fever and helping patients get out of the hospital within two weeks. The drug, which previously failed in a study on Ebola virus, is also being studied in smaller trials in China and the U.S.

Moderna Therapeutics Approach: Vaccine Stage: Phase 1
Moderna set a drug industry record with mRNA-1273, a vaccine candidate identified just 42 days after the novel coronavirus was sequenced. The company is working with the National Institutes of Health on a healthy-volunteer study expected to begin next month. If mRNA-1273 proves itself to be safe, the two organizations will enroll hundreds more patients to determine whether the vaccine protects against infection. Moderna's product is a synthetic strand of messenger RNA, or mRNA, designed to convince bodily cells to produce antibodies against the virus. The company, founded in 2010, is yet to win Food and Drug Administration approval for any of its mRNA medicines.

CureVac Approach: Vaccine Stage: Preclinical
Like Moderna, CureVac uses man-made mRNA to spur the production of proteins. And, like Moderna, it got a grant from the nonprofit Coalition for Epidemic Preparedness Innovations to apply its technology to coronavirus. CureVac has said it expects to have a candidate ready for human testing within a few months. The company is also working with CEPI on a mobile mRNA manufacturing technology, one that would theoretically allow health care workers to rapidly produce vaccines to respond at the site of an outbreak.

GlaxoSmithKline Approach: Vaccine Stage: Preclinical
GlaxoSmithKline, one of the world's largest vaccine manufacturers, is lending its technology to a Chinese biotech firm at work on a coronavirus vaccine. Under an agreement signed last month, GSK is providing its proprietary adjuvants - compounds that enhance the effectiveness of vaccines - to Clover Biopharmaceuticals, a privately held company based in Chengdu. Clover's approach involves injecting proteins that spur an immune response, thereby priming the body to resist infection. The company has not said when it expects to advance into human testing.

Inovio Pharmaceuticals Approach: Vaccine
Stage: Preclinical
Inovio has spent the last four decades working to turn DNA into medicine, and the company believes its technology could quickly generate a vaccine for the novel coronavirus. Working with CEPI grant money, Inovio has come up with a DNA vaccine it believes can generate protective antibodies and keep patients from infection. The company has partnered with a Chinese manufacturer, Beijing Advaccine Biotechnology, and is working through preclinical development with a candidate called INO-4800. The company expects to progress into clinical trials later this year.

Johnson & Johnson Approach: Vaccine and treatment Stage: Preclinical
Johnson & Johnson, which has in the past responded to outbreaks of the Ebola and Zika viruses, is taking a multipronged approach to the coronavirus. The company is in the early days of developing a vaccine that would introduce patients to a deactivated version of the virus, triggering an immune response without causing infection. At the same time, J&J is working with the federal Biomedical Advanced Research and Development Authority on potential treatments for patients who are already infected, a process that includes investigating whether any of its older medicines might work against the coronavirus.

https://www.statnews.com/2020/03/02/coronavirus-drugs-and-vaccines-in-development/

#6027596 at 2019-04-03 04:55:59 (UTC+1)
Q Research General #7709: We Are At War Edition

DoD orders $250 million worth of gas masks.

The U.S. Department of Defense (DoD) has awarded Avon Protection Systems Inc., Cadillac, Michigan, a $245,961,250 firm-fixed-price contract for production of M53A1 Chemical Biological Protective Mask systems, according to the DoD contract website.

The Army estimates M53A1 gas masks will start delivery in the second half of this financial year ending September. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, will oversee the purchase order.

Avon Protection Systems is a world leader and major supplier to the military, law enforcement, first responders, and industrial sectors globally.

The M53A1 was developed to counter multiple threats encountered on the modern battlefield. "It provides excellent protection against traditional chemical and biological warfare agents, select Toxic Industrial Materials (TIMs) and particulate matter including radioactive dust," read the M53 brochure.

According to the company, the M53A1 protects soldiers from chemical, biological, radiological and nuclear attacks. Specifically, the mask protects against mustard, sarin, soman, and VX nerve agents.

The order comes one month after the U.S. government introduced science-based guidelines for how first responders decontaminate large numbers of Americans after a chemical-weapons attack.

The guidelines, published last month, are the first in the U.S. to be based on extensive Research and testing.

"Terrorist threats and the use of chemical weapons in Syria have heightened awareness of the need for improved preparedness against chemical attacks," said Gary Disbrow, deputy director of the US Biomedical Advanced Research and Development Authority, which prepared the guidelines.

"First responders are supportive of the fact that it is evidence-based guidance, and not just, 'We used this last time, and it seemed to work,'" he added.

With lightning speed, the Army and U.S. government have been actively preparing for a biological incident on the homeland. With threats harder to anticipate today, the act of preparation suggests some fears that an attack of some sort could be imminent.

https://www.zerohedge.com/news/2019-03-27/immient-biological-attack-dod-orders-250-million-gas-masks

#4052964 at 2018-11-28 00:00:28 (UTC+1)
Q Research General #5158: Remembrance of Admiral Jeremy M. Boorda Edition

Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will test different dosages of the inactivated influenza vaccine candidate (called 2017 H7N9 IIV) as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.

H7N9 is an avian (bird) influenza virus first reported in humans in 2013 in China. Since then, six waves of H7N9 infection have occurred in China, resulting in more than 1,500 cumulative human infections, according to the World Health Organization. No human cases of H7N9 influenza have been detected to date in the United States. Currently, the virus does not spread easily from person to person; rather, people typically become infected through direct exposure to infected poultry or contaminated environments. However, if the virus mutates and becomes easily transmissible between humans, it could result in an influenza pandemic because most people have little to no immunity to it. H7N9 has a high mortality rate, resulting in death in 39 percent of those who became infected.

"As we experience one of the worst seasonal influenza epidemics in recent years here in the United States, we also must maintain a scientific focus on novel influenza viruses, such as H7N9, that have the potential to cause a pandemic," said NIAID Director Anthony S. Fauci, M.D. "These new clinical trials will build upon initial studies of earlier versions of an H7N9 vaccine candidate to provide a more detailed picture of its safety and ability to generate a protective immune response to current H7N9 strains."

The two clinical trials will test the experimental 2017 H7N9 inactivated influenza vaccine developed by Sanofi Pasteur, based in Lyon, France, supported by the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. NIAID funded previous Research (link is external) on the earlier version of the vaccine. The new version of the vaccine candidate uses an inactivated form of H7N9 influenza virus collected in 2017, to increase the likelihood that the vaccine will provide immunity against a newly-evolved strain of H7N9, which is currently circulating in the wild. During these clinical trials, some participants will receive an adjuvant, called AS03, along with the test vaccine, to confirm that the adjuvant can boost the immune response to the vaccine, as previously shown for other influenza viruses of pandemic potential. The adjuvant is produced by GSK's vaccines business, headquartered in Wavre, Belgium, with support from BARDA. Both clinical trials will be conducted by the NIAID-funded network of Vaccine and Treatment Evaluation Units (VTEUs).

One clinical trial, led by principal investigator Lisa A. Jackson, M.D., of the Kaiser Permanente Washington Health Research Institute in Seattle, will test the vaccine candidate at different dosages, both with and without the AS03 adjuvant. The study will enroll as many as 420 male and non-pregnant female volunteers ages 19 to 64 years and up to 300 volunteers older than 65 years of age. Each participant will be randomly assigned to one of five groups. Three of the groups (at least 480 volunteers in total) will receive the adjuvanted vaccine candidate, at different dosages (3.75 micrograms (mcg), 7.5 mcg or 15 mcg). The two remaining groups (at least 160 volunteers in all) will receive unadjuvanted vaccine (15 mcg or 45 mcg). All five groups will be vaccinated twice: once at the first visit, and then again 21 days later. Volunteers will be monitored for seven days following each vaccination and assessed for side effects, and blood samples will be tested for H7N9 antibodies. Clinical staff will follow the volunteers for one year. The trial is being conducted at VTEU sites in Georgia, Iowa, Maryland, North Carolina and Washington.

The second clinical trial will be led by Kathleen M. Neuzil, M.D. of the University of Maryland School of Medicine. This trial will test the H7N9 vaccine candidate with AS03 adjuvant in conjunction with a quadrivalent seasonal influenza vaccine. By administering the vaccine candidate to some volunteers who have received the seasonal influenza vaccine and some who have not, investigators will be able to learn whether the H7N9 vaccine candidate affects the immune response to the seasonal influenza vaccine, and vice versa…

https://www.niaid.nih.gov/news-events/h7n9-influenza-vaccine-clinical-trials-begin

#2150381 at 2018-07-14 05:11:42 (UTC+1)
Q Research General #2711 Court Orders Safe Passage of JA Edition

The cures .... SMALLPOX TREATMENT!!!!


https://www.sciencenews.org/article/fda-approves-first-smallpox-treatment-tpoxx

FDA approves the first smallpox treatment
The drug prevents the variola virus from infecting other cells
By Aimee Cunningham 6:06pm, May 2, 2018

Magazine issue: Vol. 193, No. 9, May 26, 2018, p. 10

Editor's note: The FDA approved TPOXX for the treatment of smallpox on July 13, 2018. This story, originally published May 2, has been edited throughout to reflect the approval.


As bioterrorism fears grow, the first treatment for smallpox has been approved.

Called tecovirimat, the drug stops the variola virus, which causes smallpox, from sending out copies of itself and infecting other cells. "If the virus gets ahead of your immune system, you get sick," says Dennis Hruby, the chief scientific officer of pharmaceutical company SIGA Technologies, which took part in developing the drug. "If you can slow the virus down, your immune system will get ahead."

An advisory committee to the U.S. Food and Drug Administration unanimously recommended approval of tecovirimat, or TPOXX, on May 1. The FDA announced the approval July 13.

Unchecked, smallpox kills about 30 percent of people infected and leaves survivors with disfiguring pox scars. Between 300 million and 500 million people died of smallpox in the 20th century before health officials declared the disease eradicated in 1980 after a worldwide vaccination campaign. For Research purposes, samples of the virus remain in two locations - one in the United States, the other in Russia.

People haven't been routinely vaccinated against the disease since the 1970s. So "it would be catastrophic if it were to reappear accidently or in the case of a bioweapon attack," says molecular virologist Robin Robinson. He is the former director of the Biomedical Advanced Research and Development Authority, a federal agency that's focused on protecting against biological and other threats and that assisted in the drug's development.

Fears that the disease could be used as a biological weapon have risen in light of anthrax attacks and other terrorist acts of this century. The National Institute of Allergy and Infectious Diseases classifies smallpox as a Category A priority pathogen, because the disease spreads easily from person to person and can be highly fatal.

Researchers tested how well the drug stops smallpox in animals, while trials to determine the safety and dose of the drug were conducted in people. In monkeys and rabbits infected with viruses related to smallpox, tecovirimat prevented around 90 percent of the animals from dying, says SIGA CEO Phil Gomez. Nearly all of the animals that did not receive the drug died.

A smallpox infection does not produce symptoms right away. After 10 to 14 days, a fever and rash occurs - that's when a person is most contagious - followed by the formation of poxes. The drug is meant to be taken at the fever and rash stage. Data from the animal studies, Hruby says, suggest that few poxes will form once the drug is taken and patients will heal more quickly.

"Preparing for disasters comes in different shapes and forms," says Grant McFadden, who studies poxviruses at Arizona State University in Tempe and was not involved with the development of tecovirimat. "This is preparing for an infectious disease disaster." In the event that smallpox reappears, "you need drugs to actually block the progression of the disease."

Two million treatments of TPOXX are already in the U.S. Strategic National Stockpile of drugs and supplies for public health emergencies, Gomez says, a move allowed under emergency preparedness legislation. FDA approval of tecovirimat would open the door to studying the drug for other ushttps://www.sciencenews.org/article/fda-approves-first-smallpox-treatment-tpoxxes (such as a treatment for related poxviruses), assure the supply of the drug and encourage other countries to place the drug in their emergency stocks.

No one can predict if or when a pox virus is going to pop up and cause problems, says Hruby. With this drug, "I'd like to think you can sleep better at night."